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“Research on rare diseases illuminates key aspects of human physiology. Common diseases 
are beginning to be dissected into collections of “rare” molecularly defined subgroups. These 
advances in our understanding of human pathophysiology have the potential to relieve human 
suffering through precision medicine. But to improve clinical medicine, new treatments for 
rare diseases and disease subtypes must be evaluated using special clinical trial designs and 
analyses that address the statistical challenges associated with small sample sizes.”
— Edward L. Korn, Lisa M. McShane and Boris Freidlin —
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Abbreviations
A2E N-retinylidene-N-retinylethanolamine
ABCA4 adenosine triphosphate (ATP)-binding cassette, sub-family A, member 4 transporter
 The ABCA4 protein was previously denoted as ABCR (Chapter 2.1). For consistency, this abbreviation has been 
changed to ABCA4 throughout this thesis.
AF autofluorescence | allele frequency
 • qAF quantitative autofluorescence
 • DDAF definitely decreased autofluorescence
 • QDAF questionably decreased autofluorescence
 • SW-AF short-wavelength autofluorescence
AMD age-related macular degeneration
ANSI American National Standards Institute
ASTM American Society of Testing and Materials
CACD central areolar choroidal dystrophy
CI confidence interval
CNV choroidal neovascularization
CF counting fingers
CT computed tomography
ELM external limiting membrane
EMA European Medicines Agency
ERG electroretinography
 • ffERG full-field electroretinography
 • mfERG multifocal electroretinography
 • PERG pattern electroretinography
ETDRS Early Treatment Diabetic Retinopathy Study
ExAC Exome Aggregation Consortium
EZ ellipsoid zone
FA fluorescein angiography
FAF fundus autofluorescence
FAM Fundus Autofluorescence Imaging in Age-related Macular Degeneration
FDA U.S. Food and Drug Administration
GA geographic atrophy
GPS[+] fine granular pattern with peripheral punctate spots 
HM hand movements
ISCEV International Society for Clinical Electrophysiology of Vision
IQR interquartile range
logMAR logarithm of the minimum angle of resolution
LOVD Leiden Open (source) Variation Database
MC Monte Carlo
MRI magnetic resonance imaging
NI not identified
NIH National Institute of Health  
NIR near-infrared reflectance
NA not available
NP not performed
OCT optical coherence tomography
 • SD-OCT spectral-domain optical coherence tomography
OD optical density
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OR odds ratio
PE phosphatidylethanolamine
PhyloP phylogenetic P values
PolyPhen-2 polymorphism phenotyping version 2
PRPH2  Peripherin-2 
RPE retinal pigment epithelium
Q1 first interquartile
Q3 third interquartile
RMSE root-mean-square error
RPE retinal pigment epithelium
SD standard deviation
 • MSDR mean-to-standard-deviation ratio
SE standard error
SIFT sorting intolerant from tolerant
STGD1 Stargardt disease
 • EO-STGD1 early-onset Stargardt disease 
 • IO-STGD1 intermediate-onset Stargardt disease
 • LO-STGD1 late-onset Stargardt disease
VA visual acuity
 • BCVA best-corrected visual acuity
 
Visual acuity conversion chart 
Decimal notation U.S. notation logMAR
Normal vision 1.6 20/12.5 -0.2
1.25 20/16 -0.1
1.0 20/20 0
0.8 20/25 0.1
Mild visual
impairment
0.63 20/32 0.2
0.5 20/40 0.3
0.4 20/50 0.4
0.32 20/63 0.5
Moderate visual
impairment
0.25 20/80 0.6
0.2 20/100 0.7
0.16 20/125 0.8
0.125 20/160 0.9
Severe visual
impairment
0.1 20/200 1.0
0.08 20/250 1.1
0.063 20/320 1.2
0.05 20/400 1.3
Profound visual
impairment
0.04 20/500 1.4
0.032 20/630 1.5
0.025 20/800 1.6
0.02 20/1000 1.7
(Near-)blindness less than 0.02 | 20/1000 1.8
1.9
2.0
2.1
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1.1 Stargardt disease
The first cases of what is now known as Stargardt disease were described in the late 
19th century. Back then, Stargardt disease, as well as most other retinal dystrophies, 
was commonly regarded as an infectious or inflammatory disease: central choroiditis. 
Patients were often suspected for tuberculosis or lues. They were treated accordingly, 
but these patients eventually could no longer read, perceive colors, or recognize faces. 
In 1885, Lang described a 30-year old woman with progressive vision loss and retinal 
features most reminiscent of Stargardt disease:1
“The patient noticed that her sight was failing six years ago, and it has gradually got worse 
since then, but without causing any discomfort […]. In the [foveal] region, there is considerable 
disturbance of the retinal pigment with increased pigmentation in one or two places. […]
In the posterior part of fundus, there are numerous small round, or oval yellowish-white 
patches scattered in every direction; they do not assume any regular distribution, but the oval 
ones generally have their long axis at right angles to the retinal vessels. They are apparently 
situated in the superficial part of the choroid.”
It was not until 1909 when these retinal features were recognized as a familial progres-
sive macular dystrophy by Karl Stargardt, whose name now has been solidly linked to 
the disease.2 A central macular atrophy with irregular or pisciform yellow-white fundus 
flecks (Figure 1) characterizes Stargardt disease (prevalence, 1:8000–1:10000).3, 4, 5 
These flecks are predominantly located in the macula and represent lipofuscin granules 
containing toxic bisretinoids. These toxic compounds accumulate over time in the retinal 
pigment epithelium, which results in atrophy of the retinal pigment epithelium and photo-
receptor cells.6, 7 Both flecks and atrophic lesions can extend beyond the vascular arcades,8 
Figure 1. (Left) Overall topography of the human retina on fundus photography. (Right) Stargardt 
disease.
1.5 mm, 5°
fovea
parafoveafoveola
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flecksperifovea
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as centrifugal expansion 
continues to progress 
into eventual retina-wide 
degeneration.9-12 
Although Stargardt disease 
was originally considered a 
juvenile macular degener-
ation,2 patients may expe-
rience the first visual com-
plaints between their first 
until the seventh decade of 
life.13-16 The heterogeneity in the age at onset reflects heterogeneity in the natural dis-
ease course. The extremes can be described as early-onset or childhood-onset Stargardt 
disease and late-onset Stargardt disease. These subtypes have distinct progressions: 
early-onset Stargardt disease is characterized by minor initial abnormalities, but with 
a rapid progression toward chorioretinal degeneration.14 Late-onset Stargardt disease 
contains features of a relatively intact fovea that is often surrounded by atrophic retinal 
pigment epithelium lesions.13, 15 The patients with an intermediate disease onset are 
expected to be in between these extremes.
Retinal imaging
On fluorescein angiography, the choroidal background fluorescence is characteristically 
blocked in Stargardt disease due to the excess lipofuscin accumulation in the retinal pig-
ment epithelium, which has been described as a dark choroid.17 The yellow-white flecks 
appear hypofluorescent at first, but eventually become hyperfluorescent as atrophy 
develops. Although these diffuse hyperfluorescent flecks may obscure a dark choroid, it 
can still be visible in the peripapillary area or in the peripheral retina.18 
Gross anatomy of the eye
Light rays diverge in all directions from their source and must be refracted to eventually come 
to a sharp focus on the retina. The strongest refraction occurs through the cornea, which is the 
front surface of the eye. It then goes through the circular opening in the iris: the pupil. The pupil 
will constrict as the light becomes brighter, and so will it dilate as the light becomes dimmer. 
The pupil contributes to the sharp focus by narrowing its size, reducing spherical and chromatic 
aberrations, which tend to blur the image. Moreover, a narrow pupil increases the depth of field: the 
distance within which objects are seen sharply. Passing through the pupil, the light goes through 
the crystalline lens, which has adjustable refractive power. This allows objects at various distances 
to be brought into sharp focus. It is then in the retina where photons are transformed into electrical 
signals. These signals are sent through the optic nerve, along the visual pathway, and finally pro-
cessed in the occipital cortex at the posterior of the brain that eventually create our vision (Figure 2).
Figure 2. Anatomy of the human eye.
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Ignacio Icke (Wikimedia Commons),
“Eye diagram“, modified by Stanley Lambertus
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In the aid of diagnosing and monitoring Stargardt disease, fluorescein angiography 
has now been replaced by fundus autofluorescence imaging. Fundus autofluorescence 
imaging visualizes the distribution of lipofuscin in the retinal pigment epithelium. The 
Figure 3. (Left) Fundus autofluorescence image of a normal retina. (Right) The yellow-white fundus 
flecks in Stargardt disease are hyperautofluorescent. This indicates increased accumulation of 
lipofuscin fluorophores. Areas of decreased autofluorescence indicate reduced lipofuscin demand due 
to photoreceptor loss.
Retinal architecture
The retina is a highly specialized transparent neural layer for capturing and processing light. How-
ever, its unique sophisticated architecture of ten layers makes it also vulnerable to dysfunction. The 
outer retina comprises the [1] retinal pigment epithelium and the photoreceptor layer. The retinal 
pigment epithelium has vital functions for the maintenance of photoreceptors, phagocytosis of 
photoreceptor outer segments being one of the most relevant one in this thesis. Photoreceptors 
are continuously being exposed to light and oxygen, which facilitates the formation of free radicals. 
These radicals damage the photoreceptor membranes over time, which therefore need to be 
continuously renewed. Old outer segments are continuously being shed by the retinal pigment 
epithelium and replaced by new discs at a 10% per 24 hour rate.19 Undigested outer segment parts 
eventually form lipofuscin granules, which accumulate as we age.7 Rods and cones, forming the [2] 
photoreceptor layer, contain an inner and an outer segment. The cell organelles are located in the 
inner segment. The inner segment ellipsoid zone reflects photoreceptor integrity and health. The 
conversion of light to electric signals, i.e., phototransduction, occurs in the outer segment. In cones, 
the outer segments contain many invaginations of the surface membrane; in rods, they are entirely 
discontinuous of the surface membrane and form individual disk membranes. The structural 
supportive junctions between photoreceptors and Müller glia compose the [3] external limiting 
membrane. The cell bodies of photoreceptors compose the [4] outer nuclear layer. Photoreceptors 
interconnect through synapses with bipolar and horizontal cells in the [5] outer plexiform layer. The 
inner retina contains the [6] inner nuclear layer, composed of amacrine, bipolar, horizontal, and 
Müller cells. These cells interconnect with ganglion cells in the [7] inner plexiform layer. The cell 
bodies of the ganglion cells are situated in the [8] ganglion cell layer, from which the axons form 
the [9] nerve fiber layer. The inner retina is finally separated from the posterior vitreous by the [10] 
internal limiting membrane (Figure 4).
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Figure 4. Spectral-domain optical coherence tomography of the human retina. A horizontal scan 
through the fovea reveals several hyperreflective (white) bands, which correlate with the anatomical 
layers of the retina. [1] retinal pigment epithelium / Bruch’s complex [2] ellipsoid zone [3] external limiting 
membrane [4] outer nuclear layer [5] outer plexiform layer [6] inner nuclear layer [7] inner plexiform layer 
[8] ganglion cell layer [9] nerve fiber layer [10] internal limiting membrane.
Figure 5. Spectral-domain optical coherence tomography in Stargardt disease. The outer retinal layers 
are thinned and recede centrifugally from the fovea. The hyperreflective band of the external limiting 
membrane is thicker than in a normal retina.
yellow-white fundus flecks are hyperautofluorescent, indicating increased accumulation 
of lipofuscin fluorophores.20, 21 These hyperfluorescent changes may be visible prior to 
changes on ophthalmoscopy. Areas of decreased autofluorescence indicate reduced 
lipofuscin demand due to photoreceptor loss. Autofluorescence is absent in case of com-
plete retinal pigment epithelium loss, which represents a late manifestation in Stargardt 
disease (Figure 3).22-25 However, there are concerns that patients with Stargardt disease 
are at risk for light toxicity during fundus autofluorescence imaging.15 The accumulation 
of bisretinoids is accelerated in Stargardt disease, and particularly these bisretinoids 
are identified as potent photosensitizers in animal studies. Whether the mechanism of 
photochemical damage involves changes in either lipofuscin or molecules within the 
visual cycle such as all-trans-retinal, patients with Stargardt disease are likely to be 
more susceptible to photic injury than healthy individuals.14, 16
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The retinal layers can be visualized with high resolution on a cross-sectional retinal scan: 
spectral-domain optical coherence tomography (Figure 4). Thickening of the external 
limiting membrane has been suggested as the earliest sign prior to any other structural 
or functional abnormalities. It may reflect a gliotic response to cellular stress at the pho-
toreceptor level).28, 29 The photoreceptor inner segment ellipsoid zone may recede earlier 
than the retinal pigment epithelium, indicating that spectral-domain optical coherence 
tomography can be more informative than fundus autofluorescence imaging in early 
stages (Figure 5).30, 31
The ABCA4 gene
Stargardt disease is an autosomal recessive retinal dystrophy associated 
with disease-causing sequence variants in the adenosine triphosphate-binding 
Figure 6. The distribution of rods and cones. The density of the receptors is shown in degrees of visual 
angle relative to the position of the fovea for the left eye. The cone receptors are concentrated in the 
fovea. The rod photoreceptors are absent from the fovea and reach their highest density 10 to 20° 
peripheral to the fovea. No photoreceptors are present in the blind spot.
Photoreceptor topography
Approximately 100 million rods dominate the peripheral retina, which extends from the vascular 
arcades to the ora serrata. Cone photoreceptors (± 5 million) dominate the central retina: the macula 
lutea (Figure 6). The border of the macula (5.5 mm), overlaps with the path of the vascular arcades. 
The macula can be subdivided in a perifoveal area, parafoveal area, fovea, foveola, and umbo. The 
umbo (0.15–0.20 mm) lies at the very center of the macula and has the highest visual acuity with 
the highest cone density. The diameter of its cones is narrowed and elongated due to crowding. At 
the foveola (0.35 mm), the metabolic demands of these densely packed cones are extremely high, 
which are met by direct contact with the retinal pigment epithelium, and through the processes of 
Müller glia cells.26, 27 The foveola, a 22° clivus, and a thick margin comprises the fovea (1.5 mm). The 
margin is surrounded by the parafoveal belt (0.5 mm width), which has a regular ten-layer retinal 
architecture. The perifoveal belt finally (1.5 mm) surrounds the parafovea (Figure 1).
Left: Ignacio Icke (Wikimedia Commons), “Schematic diagram of the human eye“, modified by Stanley Lambertus
Right: Cmglee (Wikimedia Commons),  “Human photoreceptor distribution”, modified by Stanley Lambertus
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Figure 7. The formation of bisretinoids in absence of ABCA4 protein function.
cassette, subfamily A, member 4 (ABCA4) gene.32, 33 The carrier frequency of ABCA4 
sequence variants is up to 1 in 20,34 and a nearly ever increasing number of more than 
1000 variants has been reported.35-38 The ABCA4 protein, localized in the disk mem-
branes of both cones and rods,39, 40 plays an essential role in the retinoid cycle. Via the 
retinoid cycle, 11-cis-retinal must be continuously regenerated from all-trans-retinal to 
maintain vision. All-trans-retinal is released into the lumen of the disk membranes and 
condensates with phosphatidylethanolamine (PE) to form N-retinylidene-PE.20, 41 Like-
wise, 11-cis-retinal and phosphatidylethanolamine form N-11-cis-retinylidene-PE.42, 43 
These adducts are transported by the ABCA4 protein from the lumen into the cyto-
plasmic space. Dysfunction or absence of ABCA4 leads to excessive accumulation of 
N-11-cis-retinylidene-PE and N-retinylidene-PE adducts. They can form potentially 
toxic compounds, such as N-retinylidene-N-retinylethanolamine (Figure 7).44 These bis-
retinoids undergo photo-oxidation and produce reactive oxygen and nitrogen species,45, 46
and eventually leads to the aforementioned irreversible damage to the retina.5, 6, 32
Phototransduction and the retinoid cycle
Photons are absorbed by visual pigments at the outer segment disk membranes of photoreceptors. 
Visual pigment consists of an α-helical integral membrane protein, opsin, and a chromophore: 
11-cis-retinal, a vitamin A isomer. The interaction between the opsin and 11-cis-retinal determines 
the spectral sensitivity, which is tuned to a particular wavelength of maximal absorption. In cones, 
three types of visual pigment give a continuous range of colors to our sight in photopic, i.e., bright 
conditions. Rods have one type of visual pigment for scotopic, i.e., dim conditions.47 When a 
photon is absorbed, 11-cis-retinal isomerizes to all-trans-retinal. This triggers a chain of enzymatic 
reactions, eventually leading to membrane hyperpolarization and neurotransmitter release at the 
photoreceptor terminal synapse.48, 49 Recovery starts after phototransduction, where all-trans-retinal 
dissociates from the opsin. After being transported from the lumen into the cytoplasmic space by 
ABCA4, all-trans-retinal is reduced to all-trans-retinol and then transported to the retinal pigment 
epithelium. In several steps, all-trans-retinol is then finally converted to 11-cis-retinal.
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Classifications of Stargardt disease
Several classifications and staging methods have been described for Stargardt disease. 
These classifications are based on the extent of retinal abnormalities, electrophysiologic 
findings and genotype-phenotype correlations (Table 1).
Fishman et al. differentiated four distinct retinal features that reflect the phenotypes 
of Stargardt disease: [I] an atrophic-appearing macular lesion with localized perifoveal 
flecks, [II] retinal flecks throughout the posterior pole, [III] resorbed flecks, and [IV] 
extensive atrophic-appearing changes of the retinal pigment epithelium and choroid.50,51
Lois et al. suggested phenotypic subtypes of Stargardt disease based on electroretinog-
raphy. Electroretinography measures the total electrical activity response from cones and 
rods to a light stimulus. The International Society for Clinical Electrophysiology of Vision 
(ISCEV) provides the minimum standard of measurements for electroretinography.52 
Full-field electroretinography is used to study the total degree of retinal dysfunction, in 
which the rod system is measured in dark-adapted conditions (dim flash, 0.01 cd·s/m² 
and bright flash, 11.0 cd·s/m²). The cone system is measured in light-adapted conditions 
(3.0 cd·s/m² at 2 Hz and 30 Hz). Pattern electroretinography provides information about 
macular and retinal ganglion cell function (using a temporally modulated patterned 
stimulus). In Stargardt disease, three patterns of retinal potentials were identified 
based on measurements of these ISCEV standards. The first pattern comprises severe 
pattern electroretinography abnormality with normal full-field electroretinography. It 
reflects dysfunction confined to the macula. The second pattern includes a general-
ized cone system dysfunction, consistent with a clinical diagnosis of cone dystrophy. 
The third includes both cone and rod system dysfunction, i.e., cone-rod dystrophy
(Figure 8).53-55
Van Driel et al. proposed a classification based on the expected residual function of the 
ABCA4 protein by the severity of mutations (Figure 9).56 Missense variants are generally 
Phenotype according to Fishman.
Stage I Stage II Stage III Stage IV
Atrophic macular lesion with 
localized flecks
Retinal flecks throughout 
posterior pole
Resorbed flecks Extensive atrophic-
appearing changes of retinal 
pigment and choroid
Electroretinography according to Lois.
Group 1 Group 2 Group 3
Severe pattern ERG abnormality Additional generalized
cone dysfunction
Additional generalized
rod dysfunction
Genotype according to Van Driel.
Mild Moderate Moderate/severe Severe
(Risk for) age-related 
macular degeneration
Stargardt disease Cone-rod dystrophy Retinitis pigmentosa
Table 1. Classifications and staging of Stargardt disease. ERG = electroretinography.
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associated with mild, late-onset disease, while severe “null” variants, which result in 
zero protein function, are associated with severe, early-onset disease.56-59 The classifi-
cation extends the putative associations of ABCA4 variants from the presumed mildest 
phenotype of age-related macular degeneration (one mild ABCA4 variant) to the most 
severe phenotype of retinitis pigmentosa (two severe ABCA4 variants). Arguably, vari-
ants in the ABCA4 gene are also associated with cone dystrophy, cone-rod dystrophy 
and atypical retinitis pigmentosa.56, 60-65
Figure 8. Electroretinographic findings in Stargardt disease. Group 1, severe pattern 
electroretinographic abnormality; group 2, additional generalized cone dysfunction; group 3, additional 
generalized rod dysfunction. ERG = electroretinography.
Dark-adapted
dim flash
(0.01 cd·s·m-2)
Dark-adapted
bright flash
(11.0 cd·s·m-2)
Light-adapted
30 Hz flicker
(3.0 cd·s·m-2)
Light-adapted
2 Hz
(3.0 cd·s·m-2)
Pattern ERG
Normal Normal orage-related macular degeneration
Stargardt
disease
Cone-rod
dystrophy
Retinitis
pigmentosa
ABCA4
protein function
Allele 1
Allele 2
Phenotype
Wild type
Mild variant
Moderate variant
Severe variant
Figure 9. Genotype-phenotype correlation model adapted from Van Driel et al. 
11 • CHAPTER 1: Introduction
Management and treatment
Currently, patients are advised to avoid excessive light exposure, e.g., by wearing 
ultraviolet-protective sun glasses. Bright ultraviolet light has been demonstrated to 
accelerate retinal degeneration in animal models66, 67 and there are some indications 
that total blockage of light slows down disease progression.68 Patients are also advised 
not to take vitamin A supplementation, which is supported by animal studies showing 
accelerated accumulation of lipofuscin with vitamin A supplementation.20, 69 Despite the 
lack of sound evidence, these measures will probably prevent an accelerated disease 
progression. 
However, no treatment is readily available to slow or stop disease progression. Gene 
therapies, cell-based therapies, as well as pharmacological therapies trials are now in 
progress. Gene therapy aims to slow down or prevent retinal regeneration by target-
ing intact photoreceptors and is therefore preferable in the earliest disease stages. A 
Phase I/II clinical trial is now ongoing where a functional ABCA4 gene will be injected 
subretinally using a lentiviral vector SAR422459. A proof of concept has already been 
demonstrated in animal studies,70-72 and there have been no safety concerns in humans, 
although there has not been any evidence of efficacy until now.73 Stem cell therapy aims 
to replace lost retinal pigment epithelium cells, which can be useful in late disease stages. 
A Phase I/II trial using human embryonic stem cell derived retinal pigment epithelium 
cells also showed no safety concerns,74, 75 but as the defective ABCA4 protein function is 
not corrected, it may be insufficient to slow down disease progression. Finally, pharma-
cological strategies are being developed to target several aspects of the retinoid cycle, 
and include phloroglucinol, fenretinide and C20-D3-vitamin A.76-78
1.2 A history of treatment evaluation
These new treatments need to be carefully evaluated to understand their potential 
effects. Support of the highest level of empirical evidence is required to eventually come 
toward an effective treatment. Nowadays, this process is known as a clinical trial: the 
bedrock of evidence-based medicine. “Evidence-based medicine is the conscientious, 
explicit, judicious and reasonable use of modern, best evidence in making decisions 
about the care of individual patients.” 79 It integrates the best available empirical evi-
dence, thus not solely based on theories and intuition. Both clinical expertise as well 
as external evidence are to be combined to achieve the best practice for the individual 
patient. Without clinical trials, we may conclude that useless treatments are helpful, or 
that helpful treatments are useless. Although the standards in science have evolved 
significantly, their basic concepts still hold—and continue to be refined.
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In the 1990s, David Sackett brought the ‘art of medicine’ forward from expert opinion-
based practice on to a new paradigm for health care which stresses on evidence from 
clinical research.80 Although Sackett is considered the pioneer of evidence-based 
medicine, its origins are ancient.
Fair comparisons
During the Siege of Jerusalem (597 BC), Daniel proposed King Nebuchadnezzar II of the 
Neo-Babylonian Empire a trial to prove he could be fit for service having only vegetables 
and water instead of wine and meat; after ten days, Daniel’s group appeared to be 
healthier and stronger than the royal children who dined at the King’s table.81 Arguably, 
this was the first reported clinical trial.82 Indeed, he followed two of its basic: [1] two 
groups with different treatments, and [2] a finite length for outcome evaluation.
However, it was not until 
the Islamic Golden Age (9th 
century) that the need for 
comparison with a similar 
untreated control group 
was recognized by some 
of the greatest luminaries 
in medicine that time. 
The Persian Al-Razi, a 
pioneer in neurology and 
ophthalmology, detested 
theoretical conclusions 
that did not correlate with 
clinical findings. Therefore, 
he refined his treatments by 
testing the validity of ther-
apies and theories in practice, one of which included bloodletting for early symptoms 
of meningitis. Although bloodletting would not be recommended today, his approach 
reflects the essential feature of a fair comparison by treating one group and intentionally 
withholding treatment from the other group.83, 84 
Ibn Sīnā wrote the Al-Qanun fi al-Tibb (Canon of Medicine) in 1012. This book contained 
rules for assessing the effects of drugs. He argued that not only theories “dealing with 
the principles of medicine” are important, but empirical observations “how to put those 
principles into practice” as well.85 European and Middle Eastern countries had relied on 
his work for over six centuries, and is still very relevant today. 
Figure 10. James Lind on board the H.M.S. Salisbury treating 
sailors for scurvy. His experiment is considered to be the first 
prospective controlled clinical trial.
Robert A. Thom, A History of Medicine in Pictures.
© Parke-Davis and Company, 1957
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Several centuries later, James Lind, a Scottish naval surgeon conducted a now famous 
prospective controlled trial. Back then, many sailors suffered from scurvy in a few 
months at sea. Lind hypothesized that citrus fruits could cure scurvy. In 1747, he divided 
twelve scurvy patients on board the Salisbury into six pairs. Everyone had the same 
diet, but, in addition, the first pair was given a cider, the second elixir vitriol, the third 
vinegar, the fourth seawater, the fifth oranges and lemon, and the sixth a spicy paste 
with barley water (Figure 10, previous page). The sailors who received the oranges and 
lemon clearly recovered from scurvy within a week. Nowadays, James Lind is commonly 
regarded as the father of clinical trials.86
Double-blind randomized controlled trials
From 1800 onwards, study design became increasingly important for clinical trials. In 
1894, the ophthalmologist Webster Fox performed an immediate capsulotomy follow-
ing the removal of cataract with alternating cases to allocate his patients, and concluded 
there was less danger of inflammation than when this capsulotomy was performed in a 
separate intervention later.87 Treatment allocation by alternating cases is a randomiza-
tion method to prevent foreknowledge of treatment assignments. 
The first randomized trial in ophthalmology was performed by Arnall Patz, comparing 
a high or low oxygen routine for ‘retrolental fibroplasia’ (retinopathy of prematurity) 
on a random basis, enabling unbiased analysis of the results. At the end of the first 
year, seven of twenty-eight infants in the high-oxygen group had advanced retrolental 
fibroplasia, but none of the thirty-seven cases on low oxygen.88
After World War II, the randomized clinical trial methodology developed rapidly, which 
also occurred in the field of ophthalmology with the foundation of the National Eye 
Institute, prioritizing careful trial design, of which the Diabetic Retinopathy Study is one 
of the best-known studies.89
Clinical endpoints
An important issue on trial design that still holds through time is choosing the right 
endpoint: an endpoint which is able to evaluate the safety and effectiveness of new 
treatments. An endpoint needs to distinguish a potential treatment effect from the 
effect of time. To identify such endpoints, natural history studies are needed. In 1364, 
Francesco Petrarca already stressed the effect of nature’s time, proposing trials whether 
people would be better off relying on nature rather than seeking medical treatment.90
The quality-adjusted life years won are the eventual outcomes that matter to patients. 
However, this clinical endpoint would require long follow-up when it is used as the 
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primary outcome of interventional trials. Besides clinical meaningfulness, an endpoint 
should also be feasible, reliable and sensitive. Such an endpoint may be found in other 
measurements which are expected to reflect changes in a clinically meaningful end-
point. They can enable the design of clinical trials with short observation times and 
small group sizes, and consequently allow a larger number of candidate drugs to be 
tested in a less costly and time-consuming way. Outcomes, intended to substitute for a 
clinical endpoint, are so-called surrogate outcomes. It is a ‘biomarker’, i.e., a laboratory 
measurement or physical sign which is used in therapeutic trials as a substitute for the 
eventual clinical endpoint.91 
1.3 Toward clinical trials for Stargardt disease
The past few decades have seen considerable advances in our understanding of clinical 
phenotypes, natural history, and molecular genetics of rare inherited retinal diseases, 
including Stargardt disease.92 These advances have led to the first steps to a cure with 
gene therapy,70, 71 cell-based therapy,74, 75 and pharmacological therapy.77, 78 To come 
toward an effective treatment for Stargardt disease, we need to achieve the best pos-
sible level of empirical evidence. Several clinical safety trials have passed and have now 
proceeded to the next phase, in which the efficacy of therapy is being studied.
Clinical trials for Stargardt disease face unique, but evident challenges because of inher-
ent small populations amenable to treatment and vast heterogeneity within that group. 
Stargardt disease has a remarkable wide range of severity both at clinical presentation 
and natural progression. These features are still incompletely described, and conse-
quently difficult to be recognized. Such difficulties lead to failure in detecting significant 
efficacy changes at follow-up. Moreover, obtaining an accurate description of the full 
spectra of Stargardt disease also has important implications for selecting patients to 
participate in clinical trials. The aforementioned classifications based on electrophys-
iological findings, genotypic and phenotypic characteristics are helpful in describing 
general characteristics, but still do not suffice; evidence on any therapeutic effects in 
ongoing trials is still lacking.
Despite the challenges, access to a treatment can only be provided by regulatory 
approval similar to common diseases, and thus requires establishment of its effective-
ness by evidence.93 A randomized-controlled design is still considered the gold standard 
to adjudicate therapeutic efficacy, and includes an appropriate sample size, statistical 
power, and methods to minimize bias94; all of which has been learnt since the Iron Age. 
However, this is unfeasible with conventional methods in diseases with a low preva-
lence, and potentially individually tailored therapies with specific trial populations.95, 96 
Clinical trials need to be adapted to small populations.
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1.4 Aims of this thesis
This thesis provides a strategy for future studies which aim to identify an effect of novel 
treatments in Stargardt disease. Herein, not only do the challenges of treatment eval-
uation which have been present since ancient history still apply, but its rare nature and 
vast heterogeneity also pose additional challenges. These challenges can be overcome 
by three universal steps:
• Evaluate the effect of nature’s time (Chapter 2)
• Select the right patients (Chapter 3)
• Choose the appropriate method for outcome evaluation (Chapter 4)
Natural history of Stargardt disease
Chapter 2 describes unique phenotypic and genotypic characteristics of subgroups 
within the vast heterogeneity of Stargardt disease, established in the context of pre-
viously emerged classifications and staging.50, 53, 56 Deep phenotyping will help identify 
which patients can benefit most from new treatments, and which features are most 
important to measure in clinical trials. The results are supported by genetic charac-
teristics. Understanding of the natural history provides the basis to create models to 
describe disease progression.
Diagnosing Stargardt disease
Chapter 3 reveals challenges in the clinical diagnosis of Stargardt disease from the very 
limited retinal abnormalities in young patients in early diagnosis to the abnormalities 
mimicking age-related disease in older patients. Early and correct diagnosis is of para-
mount importance in patient selection at the right time for the right trials.
Measuring progression in Stargardt disease
Chapter 4 creates models of disease progression in Stargardt disease. It reveals the 
differences in inter-eye concordance between the subtypes of Stargardt disease and 
gives insight into its consequences in clinical trial design. We simulated potential treat-
ment effects in the youngest and the oldest patients and identified the benefits of a 
composite outcome measure to assess efficacy in clinical trials for Stargardt disease. 
Fundus autofluorescence imaging is an important tool to measure disease progression. 
Its potential phototoxic effect will also be discussed here.
General discussion
Chapter 5 discusses the studies described in this thesis with broad and future perspec-
tives.
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CHAPTER 2
Natural history of
Stargardt disease
“In its natural course, early-onset Stargardt disease initially presents with variable full-field 
electroretinographic abnormalities and funduscopic findings. As this retinal degeneration 
progresses, the spectrum of phenotypes eventually converges, causing profound chorioretinal 
atrophy and severe vision loss.”
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2.1 Early-onset Stargardt disease:
 phenotypic and genotypic    
 characteristics
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OBJECTIVE: To describe the phenotype and genotype of patients with early-onset 
Stargardt disease.
DESIGN: Retrospective cohort study.
PARTICIPANTS: Fifty-one Stargardt patients with age at onset ≤10 years.
METHODS: We reviewed patient medical records for age at onset, medical history, 
initial symptoms, best-corrected visual acuity (BCVA), ophthalmoscopy, fundus photog-
raphy, fundus autofluorescence (FAF), fluorescein angiography (FA), spectral-domain 
optical coherence tomography (SD-OCT), and full-field electroretinography (ffERG). 
The ABCA4 gene was screened for mutations.
MAIN OUTCOME MEASURES: Age at onset, BCVA, fundus appearance, FAF, FA, 
SD-OCT, ffERG, and presence of ABCA4 mutations.
RESULTS: The mean age at onset was 7.2 years (range, 1–10). The median times to 
develop BCVA of 20/32, 20/80, 20/200, and 20/500 were 3, 5, 12, and 23 years, 
respectively. Initial ophthalmoscopy in 41 patients revealed either no abnormalities or 
foveal retinal pigment epithelium (RPE) changes in 10 and 9 patients, respectively; the 
other 22 patients had foveal atrophy, atrophic RPE lesions, and/or irregular yellow-white 
fundus flecks. On FA, there was a “dark choroid” in 21 out of 29 patients. In 14 out of 50 
patients, foveal atrophy occurred before flecks developed. On FAF, there was centrifugal 
expansion of disseminated atrophic spots, which progressed to the eventual profound 
chorioretinal atrophy. Spectral-domain OCT revealed early photoreceptor damage 
followed by atrophy of the outer retina, RPE, and choroid. On ffERG in 26 patients, 15 
had normal amplitudes, and 11 had reduced photopic and/or scotopic amplitudes at 
their first visit. We found no correlation between ffERG abnormalities and the rate of 
vision loss. Thirteen out of 25 patients had progressive ffERG abnormalities. Finally, 
genetic screening of 44 patients revealed ≥2 ABCA4 mutations in 37 patients and single 
heterozygous mutations in 7.
CONCLUSIONS: In early-onset Stargardt, initial ophthalmoscopy can reveal no abnor-
malities or minor retinal abnormalities. Yellow-white flecks can be preceded by foveal 
atrophy and may be visible only on FAF. Although ffERG is insufficient for predicting 
the rate of vision loss, abnormalities can develop. Over time, visual acuity declines 
rapidly in parallel with progressive retinal degeneration, resulting in profound chorio-
retinal atrophy. Thus, early-onset Stargardt lies at the severe end of the spectrum of 
ABCA4-associated retinal phenotypes.
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Introduction
Stargardt disease (STGD1) is the most prevalent inherited juvenile-onset retinal dys-
trophy, with a mean age at onset of 15.2 years.1, 2 The inheritance pattern of STGD1 
is autosomal recessive, and the disease is characterized by the presence of irregular 
yellow-white fundus flecks in the posterior pole.2–4 Over time, the disease progresses to 
include macular depigmentation and chorioretinal atrophy. Typical STGD1 patients have 
normal—or near-normal—panretinal cone and rod function on full-field electroretinog-
raphy (ffERG); however, progressive abnormalities in photopic and scotopic amplitudes 
have been reported.5–7 Blockage of choroidal fluorescence (the so-called dark choroid 
sign) on fluorescein angiography is present in 80% of STGD1 patients.8–10 The afore-
mentioned yellow-white fundus flecks are hyperautofluorescent on fundus autofluo-
rescence (FAF), presumably owing to an accumulation of lipofuscin fluorophores in the 
retinal pigment epithelium (RPE).11, 12 Spectral-domain optical coherence tomography 
(SD-OCT) can reveal changes in the outer nuclear layer, as well as photoreceptor loss, 
RPE abnormalities, and a general thinning of the retina.13
Mutations in the ABCA4 gene have been associated with a spectrum of retinal diseases 
ranging from mild phenotypes (e.g., late-onset STGD1 with relatively preserved visual 
function) to severe, early-onset retinitis pigmentosa accompanied by a rapid loss of 
central and peripheral photoreceptors.14–16 The ABCA4 gene encodes the retinal-
specific adenosine triphosphate-binding cassette transporter.17 ABCA4 is expressed 
in both cones and rods. In rod cells, the ABCA4 protein is localized at the rim of the 
outer segment discs, where ABCA4 transports all-trans-retinal from the lumen of the 
outer segment disc to the cytoplasm of the photoreceptor cell.18 The accumulation 
of all-trans-retinal—and its toxic derivatives—eventually results in the death of RPE 
cells and photoreceptor cells.19–21 The ABCA4 gene has high mutation heterogeneity;
>700 distinct mutations have been identified to date, with a wide range of effects on 
ABCA4 protein function. A model to correlate the phenotype with the functional sever-
ity of the ABCA4 mutation has been proposed.22, 23 According to this model, STGD1 
results from mild to moderate ABCA4 impairment.
Among patients who are diagnosed with STGD1, the disease has remarkably wide clin-
ical variability with respect to the general course of the disease, the retinal features, and 
the electrophysiologic findings.5, 8, 14, 15 Stargardt disease has both genetic and clinical 
overlap with cone–rod dystrophy, and this may cause confusion among general oph-
thalmologists; indeed, diagnosing STGD1 can be challenging at an early age. Therefore, 
obtaining an accurate description of the full spectrum of ABCA4-associated retinal dys-
trophies—including STGD1—is essential for providing appropriate patient counseling 
27 • CHAPTER 2: Natural history of Stargardt disease
and adequate disease management, and may have important implications for selecting 
patients to participate in gene therapy trials. Although clinical features of STGD1 
patients with a very young onset have been described in heterogeneous cohorts,5, 7, 24, 25
there is lack of studies concerning the natural history of these patients. Herein, we have 
provided a comprehensive description of the initial and longitudinal clinical and genetic 
characteristics of a large number of patients with early-onset Stargardt, which we 
defined as an age at onset ≤10 years.
Methods
Patients and genetic analysis
The database of the Department of Ophthalmology at Radboud university medical 
center (Nijmegen, the Netherlands) contains 426 patients with a clinical diagnosis of 
STGD1. For 258 of these patients, the ABCA4 gene was analyzed by the Department 
of Human Genetics at Radboud university medical center (Nijmegen, the Netherlands). 
Known mutations were screened using the arrayed-primer extension microarray (Asper 
Biotech, Tartu, Estonia), and exon duplications and/or deletions were detected using 
multiplex ligation-dependent probe amplification (MRC-Holland P151/P152). If no 
mutations or only a single heterozygous mutation was identified, the exons and intron–
exon boundaries were sequenced using the Sanger method to screen for mutations in 
the other allele. All identified mutations were confirmed using Sanger sequencing. In 
total, 199 patients contained ≥1 mutation in the ABCA4 gene.
Age at onset of disease was defined as the age at which symptoms were first noticed by 
the patient. If this information was not available, we used the patient’s age at which he 
or she first visited an ophthalmologist.
In this study, we included 51 patients with an age at onset of ≤10 years and one of the 
following criteria: ≥2 ABCA4 mutations (n = 37); 1 ABCA4 mutation and the presence 
of yellow-white flecks (n = 7); or in the absence of ABCA4 analysis, the presence of 
yellow-white flecks, and either a dark choroid or an atrophic macular lesion (n = 7).
This study was approved by the Institutional Ethics Committee and was performed in 
accordance with the Declaration of Helsinki. All patients provided informed consent 
before giving a blood sample and receiving additional ophthalmologic examinations.
Clinical Evaluation
We defined the duration of disease as the time interval between the patient’s age at 
onset (defined as described) and the age at the last visit. Best-corrected visual acuity 
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(BCVA) was measured using a Snellen chart, then transformed into the logarithm of 
the minimum angle of resolution (logMAR) for subsequent analysis. A logMAR value 
of 1.9, 2.3, or 2.7 was assigned to the patient’s ability to count fingers, detect hand 
movements, or perceive light, respectively.26 
Fundus characteristics were documented for 41 patients using fundus photography 
(Topcon TRC-50IX, Topcon Corporation, Tokyo, Japan). Fundus autofluorescence was 
performed in 32 patients using a confocal scanning laser ophthalmoscope (Spectralis,
Heidelberg Engineering, Heidelberg, Germany) fitted with an optically pumped 
solid-state laser (488-nm excitation). Atrophic chorioretinal lesions outside the fovea 
were stratified into 2 groups: (1) a patchy pattern consisting of mild disseminated hypo-
autofluorescent spots and (2) sharply demarcated chorioretinal atrophic lesions with an 
absence of autofluorescence; the extent of these lesions was then classified as either
(1) lesions that were limited to the posterior pole, or (2) lesions that extended beyond the 
vascular arcades. Cross-sectional images were obtained for 30 patients using SD-OCT 
(Spectralis, Heidelberg Engineering). Fluorescein angiography (Topcon TRC-50IX,
Topcon Corporation; Spectralis, Heidelberg Engineering) was performed in 32 patients 
to determine the presence or absence of the “dark choroid” sign. 
Full-field ERG was performed in 43 patients in accordance with the guidelines estab-
lished by the International Society for Clinical Electrophysiology of Vision (ISCEV)27 
using either Dawson-Trick-Litzkow electrodes or contact lens electrodes together with 
the RETI-port system (Roland Consults, Stasche & Finger GmbH, Brandenburg an der 
Havel, Germany). Dawson-Trick-Litzkow and contact lens electrodes have similarly high 
signal stability.28 Based on the ffERG results, the patients were assigned to 3 groups 
as described previously5: group 1 consisted of patients with normal ffERG amplitudes, 
group 2 consisted of patients with reduced photopic amplitude (<5% of normal range, 
<78 μV [B-wave]) and normal scotopic amplitude, and group 3 consisted of patients with 
reduced photopic and scotopic amplitudes (<5% of normal range, <263 μV [B-wave]).
Statistical analysis
Data were analyzed using SPSS version 20.0 (IBM Corp, Armonk, NY). Kaplan-
Meier “survival” curves were used to analyze the interval between the age at onset 
and the age at which the following endpoints were achieved: Mild visual impairment 
(≥0.2 logMAR; Snellen ≤20/32), moderate visual impairment (≥0.6 logMAR; 
Snellen ≤20/80), severe visual impairment (≥1.0 logMAR; Snellen ≤20/200), and blind-
ness (≥1.4 logMAR; Snellen ≤20/500).29 Cox regression analysis was used to compare 
the ffERG groups. Differences with a P value of ≤0.05 were considered significant.
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Results
Initial clinical characteristics
A total of 51 patients (28 men and 23 women) were included in this study. The mean
(± standard deviation) age at onset was 7.2 ± 2.2 years (median, 8; range, 1–10).
Visual acuity
In each case, the initial symptom of the disease was a decline in visual acuity noticed 
by the patient, the patient’s parents, or the school physician. Where available 
(n = 41 patients), the mean BCVA at the first visit to an ophthalmologist was 0.51 ± 0.36 
logMAR (median, 0.48; range, 0–1.15), Snellen 20/65. In 13 patients, the vision loss 
was initially unexplained. Six of these 13 patients were diagnosed with functional vision 
loss, and 6 other patients were diagnosed initially with cone–rod dystrophy. Of the 
51 patients, 22 were diagnosed with STGD1 ≥3 years after the initial symptoms 
appeared (range, 3–30).
Retinal features
Ophthalmoscopy performed at the first visit revealed no retinal abnormalities in 10 out 
of 41 patients. Nine additional patients had foveal RPE changes, and the remaining
22 patients had foveal atrophy, atrophic RPE lesions that were not limited to the fovea,
Figure 1. Retinal imaging of patient 4 (age at onset, 6 years; best-corrected visual acuity, 0.24 logMAR, 
Snellen 20/35; ABCA4 genotype, p.Thr983Ala and c.5461-10T>C (p.?)) at 7 (A1,2,3) and 8 (B1,2,3) years of 
age. Initially, only subtle foveal hyperautofluorescence was present (A2); 1 year later, small parafoveal 
hyperautofluorescent flecks were present (the arrow in B2), despite a lack of apparent abnormalities 
on ophthalmoscopy. Spectral-domain optical coherence tomography (SD-OCT) revealed foveal 
thickening of the band representing the external limiting membrane (the arrows in A3–B3). FAF = fundus 
autofluorescence; logMAR = logarithm of the minimum angle of resolution.
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B1 B2
A3
B3
Fundus
photographs FAF SD-OCT
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and/or irregular yellow-white fundus flecks. Fluorescein angiography in 29 patients 
revealed an absence of choroidal fluorescence (the so-called dark choroid) in
21 patients. In patient 4, FAF revealed subtle hyperautofluorescence of the fovea, and 
SD-OCT revealed thickening of what appeared to be the external limiting membrane 
(Figure 1A1,2,3). One year later, this patient developed several small parafoveal hyper-
autofluorescent flecks with no apparent abnormalities on ophthalmoscopy (Figure 1B2).
Electrophysiologic findings
At their first visit, ffERG data were collected for 26 patients, and the patients were 
classified based on their findings. Group 1 (patients with normal photopic and scotopic 
amplitudes) contained 15 patients (58%), group 2 (patients with reduced photopic 
amplitude and normal scotopic amplitudes) contained 4 patients (15%), and group 3
(patients with reduced photopic and scotopic amplitudes) contained 6 patients (23%). 
One patient could not be classified into 1 of these 3 groups because only the scoto-
pic amplitudes were reduced moderately, although no pigmentary retinopathy was 
observed. We found no correlation between the ffERG group classification at the first 
visit and progression toward mild visual impairment (P = 0.485), moderate visual impair-
ment (P = 0.309), severe visual impairment (P = 0.203), or blindness (P = 0.647).
Natural course
The mean disease duration was 17.1 ± 14.5 years (median, 11; range, 0–56). The 
follow-up period ranged from a single examination in 3 patients to 47 years (mean, 
12.4 ± 12.6; median, 9). The clinical and 
genetic characteristics of the patient 
cohort at the last examination are summa-
rized in Table 1.
Figure 2. Kaplan-Meier curves showing the 
cumulative fraction in early-onset Stargardt 
with the following clinical endpoints: mild visual 
impairment (≥0.2 logarithm of the minimum angle 
of resolution [logMAR], Snellen ≤20/32, triangle), 
moderate visual impairment (≥0.6 logMAR; 
Snellen ≤20/80, circle), severe visual impairment 
(≥1.0 logMAR, Snellen ≤20/200, square), and 
blindness (≥1.4 logMAR, Snellen ≤20/500, star). 
Censored observations are depicted as vertical 
bars.
1.0
0.8
0.6
0.4
0.2
0 10 20 30 40
Follow-up since age at onset (years)
C
um
ul
at
iv
e 
fra
ct
io
n
mild visual impairment (≤20/32)
moderate visual impairment (≤20/80)
severe visual impairment (≤20/200)
blindness (≤20/500)
censored
Patient Age at 
onset 
(y)
Age 
(y)*
BCVA
(logMAR 
[Snellen])*
Fundus findings ffERG*† Mutations
Flecks Dark 
choroid
Photopic Scotopic Allele 1 Allele 2
1 7‡ 18 0.30 (20/40) Yes Yes NP NP c.2588G>C, c.656G>C, c.1822T>A
2 8 14 0.89 (20/155) Yes NP NP NP c.5461-10T>C c.5461-10T>C
3 6 17 1.90 (CF) Yes Yes N MR c.5461-10T>C c.5461-10T>C
4 6 8 0.20 (20/32) Yes Yes MR N c.2947A>G c.5461-10T>C
5 6 57 2.30 (HM) Yes Yes ND ND c.768G>T c.443-?_570+?del
6 9 10 0.40 (20/50) Yes Yes SR N c.768G>T NI
7 6 40 1.30 (20/400) Yes NP NP NP c.5461-10T>C c.5714+5G>A
8 4 35 1.90 (CF) Yes Yes MR N c.4462T>C c.2919-?_3328+?del
9 9 25 1.90 (CF) Yes Yes NP NP c.768G>T NI
10 3 36 1.90 (CF) Yes Yes SR SR c.3813G>C NI
11 5 52 2.30 (HM) Yes NP MR MR c.6411T>A NI
12 7 8 1.22 (20/333) Yes Yes MR MR c.768G>T c.5461-10T>C
13 7 7 0.33 (20/43) Yes Yes MR MR NP
14 9 17 1.15 (20/286) Yes No N N c.3874C>T c.6543_6578del
15 3 14 1.00 (20/200) Yes NP N N c.4539+1G>T c.768G>T
16 9 11 1.10 (20/250) Yes No MR N NP
17 10 47 1.90 (CF) Yes Yes SR SR NP
18 7 48 2.30 (HM) Yes NP SR SR c.768G>T c.5461-10T>C
19 6 43 1.90 (CF) Yes NP SR SR c.768G>T c.5461-10T>C
20 8 33 1.10 (20/250) Yes No N N c.5161-5162delAC c.5882G>A
21 8 64 1.90 (CF) Yes NP ND ND c.2947A>G c.4506C>A
22 8 31 1.90 (CF) Yes NP SR SR NP
23 9 51 1.90 (CF) Yes Yes ND ND c.768G>T c.5461-10T>C
24 3 19 1.00 (20/200) Yes No ND N c.5461-10T>C c.6320G>A
25 9 16 1.30 (20/400) Yes NP MR N c.214G>A c.5461-10T>C
26 5 10 1.10 (20/250) Yes NP NP NP c.5762_5763dup c.2919-?_3328+?del
27 10 31 0.40 (20/50) NP§ NP§ NP NP c.455G>A c.5461-10T>C
28 9 19 0.72 (20/105) Yes NP N N c.5461-10T>C NI
29 1 28 1.90 (CF) Yes Yes SR N c.5585-10T>C NI
30 8 26 1.30 (20/400) Yes Yes N N c.5312+1G>A c.286A>G
31 10 22 1.90 (CF) Yes Yes SR N c.2588G>C c.4539+1G>T
32 9 15 0.80 (20/125) Yes Yes NP NP c.2588G>C c.4539+1G>T
33 7 18 1.15 (20/286) Yes NP N N c.1957C>T, c.6320G>A, c.3449G>A
34 10 31 1.15 (20/286) Yes Yes N N c.5461-10T>C c.5537T>C
35 7 11 0.80 (20/125) Yes NP N N c.818G>A NI
36 7 7 0.80 (20/125) No Yes N N c.872C>T;4224G>T c.2947A>G
37 8 22 1.15 (20/286) Yes NP N N c.1822T>A c.5882G>A
38 10 13 0.52 (20/67) No No N N c.5882G>A c.5882G>A
39 10 16 1.15 (20/286) Yes No N N c.768G>T c.1822T>A
40 5 24 1.30 (20/400) Yes Yes MR MR c.768G>T c.5461-10T>C
41 6 22 1.90 (CF) Yes Yes ND ND c.1622T>C;3113C>T c.1622T>C;3113C>T
42 10 22 1.30 (20/400) Yes Yes MR N NP
43 7 19 1.10 (20/250) Yes NP N N NP
44 8 19 1.00 (20/200) Yes NP SR N NP
45 5 15 1.00 (20/200) Yes Yes MR N c.3335C>A c.5461-10T>C
46 7 31 2.30 (HM) Yes No ND MR c.1822T>A c.5461-10T>C
47 9 20 0.85 (20/143) Yes NP N N c.122G>A c.286A>G
48 4 32 1.00 (20/200) Yes NP NP NP c.5882G>A NI
49 8 18 1.00 (20/200) Yes No SR ND c.286A>G c.286A>G
50 9 14 0.80 (20/125) No No ND SR c.4773+1G>A c.5461-10T>C
51 8 43 1.90 (CF) Yes No ND ND c.768G>T c.5113C>T
Table 1. Clinical and genetic characteristics of 51 early-onset Stargardt patients.
* Age, BCVA, and ffERG at last examination.
† The abbreviations reflect the B-wave amplitude: N = normal (equal to or above the lower 5% of the 
range for a normal population: photopic ≥78 μV, scotopic ≥263 μV); MR = moderately reduced (1%-5% or 
normal range: photopic ≥69 μV and <78 μV, scotopic ≥195 μV and <263 μV); SR = severely reduced (<1% of 
normal range, photopic <69 μV, scotopic <195 μV); ND = not detectable (flat amplitudes).
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Visual acuity
A survival analysis yielded a median interval and 95% CI between age at onset and a 
decline in BCVA to mild visual impairment, moderate visual impairment, severe visual 
impairment, and blindness of 3 (95% CI, 1.1–4.9), 5 (95% CI, 2.2–7.8), 12 (95% CI, 
9.3–14.7), and 23 (95% CI, 13.2–32.8) years, respectively (Figure 2). Mean patient age 
at the last recorded visit was 24.9 ± 14.0 years (median, 20; range, 7–64), and mean 
BCVA was 1.29 ± 0.58 logMAR (median, 1.15; range, 0.20–2.30), Snellen 20/386.
Retinal features 
We observed irregular yellow-white fundus flecks in 47 out of 50 patients. These flecks 
were not always evident at the first examination, but they developed within an aver-
age of 2.9 ± 4.1 years (median, 0; range, 0–17) of the first visit. The location of these 
flecks varied among the patients: In 10 patients, the flecks were present exclusively in 
the central macula; in 17 patients, the flecks were scattered throughout the posterior 
pole, but did not extend beyond the vascular arcades; and the remaining 20 patients 
presented with a fundus flavimaculatus pattern with numerous flecks in the central and 
mid-peripheral retina. Foveal atrophy was reported in 38 patients and occurred within 
1.9 ± 3.3 years (median, 0; range, 0–13) of the initial visit. Finally, 14 patients developed 
foveal atrophy before the appearance of fundus flecks (Figure 3A1,2).
 
Long-term follow-up data revealed that the initial foveal atrophy progressed to 
more widespread chorioretinal atrophy. Over time, FAF imaging revealed centrifugal 
expansion of disseminated spots in 30 out of 32 patients with a mean timeframe of 
Figure 3. Fundus photographs and autofluores-
cence (FAF) imaging of patient 37 (age at on-
set, 8 years; ABCA4 genotype, p.Phe608Ile and 
p.Gly1961Glu) at 15 (A1,2) and 22 years (B1,2) of age 
showing isolated foveal pigment alterations and 
a hypoautofluorescent lesion (BCVA, 0.52 logMAR, 
Snellen 20/66). Seven years later (B1,2), yellow-white 
parafoveal fundus flecks (the arrow in B2) devel-
oped (BCVA 1.15 logMAR; Snellen 20/283). BCVA 
= best-corrected visual acuity; logMAR = logarithm 
of the minimum angle of resolution.
A1 A2
B1 B2
FAF
14
7
1
Fundus
photographs
Years after
age at onset
‡ Mean age at onset of the total cohort is used.
§ In the patient’s medical records fundus findings were described “in accordance with Stargardt,” but no 
detailed description or imaging was made and thus were excluded from imaging analysis.
BCVA = best-corrected visual acuity; CF = counting fingers; del = deletion; dup = duplication; ffERG = 
full-field electroretinography; HM = hand movements; logMAR = logarithm of the minimum angle of 
resolution; NI = not identified; NP = not performed. 
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Figure 4. Overview of the natural course of retinal disease in early-onset Stargardt based on find-
ings obtained from 5 separate patients using fundus photography, FAF, and SD-OCT. Early-onset 
Stargardt includes foveal atrophy and parafoveal hyperautofluorescent fundus flecks (A1,2) in an early 
disease stage. On SD-OCT, there is hyperreflective abnormalities in the outer retina, loss of the ellipsoid 
zone, and thinning of the outer nuclear layer (A3). The initial foveal atrophy and parafoveal flecks then 
extend centrifugally (B1,2), and disseminated hypoautofluorescent spots appear (B2). On SD-OCT, there 
is progression of the foveal atrophy, with thinning of the retinal pigment epithelium/Bruch’s membrane 
complex (B3). Further in the course of the disease, the disseminated hypoautofluorescent spots become 
chorioretinal atrophic lesions, the central atrophy expands further (C1,2), and pigmentations (C1) are visible 
as hyperreflective deposits on SD-OCT (C3). Over time, confluence of these lesions evolves centrifugally 
(D1,2), extending beyond the vascular arcades (E1,2), with further retinal thinning and atrophy of the cho-
riocapillaris (D3–E3) visible on SD-OCT. A1,2,3, Patient 1 at age 17; B1,2,3, patient 31 at age 22; C1,2,3, patient 40 
at age 24; D1,2,3, patient 8 at age 36; E1,2,3, patient 5 at age 57. FAF = fundus autofluorescence; SD-OCT = 
spectral-domain optical coherence tomography.
9.8 ± 10.5 years (median, 8; range, 0–40; Figure 4B2). These spots extended beyond the 
vascular arcades in 24 of these 30 patients with a mean of 11.2 ± 11.0 years (median, 
9.5; range, 0–40) after the first visit (Figure 4C2). In 22 out of 32 patients, the spots 
progressed to chorioretinal atrophic lesions after a mean period of 13.5 ± 12.3 years 
(median, 10.5; range, 0–40; Figure 4C2–D2). In 11 of these 22 patients, the conflu-
ence of these lesions extended beyond the vascular arcades after a mean period of 
23.0 ± 0.3 years (median, 23; range, 5–40; Figure 4E2). The 11 patients who presented 
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with the common phenotype of chorioretinal lesions beyond the vascular arcades at the 
final examination initially presented with flecks (n = 3), foveal atrophy (n = 4), or both 
flecks and atrophy (n = 4) at their first examination.
 
Over time, SD-OCT showed thinning of the outer nuclear layer and loss of the ellipsoid 
zone, which preceded loss of the RPE/Bruch’s membrane complex. In addition, hyper-
reflective abnormalities in the outer retina were present (Figure 4A3). Progression 
occurred as an expanding loss of the outer nuclear layer, ellipsoid zone, RPE, and 
choriocapillaris (Figure 4B3–E3). Hyperreflective deposits in the inner layers of the fovea 
developed, corresponding with intraretinal pigmentations on fundus photography 
(Figure 4C1–C3).
Electrophysiologic findings
Follow-up data for 25 patients showed that 4 patients progressed from ffERG group 1 
to group 2 within a mean of 10.5 ± 4.4 years (range, 7–16), and 9 patients progressed 
from group 1 to group 3 within a mean of 27.7 ± 14.4 years (range, 3–47).
Mutation analysis
The ABCA4 gene was screened for mutations in 44 of the 51 patients; the remaining
7 patients refused genetic analysis for personal reasons. In these 44 patients, muta-
tions in the ABCA4 gene were identified in 81 of the 88 alleles (92%). Thirty-three 
of these patients had 2 ABCA4 mutations, 7 patients had 1 mutation, 3 patients had
3 mutations, and 1 patient had 4 mutations. In total, 37 distinct mutations were identi-
fied; these mutations are summarized in Table 2. 
The c.768G>T mutation was identified in 25% of the 44 patients and accounted for 13% 
of all identified mutations. The c.5461-10T>C mutation was identified in 36% of the 
patients and accounted for 22% of all identified mutations. The most prevalent ABCA4 
mutation among Dutch patients with STGD1 (c.2588G>C)23 was identified in only 4% 
of the alleles. Table 3 summarizes the non-missense mutations that were identified in 
this study.
Discussion
In this study, we examined the clinical and genetic characteristics of patients with 
early-onset Stargardt, a disease that lies within the spectrum of retinal phenotypes 
linked with mutations in the ABCA4 gene. Whenever a spectrum of disorders contains 
overlapping phenotypes as the rule rather than an exception, any cutoff point used 
to define a particular disease within that spectrum will be arbitrary. Therefore, we 
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arbitrarily defined “early-onset Stargardt” as occurring with an age at onset of ≤10 years 
of age; this definition enabled us to avoid including patients with a more typical STGD1 
phenotype. Only 4% of the 51 patients in our early-onset Stargardt cohort had visual 
Mutation Effect Allele References
Frequency Percentage
c.122G>A p.Trp41* 1 1 35
c.214G>A p.Gly72Arg 1 1 32
c.286A>G p.Asn96Asp 4 5 36
c.443-?_570+?del p.Arg149fs 1 1 This study
c.455G>A p.Arg152Gln 1 1 32, 37
c.656G>C p.Arg219Thr 1 1 38
c.768G>T p.Val256Val/p.? 11 13 16, 23, 32, 39
c.818G>A p.Trp273* 1 1 This study
c.872C>T p.Pro291Leu 1 1 34
c.1622T>C p.Leu541Pro 2 2 1, 16, 32, 40
c.1822T>A p.Phe608Ile 4 5 1, 23
c.1957C>T p.Arg653Cys 1 1 32, 41
c.2588G>C p.Gly863Ala/p.DelGly863 3 4 16, 18, 23, 32, 42
c.2919-?_3328+?del p.Ser974_Gly1110delinsCys 2 2 23
c.2947A>G p.Thr983Ala 3 4 34
c.3113C>T p.Ala1038Val 2 2 16, 31, 32, 40, 43
c.3335C>A p.Thr1112Asn 1 1 23
c.3449G>A p.Cys1150Tyr 1 1 This study
c.3813G>C p.Glu1271Asp 1 1 This study
c.3874C>T p.Gln1292* 1 1 34
c.4224G>T p.Trp1408Cys 1 1 This study
c.4462T>C p.Cys1488Arg 1 1 1, 8, 44, 45
c.4506C>A p.Cys1502* 1 1 34
c.4539+1G>T p.? 3 4 1, 23, 43, 44
c.4773+1G>A p.? 1 1 This study
c.5113C>T p.Arg1705Trp 1 1 34
c.5161_5162del p.Thr1721fs 1 1 23, 36
c.5312+1G>A p.? 1 1 46
c.5461-10T>C p.? 19 22 16, 23, 47
c.5537T>C p.Ile1846Thr 1 1 23, 45
c.5585-10T>C p.? 1 1 48
c.5714+5G>A p.? 1 1 1, 23, 32, 41, 43
c.5762_5763dup p.Ala1922fs 1 1 34
c.5882G>A p.Gly1961Glu 5 6 18, 31, 32, 44, 49
c.6320G>A p.Arg2107His 2 2 8, 31, 40, 45, 50
c.6411T>A p.Cys2137* 1 1 34
c.6543_6578del p.Leu2182_Phe2193del 1 1 1
Table 2. ABCA4 mutations in early-onset Stargardt patients. References are shown for mutations that 
have been reported previously. del = deletion; dup = duplication; fs = frameshift; ins = insertion; * stop 
signal.
Mutation Protein effect SIFT Polyphen-2 Grantham PhyloP
c.3449G>A p.Cys1150Tyr Not tolerated Benign 194 3.19
c.3813G>C p.Glu1271Asp Not tolerated Possibly damaging 45 6.10
c.4224G>T p.Trp1408Cys Not tolerated Probably damaging 215 5.86
Table 3. Characteristics of the non-missense ABCA4 mutations identified in our cohort study.
The outcome of 2 protein prediction programs (SIFT = tolerated or not tolerated; PolyPhen = benign, 
possibly damaging, probably damaging), together with Grantham (>60 pathogenic) and PhyloP con-
servation score (>2.5 pathogenic), were used to form the final conclusion. Mutations are proposed to be 
pathogenic when ≥2 categories point to pathogenicity.
Early-onset Stargardt disease: phenotypic and genotypic characteristics • 36 
acuity of ≤0.30 logMAR, Snellen <20/40 (measured at age 8 and 18 years of age in 
these 2 patients), compared with 14% to 37% of patients with typical STGD1 and 59% 
of patients with late-onset STGD1.5, 14, 24 Because patients with a relatively good visual 
acuity tended to return less often than those with progressive problems, these data may 
have overrepresented more severe cases. The majority of our patients for whom ffERG 
data were available developed abnormal ffERG amplitudes, consistent with a previous 
report by Fujinami et al.7 However, we found no correlation between the ffERG group 
classifications (which were based on the nature of the ffERG abnormalities) at the age 
of onset and the speed of vision loss in this early-onset Stargardt cohort. This finding 
differs from STGD1 cohorts that included patients with later ages at onset.5, 6 Our find-
ings indicate that early-onset Stargardt can be considered a distinct severe subtype of 
STGD1 that is characterized by early foveal abnormalities and the rapid loss of visual 
function; in contrast, in late-onset STGD1, foveal sparing is common, and visual acuity is 
often preserved to a relatively advanced age.14
Diagnosis
The natural course of early-onset ABCA4-related retinal disease in our cohort reflects a 
broad clinical spectrum both at the time of onset and at follow-up, with varying degrees 
of ffERG abnormalities and yellow-white flecks and/or atrophy at a variety of locations. 
Thus, each combination of electrophysiologic and funduscopic findings could be consid-
ered a unique phenotype at a specific time point. Moreover, these phenotypes changed 
during the course of the disease, suggesting progression of the disease. Because both 
funduscopic and electrophysiologic criteria have been proposed for establishing a 
descriptive diagnosis (e.g., Stargardt disease and cone–rod dystrophy), each individual 
patient can potentially receive several diagnoses at 1 time point and at follow-up. Impor-
tantly, receiving several diagnoses can be extremely confusing to both the patient and 
the referring ophthalmologist.
Nevertheless, we found that the spectrum of fundus presentations in this early-onset 
retinal dystrophy ultimately converges to a single clinical and functional endpoint that 
includes profound chorioretinal atrophy and severe vision loss. Therefore, we propose 
that one diagnosis of “early-onset Stargardt” should be given to patients with early-
onset central retinal dystrophy and ABCA4 gene mutations. This approach provides the 
patient with the benefit of receiving a single diagnosis throughout his or her entire life.
Genotype–phenotype correlation
Because early-onset Stargardt can be considered a severe phenotype, severe combi-
nations of mutations are expected in these patients. In our cohort, the c.768G>T and 
c.5461-10T>C mutations were significantly more prevalent (present in 25% and 36% of 
37 • CHAPTER 2: Natural history of Stargardt disease
our patients, respectively) than in other STGD1 cohorts (8% and 5%, respectively).30, 31
The c.768G>T mutation is predicted to cause a splice defect that leads to nonsense-
mediated decay owing to absence of the corresponding messenger ribonucleic acid; 
this mutation is therefore considered to be a severe pathogenic mutation. In addition, a 
founder effect has been suggested for this mutation owing to the allele frequency of 8% 
among Dutch patients with STGD1.30 On the other hand, the c.5461-10T>C mutation 
does not seem to be pathogenic, because heterologous expression of this mutation 
failed to reveal a splicing defect.32 This mutation is rare among control patients, but is 
present in 5% of patients with general STGD1. Therefore, the c.5461-10T>C mutation 
may be in linkage disequilibrium with another, currently unidentified, severe pathogenic 
mutation.31 Equally important, the most prevalent ABCA4 mutation among Dutch 
patients with STGD1—c.2588G>C, which was reported in approximately one third of 
typical STGD1 cases33—was present in only 4% of the ABCA4 alleles in our cohort of 
patients with early-onset Stargardt. To date, no homozygous carriers of this mutation 
have been identified,23 supporting the hypothesis that this is a relatively mild mutation. 
The low prevalence of this presumably mild mutation in our cohort is consistent with a 
previously proposed genotype–phenotype model that correlates the degree of residual 
ABCA4 activity with the severity of the phenotype.17, 23
We identified ABCA4 mutations in all of our patients who received genetic screening; 
in contrast, the detection rate in routine clinical practice is 73%.34 This difference can 
be explained—at least in part—by the inclusion criteria; patients who lacked a detected 
ABCA4 mutation only would have been included if yellow-white flecks and either a dark 
choroid or an atrophic macular lesion were present. However, our database did not con-
tain such patients who received genetic screening and had an early-onset disease. This 
finding supports the notion that early onset is highly predictive for identifying ABCA4 
mutations,34 possibly because of the relatively higher percentage of severe mutations, 
which are more readily identified and/or recognized.
It remains unclear why the fovea is affected early in the course of STGD1 in some 
patients, whereas it can be spared—even for many decades—in other patients carrying 
compound heterozygous mutations, including 1 severe ABCA4 mutation.14, 15 Other 
factors must therefore play a role in the development of foveal atrophy in early-onset 
Stargardt; possible factors can include pathogenic mutations or single nucleotide 
polymorphisms in genes other than ABCA4, as well as aberrant cellular processes. For 
example, the accumulation of all-trans-retinal in photoreceptor cells can directly increase 
cellular stress, thereby triggering apoptotic signaling pathways.35 Next-generation
sequencing of all retina-specific genes may help to identify the genetic factors that 
determine whether or not the fovea is involved early in the course of STGD1.
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Clinical Significance
Although diagnosing STGD1 at an early age is challenging, delaying diagnosis can have 
serious consequences. For example, 22 patients in our study did not receive the correct 
diagnosis for ≥3 years, and vision loss was initially unexplained in 13 patients. Recogniz-
ing early-onset Stargardt early in the disease course enables the timely start of potential 
measures—such as sunlight protection and low-vision counseling—and can prevent the 
inappropriate prescription of vitamin A supplements. Therefore, patients who are sus-
pected of having early-onset Stargardt should be examined thoroughly using FAF and 
SD-OCT, particularly when no abnormalities (or mild foveal abnormalities) are present 
in a child with central vision loss that is otherwise unexplained. This diagnosis should 
also be confirmed by screening for the presence of ABCA4 mutations. Finally, in light 
of future therapeutic options, such as gene therapy for treating ABCA4-related retinal 
disorders, obtaining a thorough understanding of the phenotypic spectrum and clinical 
course of STGD1 is essential for identifying the patients who will benefit most from 
these treatments.
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2.2 Progression of 
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PURPOSE: Identification of sensitive biomarkers is essential to determine potential 
effects of emerging therapeutic trials for Stargardt disease. This study aimed to describe 
the natural history of late-onset Stargardt, and demonstrates the accuracy of retinal 
pigment epithelium (RPE) atrophy progression as an outcome measure.
METHODS: We performed a retrospective cohort study collecting multicenter data 
from 47 patients (91 eyes) with late-onset Stargardt, defined by clinical phenotype, 
at least one ABCA4 mutation, and age at disease onset ≥45 years. We analyzed RPE 
atrophy progression on fundus autofluorescence and near-infrared reflectance imaging 
using semiautomated software and a linear mixed model. We performed sample size 
calculations to assess the power in a simulated 2-year interventional study and assessed 
visual endpoints using time-to-event analysis.
RESULTS: Over time, progression of RPE atrophy was observed (mean, 0.22 mm/
year; 95% confidence interval [CI], 0.19–0.27). By including only patients with bilateral 
RPE atrophy in a future trial, 32 patients are needed to reach a power of 83.9% (95% 
CI, 83.1–84.6), assuming a fixed therapeutic effect size of 30%. We found a median 
interval between disease onset and visual acuity decline to 20/32, 20/80, and 20/200 of 
2.74 (95% CI, 0.54–4.41), 10.15 (95% CI, 6.13–11.38), and 11.38 (95% CI, 6.13–13.34) 
years, respectively.
CONCLUSIONS: We show that RPE atrophy represents a robust biomarker to monitor 
disease progression in future therapeutic trials. In contrast, the variability in terms of the 
course of visual acuity was high.
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Introduction
Stargardt disease is an autosomal recessive retinal dystrophy caused by mutations in 
the ABCA4 gene, and affects 1:8000 to 1:10,000 people worldwide.1 Patients generally 
develop central loss of vision in childhood or early adulthood.2-4 However, late-onset 
Stargardt can be diagnosed at age ≥45 years, and has been associated with carrying one 
or two mutant ABCA4 alleles.5, 6 Patients with this late-onset variant may first present 
with metamorphopsia or oscillopsia without any decrease in visual acuity. Occasionally, 
these patients are asymptomatic and are coincidentally diagnosed during screening 
tests for other retinal diseases, such as glaucoma, diabetes or thyroid disease.
 
The natural course of late-onset Stargardt includes a typical phenotype of yellow-white 
flecks and retinal pigment epithelium (RPE) atrophy. Patches of atrophy initially occur 
in the parafoveal retina and radially expand in size over time. New atrophic areas can 
arise; multifocal atrophic areas coalesce. Atrophic areas can form a ring encircling the 
intact and still-functioning fovea. Then, it is only until late in the disease course that the 
fovea will be involved in the atrophic process.7-9 The patient’s fixation point eventually 
shifts eccentrically, which leads to a substantial loss of visual acuity.10 However, central 
atrophy can also develop early in the disease course, and only minor disease progression 
has been described in other patients.5 Indeed, substantial variations in RPE atrophy 
progression have been reported before in small groups of typical Stargardt patients.11 
Yet analyses of the natural course of large late-onset Stargardt cohorts are missing. 
In light of recently upcoming therapeutic options for Stargardt disease,12-14 accurate 
biomarkers to determine their potential effects are crucial. The well-defined area of RPE 
atrophy is a frequent feature of late-onset Stargardt, showing similarities to geographic 
atrophy in age-related macular degeneration (AMD). Fundus autofluorescence (FAF) 
imaging can clearly visualize such areas of RPE atrophy,15, 16 and change in RPE atrophy 
over time by FAF has already been accepted as a clinical endpoint by the U.S. Food and 
Drug Administration in AMD.17 We hypothesize that areas of RPE atrophy could also 
serve to sensitively monitor the effect of a drug trial in late-onset Stargardt. This would 
make patients with late-onset Stargardt appropriate candidates for upcoming therapeu-
tic trials. In this study, we describe the natural history in late-onset Stargardt patients, 
and identify cohorts based on imaging parameters that determine the visual course in 
these patients. We quantify atrophy progression with semiautomated software, previ-
ously validated for AMD,18 showing the accuracy of this outcome measure, and include 
sample size calculations that are valuable for the design of upcoming therapeutic trials. 
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Methods
Patient selection
We identified patients from the Stargardt database of the Department of Ophthal-
mology at Radboud university medical center (Nijmegen, the Netherlands) and from 
the participants in the prospective natural history study Fundus Autofluorescence in 
Age-related Macular Degeneration (FAM; ClinicalTrials.gov, NCT00393692). 
We included 47 patients with a late disease onset, defined by an age ≥45 years at which 
symptoms were first noticed.5 If the patient did not report any symptoms, we used the 
age at which the patient was diagnosed by an ophthalmologist. We clinically considered 
patients to have late-onset Stargardt when typical yellow-white flecks or dots were 
seen that correlated with hyperautofluorescent flecks on 488-nm FAF imaging. 
Patients were analyzed for the presence of mutations in the adenosine
triphosphate-binding cassette, subfamily A, member 4 (ABCA4, NM_000350.2) gene. 
Clinical diagnosis was confirmed by genetic testing if at least one ABCA4 mutation was 
found. We excluded patients without evidence of ABCA4 mutations. In patients carry-
ing only one ABCA4 mutation, we performed additional sequencing of the peripherin-2 
gene (PRPH2, NM_000322.4) to exclude pseudo-Stargardt pattern dystrophy and 
central areolar choroidal dystrophy.19, 20
This cohort study was carried out with approval from the Institutional Ethics Committee 
at Radboud university medical center (Nijmegen, the Netherlands) and the University 
Hospital of Bonn (Bonn, Germany), and adhered to the tenets of the Declaration of 
Helsinki. All patients provided informed consent before giving a blood sample and 
receiving additional ophthalmologic examinations to complete the clinical assessment. 
Clinical assessment
We reviewed the patients’ records for ophthalmologic history and available technical 
examinations, including sex, age at disease onset, and age at baseline. Best-corrected 
visual acuity (BCVA) was measured using a Snellen or Early Treatment Diabetic Retinop-
athy Study (ETDRS) chart, then transformed into the logarithm of the minimum angle of 
resolution (logMAR) for subsequent analysis. Fundus characteristics were documented 
using fundus photography (Topcon TRC-50IX; Topcon Corporation, Tokyo, Japan; or 
Visucam 500; Carl Zeiss Meditec, Jena, Germany). Fundus autofluorescence (λ = 488 nm;
emission 500–700 nm) and near-infrared reflectance (NIR; λ = 820 nm) imaging were 
performed using a confocal scanning laser ophthalmoscope (Spectralis HRA+OCT or 
HRA2; Heidelberg Engineering, Heidelberg, Germany) in a subset of visits. The field of 
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view was set at 30°×30° or 55°×55° and was centered on the macula. Eyes with signs of 
choroidal neovascularization were excluded from further analysis. 
Image grading and cohorts
For each visit, two independent graders (M.F. and M.L.), blinded to each other’s results, 
evaluated the status of the fovea and the presence of clearly demarcated RPE atrophy 
(analogous to “definitely decreased autofluorescence,” the term recently used by 
Kuehlewein et al.21) on all available imaging modalities. Atrophy was graded as follows: 
(1) no RPE atrophy with an intact fovea, (2) extrafoveal (but not fovea encircling) 
RPE atrophy, (3) a typical “foveal sparing” phenotype in which RPE atrophy encircled 
the fovea by ≥180°,10 or (4) foveal involvement. Foveal involvement was indicated 
by a mottled or absent autofluorescent signal (equaling what was ultimately termed 
“well-/poorly demarcated questionably decreased autofluorescence”21). In cases of 
discrepancy, a third grader (S.L.) evaluated the images. His agreement with one of the 
independent graders was finally used. Based on this grading, eyes were exploratively 
analyzed in order to form cohorts that might be predictive for visual acuity loss. 
Quantitative measurements of retinal pigment epithelium atrophy
Two independent graders (M.F. and M.L.), blinded to each other’s results, performed 
measurements of the area of RPE atrophy using the RegionFinder software (version 
2.5.5.0, Heidelberg Engineering) on FAF images, as previously established for AMD.18 
In cases in which the foveal borders of the atrophy could not be well determined in FAF 
images, NIR images were included in the analysis wherever available.22 The final value 
was defined as the average of the two measurements between the readers, provided that 
the two measurements did not differ by >0.15 mm2. If the difference exceeded 0.15 mm2,
a senior reader (M.M.M.) additionally performed the measurement.18 We calculated the 
final value by averaging the senior reader measurement along with the closer of the two 
other reader measurements. 
Statistical analysis
We analyzed data using SAS Statistical Analysis Software Version 9.2 (SAS Institute, 
Cary, NC, USA) and R Version 3.1.2.23. Supplemental Figure S1 gives an overview of the 
analytical process applied in this work. Changes in visual acuity over time were assessed 
by time-to-event curves (cumulative distribution functions), and atrophy progression 
was analyzed using linear mixed-effects models. We performed a simulation study for 
power calculation for possible future interventional trials. Unless otherwise stated, all 
values given in the text represent median, minimum, and maximum values. Groups were 
compared by Mann–Whitney U tests. Details on the statistical procedures can be found 
in Supplemental Text S1. 
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Results
Patient features and initial symptoms
A total of 91 eyes of 47 patients (19 men, 28 women) were included in this study. Two 
mutations in the ABCA4 gene were found in 20 patients (42.6%) and one mutation in
27 (57.4%; Supplemental Table S1). The median age at disease onset was 54 years (range, 
45–84). Self-reported initial symptoms were obtained for 42 patients and included 
a decrease in visual acuity (n = 24; 50%), metamorphopsia (n = 12; 29%), nyctalopia
(n = 5; 12%), paracentral scotomas (n = 4; 10%), or oscillopsia (n = 1; 2%). Twelve 
patients (29%) did not report any visual complaints. In five patients, initial symptoms 
were not unequivocally denoted in the patient’s file. 
Course of visual acuity
Overall, visual acuity data were available from 632 eye visits. At the first presentation 
after disease onset, the median disease duration was 0.9 years (range, 0–25.6) with 
a median BCVA of 0.10 logMAR (range, −0.14 to 1.70; Snellen 20/25). The median 
follow-up time of the patients with more than a single visit (45 out of 47 patients) was 
4.8 years (range, 0.04–25.0). Time-to-event analysis yielded a median and 95% con-
fidence interval (CI) between the age at onset and a decline in BCVA to mild visual 
impairment (n = 62), moderate visual impairment (n = 39), and severe visual impairment
(n = 35) of 2.74 (0.54–4.41), 10.15 (6.13–11.38), and 11.38 (9.34–13.34) years, respec-
tively (Figure 1). The median disease duration at the final visit was 6.8 years (range, 0–30.9). 
The median BCVA at the final visit was 0.37 logMAR (range, −0.10 to 1.80; Snellen 20/47). 
Assessment of retinal features
For each patient, clinical imaging data 
were available for a subset of visits
(241 eye visits of 91 eyes). At baseline 
(first visit with imaging data available), 
yellow-white flecks were observed in all 
but one patient, in whom small yellowish 
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Figure 1.  Time-to-event curve (computed as 
1 minus the Turnbull estimates) showing the 
cumulative fraction of eyes in late-onset Star-
gardt patients reaching the following clinical 
endpoints: mild visual impairment (≥0.2 logMAR, 
Snellen ≤20/32; triangle), moderate visual impair-
ment (≥0.6 logMAR, Snellen ≤20/80; square), and 
severe visual impairment (≥1.0 logMAR, Snellen 
≤20/200; circle). logMAR = logarithm of the mini-
mum angle of resolution.
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spots were noted. An apparently intact fovea (Figure 2A) without mottled or sharply 
decreased autofluorescence indicating RPE atrophy was present in 58 eyes. Out of these 
58 eyes without foveal involvement, 22 had no RPE atrophy (Figure 2B), 16 had extra-
foveal (but not fovea encircling) atrophy (Figure 2C), and 20 had a foveal sparing pattern 
of RPE atrophy encircling the fovea ≥180° (Figure 2D). The other 32 eyes had an involved 
fovea by either a mottled appearance (23 eyes; Figure 2E) or central RPE atrophy (9 eyes; 
Figure 2F). One eye was excluded because it was inconclusive if the fovea appeared 
mottled. There was no significant difference in patient’s age between eyes that initially 
had foveal involvement and those that did not (median, 60.4 [n = 32] and 61.0 years
[n = 58] respectively; P =0.421). 
Cohorts
Assessment of retinal features over the entire imaging interval (Table 1) enabled us 
to categorize the eyes into four clearly distinctive cohorts. During the entire follow-up 
period, 20 eyes (22.2%) showed only flecks without any mottled foveal alterations 
or RPE atrophy (cohort I). Eleven eyes (12.2%) showed extrafoveal (but not fovea 
encircling) RPE atrophy (cohort II). Twenty-six eyes (28.9%) developed foveal sparing 
(RPE atrophy encircling the fovea ≥180°; cohort III). In four of these 26 eyes, the fovea 
eventually involved in the atrophic process at the last visit. Thirty-three eyes (36.7%) 
had eventual foveal involvement without passing through a foveal sparing phenotype 
during the observational interval (cohort IV). 
Figure 2.  The assessment of retinal features in late-onset Stargardt patients was done by grading 
foveal involvement and RPE atrophy. The foveal signal (triangles) was graded as either (A) “uninvolved/
normal” or (E) “involved” (mottled or absent). RPE atrophy (asterisks) was graded as (B) none, (C) extra-
foveal but not fovea encircling, (D) foveal sparing ≥180° encircling the fovea, or (F) central RPE atrophy. 
RPE = retinal pigment epithelium.
No foveal involvement Foveal involvement
No RPE atrophy Extrafoveal RPE atrophy
(not encircling the fovea)
Foveal sparing
(RPE atrophy encircling ≥180°)
Central RPE atrophy
Normal foveal signal Mottled appearance
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The median follow-up periods of the entire imaging interval of cohorts I, II, III, and IV 
were 3.4 (range, 0–10.4), 3.3 (range, 0.1–11.7), 8.7 (range, 2.1–30.9), and 11.4 (range, 
0.3–30.9) years, respectively. Eyes in cohorts I and II had a median disease duration of 
3.4 years (range, 0–11.7), which was shorter (P = 1.0 × 10−6) than in cohort III and IV 
(median, 11.0 years; range, 0.3–30.9). 
Based on the morphologic observation of distinct cohorts among collective late-onset 
Stargardt patients, we further analyzed eyes with long follow-up grouped into the 
“foveal sparing” (cohort III) and “foveal involvement” (cohort IV) cohorts for possible 
distinctive long-term visual courses among these cohorts. Eyes that formed foveal spar-
ing cohort III took an overall favorable visual course when compared to eyes from foveal 
involvement cohort IV. Survival analysis for the endpoints ≥0.2 logMAR, ≥0.6 logMAR, 
At baseline Clinical course Resulting 
cohortInitial features Eyes Median visual 
acuity,
logMAR (range)
Change in features Median visual acuity,
final visit, 
logMAR (range)
No foveal involvement
No RPE atrophy 22 0.10 (-0.20 to 0.64) 20 unchanged
2 eyes developed extrafoveal atrophy
0.06 (-0.06 to 0.58)
-0.02 (-0.06 to 0.02)
I
II
Extrafoveal but not 
fovea encircling
16 0.05 (-0.10 to 0.72) 9 unchanged
6 progressed to foveal sparing
1 developed foveal involvement
0.12 (0 to 1.54)
0.44 (-0.06 to 0.74)
0.36
II
III
IV
Foveal sparing 
encircling ≥180°
20 0.12 (0 to 0.52) 16 unchanged
4 eyes loss of foveal sparing
0.22 (-0.04 to 1.80)
1.25 (0.94 to 1.50)
III
III
Foveal involvement
Central RPE atrophy 
 
9 0.98 (0.30 to 1.50) IV
Mottled 23 0.30 (-0.08 to 1.80) 20 eyes unchanged
3 eyes changed to central RPE 
atrophy
IV
IV
Table 1. Retinal features in late-onset Stargardt over the entire observational interval. Cohort I 
had only flecks without any mottled foveal alterations or RPE atrophy, Cohort II had extrafoveal (but 
not fovea encircling) RPE atrophy until the last visit, Cohort III developed foveal sparing (RPE atrophy 
encircling the fovea ≥180°), and cohort IV had foveal involvement by either a mottled fovea or central 
RPE atrophy without passing through a foveal sparing phenotype during the observational interval.
logMAR = logarithm of  minimum angle of resolution; RPE = retinal pigment epithelium.
Cohort Mild impairment
≤20/32, ≥0.2 logMAR
Moderate impairment
≤20/80, ≥0.6 logMAR
Severe impairment
≤20/200, ≥1.0 logMAR
Foveal sparing (cohort III) 0.95 (NA*–6.61) 10.15 (3.09–13.34) 23.3 (13.6–NA*) 
Foveal involvement (cohort IV) 0.51 (NA*–4.41) 7.73 (4.30–22.89) NA* (24.0–NA*)
Log-rank test 0.57 0.07 0.06
Table 2. Median times (years; 95% confidence interval) of best-corrected visual acuity decline since 
the age at onset compared between eyes of late-onset Stargardt patients who developed foveal 
sparing and those who had early foveal involvement. logMAR = logarithm of the minimum angle of 
resolution; NA = not available. *Values could not be calculated, as too many events occurred outside the 
observational interval.
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and ≥1.0 logMAR showed a notably later, though not significant, occurrence of each of 
these events in eyes from foveal sparing cohort III (Table 2).
Modeling of retinal pigment epithelium atrophy
We assessed changes in RPE atrophy area over time in a subset of visits from 66 eyes 
(from 21 female and 17 male patients). The median follow-up time with FAF imaging 
was 2.3 years (range, 0.07–7.7). Measurement of RPE atrophy size was possible with 
high agreement between two independent readers (Supplemental Figure S2). At the 
first visit, the mean (± standard deviation) RPE atrophy size was 6.26 ± 7.3 mm2). Square 
root transformed data were used for all further analysis. Modeling RPE atrophy over 
time revealed an annual atrophy progression rate (slope) of 0.22 mm/year (95% CI: 
0.19–0.27). 
For 28 patients, data on RPE atrophy progression were available from both eyes for the 
same observational interval, and revealed that atrophy progression rates moderately 
correlated between the two eyes of a single patient (Pearson’s r = 0.52; Supplemental 
Figure S3). 
Sample Size Calculations
Based on the observed progression kinetics and the agreement between two eyes 
of a single individual, we were able to perform sample size calculations for possible 
future therapeutic trials. The assumption of a trial duration of 2 years and inclusion of 
only patients with bilateral RPE atrophy resulted in the sample size–power relationship 
depicted in Figure 3, with expected effect sizes of 50%, 40%, and 30% reduction in 
RPE atrophy progression. For effect sizes of 50% and 40%, fewer than 25 patients 
would be needed to obtain a statistical power of 0.9 at the 5% significance level, while 
for an effect size of 30%, a power of 0.8 
would be reached if at least 32 patients 
were included. 
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Figure 3. Statistical power as a function of 
sample size. Calculations were performed for 
expected effect sizes of 50%, 40%, and 30%
reduction of atrophy progression. The figure 
shows the power values ± 95% confidence inter-
vals for each value of the effect size, as estimated 
from a simulation study with 10,000 runs. The sig-
nificance level was set to 0.05. A trial duration of
2 years was assumed.
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Discussion
The natural history of late-onset Stargardt features expanding, well-demarcated areas 
of RPE atrophy, which can be a promising clinical biomarker to monitor disease progres-
sion. Although clinical features have been previously described,5 we comprehensively 
report on visual course and specific RPE atrophy progression rates in a large multicenter 
cohort that was well defined by clinical, genetic, and validated imaging parameters. In 
addition, we used advanced statistical methods to deliver robust results,24 as these are 
required for planning and conducting clinical trials. These measures ensured the highest 
levels of data integrity. As a result, this work showed that a future therapeutic trial 
can be realized with sufficient statistical power with a cohort of as few as 35 patients 
(Figure 3). 
In contrast, visual acuity loss may not be a useful outcome measure in clinical trials due 
to its high interindividual variance2 and overall slow decline; this would result in unreal-
istic large cohorts and long follow-up. Surrogate biomarkers may be more convenient, 
ideally predicting long-term changes in functional disease progression by detecting 
small short-term changes.25 Indeed, both visual acuity loss and atrophic RPE lesions, in 
which small changes are measurable, progress over time. Although this relationship may 
justify using RPE atrophy as a surrogate, there is a profound disconnect, particularly in 
late-onset Stargardt, between the area of RPE atrophy and vision. This discordance can 
be explained by clinically distinct progression subtypes: progression to either a foveal 
sparing phenotype in which RPE atrophy encircles the fovea in a horseshoe- or donut-
like fashion (cohort III),7, 8, 10, 22 or a subtype in which no such foveal sparing occurs (cohort 
IV). Foveal involvement can determine the eventual vision loss, either early when the eye 
has an initially involved fovea, or late when it exhibits a foveal sparing phenotype. 
As discussed above, visual acuity can vary widely, and for now, unpredictably, depending 
on the eventual foveal involvement. As the present data show, a large group of 37% with 
foveal involvement will do poorly, the rest relatively well. To determine those patients 
that would benefit most from therapy in terms of future clinical trials, analysis of addi-
tional imaging modalities could be helpful. While mottled decreased areas are difficult 
to quantify,21 other imaging biomarkers, in particular, spectral-domain optical coherence 
tomography, could indicate what drives the disease process toward foveal involvement. 
It has been demonstrated that outer retinal involvement precedes RPE loss. Specifically, 
outer nuclear layer and ellipsoid zone thinning can occur in regions of normal RPE thick-
ness, suggesting that photoreceptor thinning may precede RPE degeneration.26 Hence, 
outer retinal damage on spectral-domain optical coherence tomography would precede 
recognition on FAF. In addition, environmental and genetic factors could significantly 
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influence the development of RPE atrophy as identified in atrophic AMD.27, 28 Such data 
were not included in this study and need to be addressed in future work. 
Further limitations include the retrospective nature of the study and the resulting 
heterogeneity of the patients’ data, which may have been the reason for failing to show 
significance between different subtypes of late-onset Stargardt. For instance, some 
patients did not report any symptoms, and were more likely to have no RPE atrophy 
or only extrafoveal RPE atrophy not encircling the fovea. These patients would need 
a longer follow-up to identify in which direction the disease will develop. Analogously, 
heterogeneity within the imaging data, for example, the fields of view in NIR and FAF 
imaging, might have led to the nondetection of more peripheral atrophic lesions in 
patients with a 30° field of view, while such lesions would have been detected in eyes 
imaged with a 55° objective. 
In recent years, identifying biomarkers in retinal disease has become a central issue for 
therapeutic trials that aim to test the efficacy of a drug. A surrogate outcome measure 
accepted by the U.S. Food and Drug Administration is geographic atrophy in AMD,17 
to which areas of RPE atrophy show close similarities. As this study now has shown 
that RPE atrophy can also be used as an outcome measure in late-onset Stargardt, it 
may even be valuable in other retinal diseases affecting the RPE. Of special interest 
is the precise characterization of late-onset Stargardt patients; their adult age makes 
them ethically more appropriate candidates to participate in clinical trials than patients 
who are of minor age. This study provides important knowledge on the natural history 
of late-onset Stargardt, quantitatively describing the course of visual loss and atrophy 
progression. In addition, it provides fundamental information necessary to conduct 
clinical trials in patients with Stargardt disease. 
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CHAPTER 3
Diagnosing 
Stargardt disease
“A lack of obvious fundus abnormalities left an alarming number of children with Stargardt 
disease without the correct diagnosis. We hope that greater awareness of this subtype avoids 
misdiagnosis and years of inappropriate treatment.”
Nathalie M. Bax
Stanley Lambertus
Frans P.M. Cremers
B. Jeroen Klevering
Carel B. Hoyng
Submitted
3.1 The absence of fundus   
 abnormalities in Stargardt disease
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PURPOSE: To raise awareness of Stargardt disease (STGD1) patients without fundus 
abnormalities.  
DESIGN: Retrospective cohort study.
PARTICIPANTS: Thirty-one STGD1 patients with ≥1 ABCA4 variants in whom no 
fundus abnormalities were described at first ophthalmic consultation.
METHODS: Medical records were evaluated for age at onset, initial symptoms and 
diagnosis, delay reason for delay of diagnosis, age at STGD1 diagnosis, best-corrected 
visual acuity (BCVA), ophthalmoscopy, fundus photography, fundus autofluorescence 
(FAF), fluorescein angiography (FA), spectral-domain optical coherence tomography 
(SD-OCT), full-field electroretinography (ffERG), color vision test, and the presence of 
ABCA4 variants.
MAIN OUTCOME MEASURES: Age at onset, reason for delay of diagnosis, initial diag-
nosis, age at STGD1 diagnosis, presence of ABCA4 variants.
RESULTS: In 11.1% of our STGD1 cohort, no fundus abnormalities were observed 
at first ophthalmic consultation. The median age at onset was 8 years (range, 1–18). 
There was a median delay in diagnosis of 3 years (range, 0–19) in 27 out of 31 patients, 
which resulted in a median age at diagnosis of 12 years (range, 7–26). Patients were 
misdiagnosed with amblyopia, myopia, optic disk pathology, mental health problems, 
tension headache, neuritis bulbaris, and uveitis. Subtle abnormalities, such as lipofuscin 
accumulation, were seen on FAF at an earlier disease stage than in ophthalmoscopy. 
On SD-OCT, this included a thickened external limiting membrane. Color vision tests 
showed red-green insufficiency in 79% of patients. Reduced ffERG amplitudes were 
only present in 26%, and a dark choroid sign in 65% of the patients. Visual acuity con-
siderably fluctuated in the first 5 years after onset. The majority of the patients (65%) 
carried a least one variant with a severe effect on ABCA4 function. 
CONCLUSIONS: A high number of childhood-onset STGD1 patients were diagnosed 
with a major delay. The presence of accurate competence, equipment and the possibility 
for genetic screening is required, therefore we recommend to refer children with visual 
complaints without initial fundus abnormalities to a specialized ophthalmologic center. 
In particular, to diagnose patients at an early stage of disease is of increased importance 
with the advent of new therapeutic possibilities.
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Introduction
Stargardt disease (STGD1) is arguably the most common retinal dystrophy and affects 
1:10000 people worldwide.1. This autosomal recessive disease is caused by variants 
in the ABCA4 gene that encodes for a retinal-specific adenosine triphosphate-binding 
cassette transporter protein. Dysfunction of the ABCA4 protein leads to toxic accumu-
lation of byproducts from the visual cycle in the photoreceptor cell and retina pigment 
epithelium (RPE), which eventually leads to irreversible damage of the outer retinal 
layers.2, 3
Up to 5,962 variants in the ABCA4 gene have been identified; the specific combinations 
of variants in conjunction with largely unknown modifying factors in each patient result 
in a highly heterogenic phenotype. Patients with STGD1 present with progressive vision 
loss, which typically occurs in the second decade but early and late forms have been well 
recognized.4-6 In general, the fundus picture is characterized by the presence of irregular 
yellow-white fundus flecks in the posterior pole. During the course of the disease, macu-
lar atrophy develops, sometimes with a ‘beaten bronze’ aspect; in other patients a bull’s 
eye pattern can be observed. Lipofuscin accumulates in the outer retinal layers, which 
results in a ‘dark choroid’ on the fluorescein angiogram in approximately 80% of the 
patients.7-10 In early forms with a disease onset ≤10 years of age, atrophy of the macula 
is a prominent and early feature; the yellow flecks may be absent or hardly notable.4, 11, 12
The flecks are much more common in the classic form of STGD1 with an age of onset 
in the early teens, sometimes extending beyond the vascular arcades resulting in the 
fundus flavimaculatus phenotype.13, 14 Late-onset forms of the disease are characterized 
by atrophy of the retinal pigment atrophy, subtle flecks, and foveal sparing.5, 15, 16
The diagnosis of STGD1 can be challenging in early disease especially, as no apparent 
changes may be present on ophthalmoscopy despite the loss of visual function.4 This 
lack of clinical signs in combination with the limited capabilities for expression in young 
children may delay the correct diagnosis. Not only is early identification of these patients 
essential for the emotional aspect of a timely diagnosis, it is also important in the light 
of emerging therapeutic options for STGD1 disease, such as gene augmentation
(ClinicalTrials.gov, NCT01367444 and NCT01736592), stem cell therapy (ClinicalTrials.
gov,  NCT01469832), and small-molecule drugs (ClinicalTrials.gov, NCT02402660).
In this study, we describe—in detail—the clinical and molecular genetic findings in a 
group of STGD1 patients, which presents without initial fundus abnormalities in oph-
thalmoscopy. We hope that a heightened awareness avoids misdiagnosis, such as func-
tional visual loss in these children and, in worst case scenarios, years of inappropriate 
treatment.
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Methods
Patients 
The database with STGD1 patients of the Department of Ophthalmology, Radboud 
university medical center (Nijmegen, the Netherlands) contains 448 patients of all ages 
and disease onset, of whom 294 were screened for variants in the ABCA4 gene. In 
280 patients, ≥1 ABCA4 variants could be identified. We included 31 patients who 
did not show obvious fundus abnormalities at the first presentation. This study was 
approved by the Institutional Ethics Committee and was performed in accordance with 
the Declaration of Helsinki. 
Clinical evaluation
We collected the clinical data from the medical records. These included age at onset, 
initial symptoms, initial diagnosis and examinations or therapy, age at STGD1 diagnosis, 
delay of diagnosis and reason for this delay, number of referrals before diagnosis, and 
general medical history. Age at onset was defined as the first manifestation of the 
disease, these symptoms could have been noticed by the patient, but also their family 
members and/or the school physician. 
The standard ophthalmic examination included best-corrected visual acuity (BCVA) 
using Early Treatment Diabetic Retinopathy Study (ETDRS) or Snellen charts, slit-lamp 
biomicroscopy and detailed fundus examination. Best-corrected visual acuity was trans-
formed into the logarithm of the minimum angle of resolution (logMAR) for statistical 
analysis. For fundus photography, we used the Topcon TRC50IX (Topcon Corporation, 
Tokyo, Japan). Fluorescein angiography and cross-sectional images using spectral-
domain optical coherence tomography (SD-OCT) centered at the macula were obtained 
with the Spectralis (HRA+OCT, Heidelberg Engineering, Heidelberg, Germany). Short-
wave fundus autofluorescence (FAF) imaging (λ = 488 nm, emission 500–700 nm) was 
performed using a confocal scanning laser ophthalmoscope (Spectralis HRA+OCT or 
HRA2, Heidelberg Engineering, Heidelberg, Germany). The field of view was set at 
30°×30° or 55°×55°, centered at the macula. For evaluation of color vision, we employed 
the Ishihara or Panel D-15 test. Full-field electroretinography (ffERG) was performed 
using Dawson-Trick-Litzkow electrodes and the RETI-port system (Roland Consults, 
Stasche & Finger GmbH, Brandenburg an der Havel, Germany). The recordings were 
performed in accordance with the guidelines of the International Society for Clinical 
Electrophysiology of Vision (ISCEV).17 We grouped ffERG results as described by Lois 
et al.18: group 1, patients with normal ffERG responses; group 2, patients with reduced 
photopic amplitudes (<5% of normal range); and group 3, patients with reduced phot-
opic and scotopic amplitudes (<5% of normal range).
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Genetic analysis
Genetic analysis of the ABCA4 gene was performed at the Department of Human 
Genetics at the Radboud university medical center (Nijmegen, the Netherlands) using 
arrayed primer extension analysis (Asper Biotech, Tartu, Estonia). If the Asper microar-
ray screening revealed only one ABCA4 variant, exon and intron-exon boundaries 
were sequenced in the ABCA4 gene to identify additional variants. All variants were 
confirmed with Sanger sequencing. The following variants were defined as severe: 
protein-truncating, canonical splice-site variants, as well as deletions spanning at least 
one exon.
Statistical analysis
We used SPSS version 22.0 (IBM Corp, Armonk, NY) for statistical data analysis, using 
descriptive statistics by median and range for continuous variables, and percentages 
for categorical variables. We employed Kaplan-Meier estimators to analyze the interval 
between age at onset and age at which four different visual endpoints were reached. 
These four points were based on the classification of visual impairment of the World 
Health Organization: (near-)normal to mild visual impairment ≥0.2 logMAR (≤20/32 
Snellen), moderate visual impairment ≥0.6 logMAR (≤20/80 Snellen), severe visual 
impairment ≥1.0 logMAR (≤20/200 Snellen), and blindness ≥1.4 logMAR (≤20/500 
Snellen). 
Results
Clinical characteristics
In 31 of 280 (11.1%) STGD1 patients, no obvious fundus abnormalities were observed 
at the first ophthalmic consultation. The group consisted of 15 males and 16 females 
with six siblings from three different families, and 25 isolated cases. An overview of 
the clinical findings and the diagnostic process is given in Table 1. In one-third of cases, 
symptoms of a decreased visual acuity were not noticed by the patient but by the parents 
or a school physician. Age at onset occurred at a median age of 8 years (range, 1–18). 
In 87% of the patients, there was a delay in diagnosis: a median delay of 3 years (range, 
0–19), which resulted in a median age at diagnosis of 12 years (range, 7–26). The main 
reason for delayed STGD1 diagnosis was misdiagnosis, in particular amblyopia treated 
with occlusion therapy (6 patients) and mental health issues (5 patients). The majority of 
patients (94%) visited more than two hospitals before the correct diagnosis was made. 
All patients were finally diagnosed with STGD1 in tertiary referral centers. The first 
fundus abnormalities were observed at a median time of 3 years (range, 0.5–16) after 
first symptoms. These included central RPE alterations (43%), bull’s eye maculopathy 
(33%), and/or parafoveal flecks (24%). Once these features had been observed, STGD1 
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was generally diagnosed relatively quickly in 
the majority of patients (median, 0.7 years; 
range, 0.1–3). 
We could retrieve the BCVA at the first 
ophthalmic visit in 21 out of 31 patients; the 
median BCVA at that time was 20/32 Snellen 
(20/20–20/400). The median interval and 
95% confidence interval (CI) between the age 
at onset and decline in BCVA to mild, mod-
erate, severe visual impairment and blindness 
was 1 year (95% CI, 0.0–2.25), 4 years
(95% CI, 3.1–4.9) and 12 years (95% CI, 
7.8–16.2). One patient reached blindness 34 
years after the first symptoms of onset at age 
9. In many patients, the visual acuity findings 
were quite variable early in the course of the 
disease as shown in Figure 1. 
In 29 out of 31 patients, fundus flecks were 
eventually noticed at a median time of
3.5 years (range, 0.1–16.5) after the initial 
ophthalmic consultation. In 17 patients 
(59%), subtle parafoveal flecks could be 
seen, in 5 patients (17%) flecks were noticed 
within the vascular arcades, and in 7 patients 
(24%) flecks extended to the periphery. In 
2 patients, no fundus flecks were reported 
at any time during the course of the disease 
(follow-up time, 1 and 10 years). 
In 23 of 31 patients, the first SD-OCT scan 
was performed at 9 years (range, 0.1–24) 
after disease onset. No SD-OCT scans were 
performed in the remaining 8 patients. All 
SD-OCT scans showed abnormalities by 
disorganized or absent RPE. A thickened 
external limiting membrane (ELM) was seen 
in 2 patients (0.5 and 1 year after disease 23
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onset). A dark choroid was observed in 15 of 23 (65%) patients in whom fluorescein 
angiography was performed. In 22 patients, the first FAF was performed 3.5 years
(0.5–24) after onset. No atrophy was seen (median, 1 year after onset) in 5 patients, (peri)
foveal atrophy in 9 (median, 4 years after onset), atrophy within the vascular arcades in 7
(median, 15 years after onset), and panretinal atrophy (15 years after onset) in 1.
In 4 patients, abnormalities were seen on FAF, but were missed on ophthalmoscopy.
The first ffERG was performed 2 years (0.1–27) after onset in 27 patients. Normal ffERG 
recordings (group 1) were present in 20 patients (74%), 2 years (0.1–21) after disease 
onset.  We found group 2 ffERGs in 4 patients (15%) with 1 year (0.1–3.5) after onset, 
and group 3 recordings in 3 patients (11%) with 18 years (6–27) after onset. Follow-up 
for ffERG recordings was available in 21 patients. In 4 of these patients progressed from 
group 1 to group 2 (median time, 8 years; range, 7–16), 2 patients progressed from group 
2 to group 3 (within 2 and 3 years), and 1 patient progressed from group 1 to group 3 in 
6 years. In 17 patients, color vision was tested. In 15 patients (79%) abnormalities were 
noticed, red-green defects in 14 patients and a blue-yellow defect in 1 patient.
Various imaging modalities of patient 28 and patient 21 are depicted in Figure 2 and 3, 
respectively.
Follow-up after first ophthalmic consultation (years)
1086420
B
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VA
 (l
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ID
2
6
13
15
16
21
25
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Figure 1. Course of the best-corrected visual acuity (BCVA) in logMAR in ten patients. The visual 
acuity varies greatly during the first five years after first ophthalmic consultation. LogMAR 0 = 20/20 
Snellen, LogMAR 0.5 = 20/63 Snellen, LogMAR 1.00 = 20/200 Snellen, LogMAR 1.50 ≈ 20/630 Snellen, 
LogMAR 2.00 = 20/2000 Snellen. Each patient (ID = patient identification) is shown in a different color. 
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Figure 2. Three-and-a-half-year follow-up in patient 28. Age at onset: 6.5 years. One year later, fun-
dus autofluorescence (FAF) imaging showed a perifoveal ring of hyperautofluorescence (A2), and on 
spectral-domein optical coherence tomography (SD-OCT), a discrete thickening of the external limiting 
membrane (ELM) can be seen (arrow, A3). Only 6 months later, a subtle hyperautofluorescent perifoveal 
lesion developed (arrow, B2). Over time, the hyperautofluorescent flecks become more visible on FAF 
imaging. In addition, the flecks became noticeable on color fundus photographs. The thickened ELM 
remained present during the entire follow-up time (arrows, A3 ,C3-H3). FA = fluorescein angiography, 
NP = not performed.
Color fundus photograph SD-OCT
(only B3 = FA)
Age (y)
7.5    20/35
8    NP
8.5    20/25
9    20/32
9.5    20/25
10    NP
10.5   20/38
11    20/36
A2 A3
B1 B2 B3
C1 C2 C3
D1 D2 D3
E1 E2 E3
F1 F2 F3
G1 G2
H1 H2 H3
 Visual acuity
 (Snellen)
Fundus autofluorescence
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Genetic characteristics
Overall, genetic analysis 
was not performed at first 
visit, but with a median 
delay of five years (range, 
0–30) after first visit. 
An overview of ABCA4 
variants in our cohort is 
described in Table 2.  
Variants in the ABCA4 
gene were identified in 59 
of 62 alleles (95%). Three 
variants were found in one 
patient, two ABCA4 vari-
ants in 27, and one variant 
in three. In total, 32 distinct 
variants were detected. 
The majority of the patients 
(65%) carried at least 
one variant with a severe 
effect on ABCA4 function 
(Table 2, bold).
Discussion
A lack of obvious fundus abnormalities left a high number of children with STGD1 
disease without the correct diagnosis. Instead, these patients underwent unnecessary 
investigations, such as psychic evaluations, brain MRIs or CTs, and lumbar punctures. 
Many of these children were treated for mental illness and/or amblyopia with pointless 
and possibly harmful treatments, including years of occlusion therapy.
In patients with adult-onset STGD1, initial ophthalmoscopic features typically include 
yellow-white flecks and central macular atrophy, and cases without fundus abnormali-
ties have not been described.5 In young children, the clinical presentation can be confus-
ing for the general ophthalmologist. Fujinami et al. noticed that one third of their child 
cohort (<17 years) initially had a normal fundus appearance.6 Lambertus et al. described 
a cohort of 41 STGD1 patients younger than 10 years, and 10 of these patients (24%) 
Figure 3. Multimodal imaging in patient 21 at age 25, 15 years 
after the first symptoms. The visual acuity is 20/1000 Snellen. 
Color fundus photography (A) shows attenuated retinal vessels 
(especially the veins), para-arteriolar pigmentations and diffuse 
chorioretinal atrophy. Fundus autofluorescence imaging (B) shows 
widespread hypoautofluorescence, especially at the macula, indi-
cating RPE cell loss. Fluorescein angiography (C) shows widespread 
granular hyperfluorescent lesions as a result of RPE damage, and 
on spectral-domain optical coherence tomography, (D) loss of the 
outer retinal layers, as well as the choriocapillaris, can readily be 
observed. 
 A  B
 C  D
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also did not have fundus abnormalities.4 These studies show that the absence of readily 
observable fundus abnormalities in young STGD1 patients is not an isolated finding, but 
a relative common part of the clinical spectrum.
In our cohort, when fundus abnormalities did occur, these were often not the typical 
yellowish flecks but rather RPE alterations, often in a bull’s eye pattern. A hypothesis for 
the absence of typical fundus flecks may lie in the relative high pathogenicity of ABCA4 
variants. As the majority of our cohort (65%) carried at least one severe variant, there 
may be little ABCA4 function left in these patients, leading to a very early manifestation 
of the disease. The built-up of toxic N-retinylidene-N-retinylethanolamine in RPE cells 
develops rapidly, thereby causing early cell death without the opportunity for lipofuscin 
to accumulate and subsequent fleck formation. 
Blocking of the choroidal vessels on FA resulting a dark or silent choroid is frequently 
used as diagnostic marker for STGD1. The prevalence of this FA finding in STGD1 
patients has been described in up to 86% of patients.19 A dark choroid was present 
in 65% in our relatively small cohort. A correlation has been described between the 
presence of yellow-white fundus flecks and the appearance of dark choroid,8, 20 which 
might account for the relative low percentage of patients with a dark choroid in this 
cohort. Fundus autofluorescence imaging is a relative new modality that may be used to 
identify early and subtle lipofuscin.21 In addition, a thickened ELM on SD-OCT may also 
serve as an early marker for STGD1.22 However, in the study of Lee et al, this distinct 
ELM thickening was described to occur in all (26/26) cases. In our cohort, only 2/23 
cases with performed SD-OCT were observed to have this feature. The delay of per-
forming an SD-OCT (mean, 9 years after disease onset) could be an explanation of the 
difference in appearance of ELM thickening in both cohorts. The two cases of our cohort 
with this distinct feature was SD-OCT performed 0.5 and 1 year after disease onset, so 
suggestive for early disease marker. Abnormal color vision was observed in 79% of our 
STGD1 patients, which corresponds with the previously reported percentages.23 
Although STGD1 is the most common juvenile macular dystrophy, it remains a relative 
rare disorder. Clinicians in a general ophthalmic practice may lack the experience to 
identify and interpret the subtle abnormalities in these young children. When we con-
sider the relative difficulty associated with the ophthalmic examination of (very) young 
children, the high number of misdiagnoses in the early-onset STGD1 patient group may 
not come as a surprise. Therefore, we want to make ophthalmologists aware of early 
findings in STGD1, especially appearing in children. First, visual acuity often fluctuates in 
these patients which should not automatically rule out the possibility of a photoreceptor 
disease. Second, a fundus photograph can be helpful in discerning very subtle fundus 
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abnormalities and may be useful in follow-up. Third, non-invasive investigations such as 
SD-OCT (thickening of the ELM), FAF (subtle lipofuscin accumulation) and color vision 
tests may help in the diagnostic process. Fluorescein angiography is invasive, apart from 
the oral variant, but may also be less helpful in patients without fundus abnormalities in 
the light of the relative low percentage of dark choroids in these patients. 
In children with visual disturbances, retinal dystrophies should be considered and ruled 
out when possible, even in the absence of fundus abnormalities on ophthalmoscopy. 
Instead of wait and see, we would recommend referring these children to a tertiary 
ophthalmic center and performing SD-OCT and FAF to define early findings of STGD1. 
A correct and early diagnosis of STGD1 prevents a lot of distress, unnecessary inves-
tigations and harmful therapies; in addition, early identification may prove important in 
the light of emerging therapeutic options. 
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PURPOSE: To compare the disease course of retinal pigment epithelium (RPE) atrophy 
secondary to age-related macular degeneration (AMD) and late-onset Stargardt disease 
(STGD1).
METHODS: Patients were examined longitudinally by fundus autofluorescence, 
near-infrared reflectance imaging and best-corrected visual acuity (BCVA). Areas of 
RPE atrophy were quantified using semi-automated software, and the status of the 
fovea was evaluated based on fundus autofluorescence and near-infrared reflectance 
images. Mixed-effects models were used to compare atrophy progression rates. BCVA 
loss and loss of foveal integrity were analyzed using Turnbull’s estimator.
RESULTS: A total of 151 patients (226 eyes) with RPE atrophy secondary to AMD and 
38 patients (66 eyes) with RPE atrophy secondary to late-onset STGD1 were exam-
ined for a median time of 2.3 years (interquartile range, 2.7). Mean baseline age was
74.2 years (SD, 7.6) in AMD and 63.4 (SD, 9.9) in late-onset STGD1 (P = 1.1 × 10-7). 
Square root atrophy progression was significantly faster in AMD when compared with 
late-onset STGD1 (0.28 mm/year [± standard error (SE), 0.01] versus 0.23 [± SE, 0.03]; 
P = 0.030). In late-onset STGD1, the median survival of the fovea was significantly 
longer when compared with eyes with AMD (8.60 versus 3.35 years; P = 0.005) with a 
trend to a later BCVA loss of ≥3 lines (5.97 versus 4.37 years; P = 0.382).
CONCLUSIONS: These natural history data indicate differential disease progression in 
AMD versus late-onset STGD1. The results underline the relevance of refined pheno-
typing in elderly patients presenting with RPE atrophy in regard to prognosis and design 
of interventional trials. 
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Introduction
Atrophy of the retinal pigment epithelium (RPE) represents a common late-stage 
manifestation of various retinal diseases, including late-stage dry age-related macular 
degeneration (AMD) and Stargardt disease (STGD1).1 In industrialized countries, late-
stage neovascular or advanced dry AMD is the leading cause of legal blindness in the 
elderly.2 Although the exact pathogenetic mechanisms leading to geographic atrophy3 
are still poorly understood, chronic inflammatory processes, excessive lipofuscin accu-
mulation in the RPE lysosomal compartment, complement system dysregulation, and 
vascular factors have been implicated in the development of AMD.4 
In contrast to the multifactorial etiology of AMD, STGD1 is an autosomal recessive 
retinal dystrophy caused by pathogenic sequence variants in the adenosine triphosphate-
binding cassette, subfamily A, member 4 (ABCA4, MIM 601691) gene. ABCA4 encodes 
an integral transmembrane protein, expressed in retinal photoreceptors. It is involved in 
the clearance of all-trans-retinal aldehyde, a byproduct of the retinoid cycle of vision.5 
ABCA4 dysfunction leads to the accumulation of lipofuscin and its constituent, di-
retinoid-pyridinium-ethanolamine, finally resulting in RPE atrophy development.6, 7 
Comparable ages of onset as well as funduscopic parallels result in a certain risk in con-
founding AMD and late-onset STGD1.8 It is well understood that distinction between 
both conditions is of practical relevance to an individual patient with regard to genetic 
counseling. Yet to what extent differentiation between both conditions also influences 
individual prognosis in terms of visual acuity loss and RPE atrophy progression has not 
been assessed. Extending our analysis on two recently described cohorts,9, 10 in the pres-
ent work we identify significant differences in the course of AMD and late-onset STGD1. 
These results underline the relevance of refined phenotyping in patients presenting with 
RPE atrophy. Furthermore, the improved understanding of the distinct kinetic of disease 
progression will be relevant for emerging therapeutic approaches. 
Methods
Patient identification
The present study consists of the following two distinct cohorts: patients with RPE 
atrophy secondary to AMD and patients with RPE atrophy associated with late-onset 
STGD1. Inclusion criteria for the current analysis for both cohorts were the following: 
(1) at least one well-defined contiguous area of RPE atrophy corresponding to areas 
of reduced fundus autofluorescence (FAF) to an extent of ≥0.05 mm2 (the size of the 
smallest atrophic area in cases of multifocality) in one or both eyes and (2) clear ocular 
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media allowing for acquisition of high-quality FAF images. For inclusion into the AMD 
cohort, soft drusen and/or retinal pigment abnormalities consistent with the diagnosis 
of AMD had to be present. For inclusion into the late-onset STGD1 cohort, patients 
had to exhibit typical yellow-white flecks or dots correlating with hyperautofluorescent 
flecks on 488-nm FAF imaging. This FAF pattern had previously been termed “fine 
granular pattern with peripheral punctate spots (GPS[+])”.11, 12 The clinical phenotype 
of late-onset STGD1 was supported by at least one (likely) pathogenic variant in the 
ABCA4 (NM_000350.2) gene. The peripherin-2 gene (PRPH2; NM_000322.4) was 
additionally sequenced in patients with fewer than two ABCA4 (likely) pathogenic 
variants to exclude autosomal-dominant multifocal pattern dystrophy or central areolar 
choroidal dystrophy.13, 14 Patients had to be at least 45 years of age at self-reported 
symptom onset. Both eyes of a patient were included in the analysis if the inclusion 
criteria were met. General exclusion criteria for both cohorts were the presence of retinal 
disease that could possibly confound observations (e.g., diabetic retinopathy, present or 
past exudative events, idiopathic serous chorioretinopathy). 
All of the patients were recruited in the context of the Fundus Autofluorescence in 
Age-Related Macular Degeneration (FAM) Study or at the outpatient department of 
Radboud university medical center. The study followed the tenets of the Declaration 
of Helsinki. Approval by the institutional review boards was obtained by each of the 
participating centers. Informed consent was obtained from each participant after an 
explanation of the study’s nature and possible consequences of participation. Both 
cohorts have previously been reported elsewhere.8–10, 12, 15 
Assessment of visual acuity
At each visit, best-corrected visual acuity (BCVA) was determined using a Snellen or 
Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Visual acuity is reported 
in logarithm of the minimum angle of resolution (logMAR) notation. Visual acuity of 
counting fingers was set to 1.8 logMAR and hand motions to 2.2 logMAR.16 
Image acquisition and grading
Fundus autofluorescence images were acquired using HRA2 or Spectralis HRA+OCT 
(Heidelberg Engineering, Heidelberg, Germany) with an excitation wavelength of
488 nm and an emission spectrum of 500 to 700 nm using the high-speed mode. Near-
infrared (NIR) reflectance images were obtained with an excitation wavelength of
820 nm. The field of view was centered on the fovea and set to 30°×30° or 55°×55° 
to fit the entire area of atrophy. Images were acquired with a minimum resolution of 
512×512 pixels and single FAF images were automatically aligned and averaged to 
maximize the signal-to-noise ratio using the manufacturer’s software. 
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Areas of RPE atrophy were 
measured on FAF images 
applying image processing 
software based on gray 
value detection for semi-
automated identification of 
atrophic RPE areas. Only 
areas of decreased auto-
fluorescence >0.05 mm2 
were considered to repre-
sent RPE atrophy.17–20 The 
involvement of the fovea by 
the atrophic process was 
determined based on FAF 
and NIR reflectance images 
and was graded as follows: 
definitely involved, proba-
bly involved, probably not 
involved, and definitely not 
involved. For further anal-
ysis, these gradings were 
summarized to “involved” 
and “not involved.” A 
representative example of 
an eye with RPE atrophy 
secondary to AMD and 
RPE atrophy secondary to 
late-onset STGD1 is pro-
vided in Figure 1. 
Statistical analysis
The total atrophy size measured for each visit was square-root transformed to reduce 
the dependency of enlargement rates on baseline lesion size (√ area [mm]) as previously 
suggested.21 To quantify atrophy progression rates within the patient collective, a linear 
mixed-effects model was used as described earlier.22, 23 The two-level, random-effects 
model used here separates eye-specific and patient-specific effects and accounts 
for dependencies between measurements that were obtained from the same patient
and/or eye. 
AMD
76 y/o female
LO-STGD1
63 y/o female
Figure 1. Multimodal imaging as performed in this study of rep-
resentative left eyes of a patient with retinal pigment epithelium 
atrophy secondary to age-related macular degeneration (AMD) 
and a patient with retinal pigment epithelium atrophy second-
ary to late-onset Stargardt disease (LO-STGD1).
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The factor “AMD” versus “LO-STGD1” was included as a fixed effect in the model. Back-
ward selection of the other covariates, including higher order interactions, was used to 
build the final linear mixed-effects model. 
Turnbull’s estimator24 was used to estimate the percentages of eyes with BCVA loss 
≥0.3 logMAR (≥3 ETDRS chart lines) and ≥0.6 logMAR (≥6 ETDRS chart lines) from 
baseline, as previously reported.9 A similar approach was used to estimate the percent-
age of eyes with loss of foveal integrity over time (status transition of the fovea from “not 
involved” to “involved”). A comparison of the course of BCVA and of the foveal status 
between AMD versus late-onset STGD1 was performed using the log-rank test. 
Results
Patients
A total of 226 eyes (151 patients; 55 males, 96 females) with RPE atrophy secondary 
to AMD and 66 eyes (38 patients; 17 males, 21 females) with RPE atrophy secondary 
to late-onset STGD1 were examined over time. At baseline, 113 patients exhibited 
bilateral RPE atrophy (86 patients with AMD and 27 patients with late-onset STGD1). In 
24 patients, the fellow eye had early changes, that is, disease-related alterations without 
atrophy or neovascularization (15 patients with AMD and nine patients with late-onset 
STGD1; P = 0.117), and 41 patients exhibited neovascularization in the fellow eye
(39 patients with AMD and two patients with late-onset STGD1; P = 0.006). In
11 patients, only one eye was included because the fellow eyes fulfilled any of the exclu-
sion criteria (e.g., insufficient imaging quality). One eye did not contribute to the analysis 
because neovascularization developed right after the first visit. 
Baseline characteristics
Mean age at baseline was 74.2 years (SD, 7.6) in the AMD and 63.4 years (SD, 9.9) in 
the late-onset STGD1 patient cohort. At first presentation, RPE atrophy size in AMD 
patients was 6.3 mm2 (SD, 5.0) and 6.2 mm2 (SD, 7.3) in late-onset STGD1 (P = 0.914). 
At baseline, the fovea was graded as “not involved” in 54.0% of eyes (122 of 226 eyes) 
with AMD and in 86.4% of eyes (57 of 66 eyes) with late-onset STGD1 (P = 4.1 × 10−6). 
BCVA at baseline was significantly different between both cohorts with 0.6 logMAR 
(SD, 0.4) in AMD and 0.4 logMAR (SD, 0.5) in late-onset STGD1 (P = 1.3 × 10−3). An 
overview on baseline characteristics is given in Table 1. 
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Disease Progression
Data of a total of 897 eye visits were included in the analysis. The median follow-up 
time was 2.2 years (interquartile range [IQR], 2.6) in AMD and 2.5 years (IQR, 3.6) in 
late-onset STGD1 (P = 0.774). To compare atrophy progression kinetics between AMD 
and late-onset STGD1, a linear mixed-effects model was used. Average square-root 
transformed atrophy progression was 0.28 mm/year (SE, 0.01) in AMD, and 0.23 mm/
year (SE, 0.03) in late-onset STGD1 (P = 0.030). Model results were corrected for dis-
tinct age structures between the cohorts by including age as a fixed effect (coefficient 
estimate, 0.02 ± 0.00; P = 0.011). 
Transition of the status of the fovea from “not involved” to “involved” during the obser-
vational period was observed in 48 eyes with AMD (39.3% of eyes with “not involved” 
fovea at baseline) and in only 5 eyes with late-onset STGD1 (8.8% of eyes with “not 
involved” fovea at baseline). Notably, the follow-up period in late-onset STGD1 patients 
was longer than in AMD patients (see earlier). Time-to-event analyses revealed a median 
time from noninvolvement of the fovea at baseline to foveal involvement of 3.35 years 
(95% confidence interval [CI], 2.50–4.15) in AMD and 8.60 years (CI, not available) in 
late-onset STGD1 (Table 2). In parallel, a visual acuity loss of ≥3 and ≥6 lines, respec-
tively, occurred consistently, although not significantly later in late-onset STGD1 when 
compared with AMD (Table 2). Figure 2 shows two representative disease courses in an 
eye with late-onset STGD1 and an eye with AMD.
Characteristic AMD Late-onset STGD1 P value
Patients, n (%) Mean ± SD Patients, n (%) Mean ± SD
Gender
  Male 55 (36.4%) 17 (44.7%) 0.449*
  Female 96 (63.6%) 21 (55.3%)
Disease status
  Bilateral RPE atrophy 86 (61.4%) 27 (71.1 %)
  RPE atrophy + CNV in fellow eye 39 (27.9%) 2 (5.2%) 0.006*
  RPE atrophy + ‘‘early’’ changes in fellow eye 15 (10.7%) 9 (23.7%) 0.117*
Follow-up time, years 2.2 (IQR, 2.6)† 0.774‡
Age, years 74.2 ± 7.6 <0.001§
Eyes, n (%) Mean ± SD Eyes, n (%) Mean ± SD
Atrophy size, mm² 226 6.3 ± 5.0 66 6.2 ± 7.3 0.914§
Status of the fovea at baseline
  Not involved 122 (54%) 57 (86.4%) <0.001*
  Involved 104 (46%) 9 (13.6%)
Visual acuity, logMAR 226 0.6 ± 0.4 66 0.4 ± 0.4 0.001§
Table 1. Baseline characteristics of patients with age-related macular degeneration and late-onset 
Stargardt. * χ²-Test; † median; ‡ Mann-Whitney U; § t-test. 
AMD = age-related macular degeneration; CNV = choroidal neovascularization; IQR = interquartile 
range; RPE = retinal pigment epithelium; SD = standard deviation; STGD1 = Stargardt disease.
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Discussion
This study reveals differences between AMD and late-onset STGD1 with respect to 
both atrophy progression and changes in visual acuity. We found a significantly faster 
atrophy progression in eyes with AMD along with significantly lower BCVA scores at 
baseline and faster, albeit not significant, loss of BCVA. 
Atrophy progression and visual acuity courses have been previously assessed inde-
pendently in both AMD and STGD1. Although distinct analytic strategies preclude direct 
comparisons, our data are overall compatible with previously published values.10, 25–28 
Despite similar lesion size at baseline, patients with late-onset STGD1 had a better 
BCVA, presumably because their fovea was more frequently intact (86.4% versus 54% 
of eyes with AMD). Moreover, they had both atrophy progression kinetics and survival 
times of the fovea in favor, but the difference in decline in BCVA when compared with 
AMD was less pronounced. We have recently reported that the parameters “status of 
Baseline:
0.1 logMAR
+12 months:
0.1 logMAR
+24 months:
0.0 logMAR
+36 months:
0.1 logMAR
+57 months:
0.5 logMAR
Baseline:
0.2 logMAR
+12 months:
0.2 logMAR
+24 months:
0.3 logMAR
+36 months:
0.4 logMAR
+57 months:
0.6 logMAR
Figure 2. Fundus autofluorescence and corresponding visual acuity values of an exemplary course 
of late-onset STGD1 (upper row) and AMD (lower row). Square root atrophy progression rate in the 
late-onset STGD1 eye shown is 0.25 mm/year, whereas it is 0.58 mm/year in the age-related macular 
degeneration (AMD) eye. Note that the eye with late-onset STGD1 shown has a larger non–square root 
transformed progression as a result of the larger baseline atrophy size. AMD = age-related macular 
degeneration; logMAR = logarithm of the minimum angle of resolution; STGD1 = Stargardt disease.
Event AMD Late-onset STGD1 P value
Median, years CI Median, years CI Log-rank
Fovea becomes involved 3.35 2.50–4.15 8.60 NA 0.005
Visual acuity loss ≥3 lines 4.37 2.96–4.37 5.97 0.449*
Visual acuity loss ≥6 lines 7.52 7.52–∞ 33.2% had event after 7.50 years 0.320
Table 2. Median times to event for foveal involvement and vision loss in age-related macular degen-
eration and late-onset Stargardt. CI = confidence interval; NA = not available.
Differential disease progression in atrophic AMD and late-onset STGD1 • 84
the fovea”, “total lesion size”, and the “age at baseline” in eyes with atrophy as a result 
of AMD have a significant impact on BCVA and that these factors together explain 65% 
of BCVA variability.9 The remaining 35% of BCVA variability may be explained by other 
factors, such as media opacities and the general mental status. In addition, it may be 
explained by BCVA test variability itself.9 
Foveal sparing is observed in several retinal diseases,8, 10, 15, 20, 29–33 exhibiting a specific 
pattern of RPE atrophy surrounding an intact foveal island. Although the present study 
did not differentiate between this typical pattern of foveal sparing and general foveal 
noninvolvement, patients with a long-term preservation of foveal integrity may develop 
eventual foveal sparing. Interestingly, eyes with an uninvolved fovea at baseline pro-
gressed to foveal atrophy during the review period in almost 40% of eyes with AMD, but 
only 8.8% of eyes with late-onset STGD1, despite their slightly longer follow-up. Atrophy 
being more closely to the fovea at first presentation may be a reason for requiring less 
time to involve the fovea into the atrophic process in AMD. Another explanation may be 
a longer foveal survival because of the protecting mechanisms in late-onset STGD1. Yet 
foveal sparing can be present in phenotypes that are independent of ABCA4 sequence 
variants, including AMD,8, 15, 20, 29–33 and is infrequent in a general STGD1 population.15 
Therefore, other genetic factors and distinct anatomical, metabolic, and/or biochemical 
aspects are likely involved. 
A further hallmark contrast between both cohorts was the frequency of neovasculariza-
tion observed in fellow eyes, which was less frequent in late-onset STGD1. For AMD, it 
has been described that atrophy progression is slower in eyes with a fellow eye exhib-
iting neovascularization.34 We did not correct for this factor in the linear mixed-effects 
model. Yet from the available data on AMD,34 we would expect the difference between 
AMD and late-onset STGD1 to become even larger when correcting for this factor. 
Our patients with biallelic—but also with mono-allelic—ABCA4 variants share an iden-
tical phenotype that exhibits typical flecks of increased FAF surrounding the atrophic 
lesion; it resembles the FAF pattern in patients with typical STGD1. Given the high car-
rier frequency up to 1:25,35 it is highly unlikely that a single pathogenic ABCA4 variant 
can cause this phenotype on its own. In analog, several cases with typical STGD1 are to 
date also genetically still unsolved by failing to detect a second pathogenic ABCA4 vari-
ant. However, these second “missing” pathogenic variants are now increasingly being 
found with recent genetic techniques.36 We postulate that either a second sequence 
variant affecting ABCA4 function or other genetic factors that lower the total ABCA4 
function are still to be found in our patients with mono-allelic ABCA4 variants. They 
may be sufficient to cause this distinct phenotype at the mild end of STGD1 and in 
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the disease spectrum of AMD. With regard to these hypotheses, recent studies are of 
particular interest quantifying normal levels of lipofuscin in parents of patients with 
STGD1.37,38 Furthermore, it has also been reported that abca4+/− mice show increased 
levels of some bis-retinoids.39 Overall, the pathogenesis of cases with a typical STGD1 
phenotype and only one identified pathogenic ABCA4 variant remains controversial. 
Nonetheless, it appears reasonable to require detection of at least one pathogenic 
ABCA4 variant in patients with this distinct late-onset phenotype to assign the clinical 
diagnosis late-onset STGD1. 
One may argue about how this distinct late-onset atrophy phenotype associated with 
ABCA4 should be entitled. In the FAM Study, this phenotype was originally termed 
“fine granular pattern with peripheral punctate spots” (GPS[+]) and was classified as 
a subtype of AMD.11, 12 In two independent approaches, we found an association of this 
late-onset phenotype with mono- and biallelic ABCA4 variants.8, 11 Here, we postulate 
that late-onset STGD1 and GPS[+] describe the same entity. Analyses of ABCA4 gene 
variants in AMD were not performed in this study. Several earlier works have addressed 
the issue of ABCA4 in large cohorts from a genetic point of view, giving controversial 
results.40–42 A recent study in AMD did not detect increased lipofuscin levels, which 
should be expected in retinal disease associated with ABCA4.43 However, further con-
tributing to this controversy will require (1) a clinically well-phenotyped AMD cohort 
where late-onset STGD1/GPS[+] patients are excluded, (2) a well-matched control 
cohort, and (3) state-of-the-art genetic approaches to identify relevant variants, which 
was beyond the scope of this work. 
Optical coherence tomography was not included in this study, which may have caused 
uncertainty to the grading of foveal involvement. In particular, only the definite gradings 
“involved” versus “not involved” were compared in contrast to other works.9, 44 Another 
limitation included the two cohorts being unequal in number of patients; because of the 
smaller late-onset STGD1 cohort, time-to-event curves were affected more strongly by 
the potential loss of follow-up here when compared with a dropout of an AMD patient. 
Yet time-to-event analyses are robust against such dropouts as long as patients who are 
more likely to suffer the event early during follow-up are not more (or less) likely to drop 
out. These limitations are balanced by the large cohorts of both AMD and late-onset 
STGD1 patients who were included into this study and followed during a long period of 
time. 
Differential disease progression between AMD and late-onset STGD1 are particularly 
important to emerging therapeutic trials. Strategies in multifactorial AMD range from 
choroidal perfusion enhancers over neuroprotective agents to complement inhibitors.4 
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Preclinical data suggest that complement activation is a final common pathway lead-
ing to RPE cell death in both conditions45, 46; for AMD, the MAHALO trial also shows 
therapeutic effects in human.47 Yet patients with ABCA4-related late-onset STGD1 will 
rather benefit if earlier and more specific disease processes are targeted, for example, 
by focusing on the visual cycle or retinal ABCA4-gene delivery (e.g., ClinicalTrials.gov, 
NCT01367444 and ref.48). Therefore, it appears prudent to carefully distinguish between 
late-onset STGD1 and AMD. Inclusion of late-onset STGD1 patients into interventional 
AMD trials, and vice versa, would blur the therapeutic effect under observation and 
potentially lead to a fail in proving efficacy. 
Furthermore, although the clinical diagnosis of late-onset STGD1 can be supported by 
the detection of one disease-causing ABCA4 variant, it would be prudent to require 
the identification of two disease-causing variants before enrollment in early therapeutic 
trials involving late-onset STGD1 patients. 
In summary, the present analysis reveals distinct progression characteristics in eyes with 
RPE atrophy associated with AMD and late-onset STGD1. These results underscore the 
relevance of refined phenotyping to predict the course of disease in a patient presenting 
with RPE atrophy. The results enable more sophisticated prognosis for the individual 
patient and should be considered when designing future interventional trials for both. 
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CHAPTER 4
Measuring progression in 
Stargardt disease
“Asymmetric inter-eye progression in Stargardt disease is most likely observed in patients with 
a later onset and patients carrying lower pathogenic ABCA4 combinations. This needs to be 
considered in novel therapeutic trials with a fellow-eye paired controlled design to optimize the 
power of a study.”
Stanley Lambertus
Nathalie M. Bax
Joannes M.M. Groenewoud
Frans P.M. Cremers
Gert Jan van der Wilt
B. Jeroen Klevering
Thomas Theelen
Carel B. Hoyng 
Invest Ophthalmol Vis Sci. 2016 Dec 1;57(15):6824-6830.
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4.1 Asymmetric inter-eye progression  
 in Stargardt disease
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PURPOSE: Asymmetry in disease progression between left and right eyes can occur 
in Stargardt disease (STGD1) and this needs to be considered in novel therapeutic 
trials with a fellow-eye paired controlled design. This study investigated the inter-eye 
discordance of best-corrected visual acuity (BCVA) and progression of retinal pigment 
epithelium (RPE) atrophy in STGD1.
METHODS: We performed a retrospective cohort study collecting 68 STGD1 patients 
(136 eyes) with ≥1 ABCA4 variants and ≥0.5 year follow-up on BCVA and fundus auto-
fluorescence. We compared inter-eye correlations of RPE atrophy progression between 
early-onset (≤10 years), intermediate-onset (11–44), and late-onset (≥45) STGD1 and 
ABCA4 variant combinations by χ²-tests. We identified associations of discordant 
baseline BCVA and RPE atrophy with discordant RPE atrophy progression by odds 
ratios (OR). We defined discordance by differences >1.5 interquartile ranges ± first/
third interquartiles.
RESULTS: Progression of RPE atrophy correlated moderately between eyes (ρ = 0.766), 
which decreased with later onset (P = 9.8 × 10-7) and lower pathogenicity of ABCA4 
combinations (P = 0.007). Twelve patients (17.6%) had discordant inter-eye RPE 
atrophy progression, associated with baseline discordance of RPE atrophy (OR, 6.50
[1.35 –31.34]), but not BCVA (OR, 0.33 [0.04–2.85]).
CONCLUSIONS: Lower inter-eye correlations are more likely found in late-onset STGD1 
and patients carrying low pathogenic ABCA4 combinations. To achieve the highest 
power in a therapeutic trial, early-phase studies should minimize inter-eye discordance 
by selecting early-onset STGD1 patients carrying severe ABCA4 variants without evi-
dence of asymmetry at baseline.
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Introduction
Stargardt disease (STGD1) is one of the most common retinal dystrophies. Loss of 
macular function causes bilateral loss of visual acuity—usually at childhood.1, 2 The 
first manifestations of the disease may also occur in older patients, up to the seventh 
decade.3, 4 In general, the severity of the disease is associated with the age of onset: 
young patients tend to do worse.5 The variation in age of onset and rate of progression 
is, for the most part, the result of combinations of over 900 variants in the ABCA4 gene.6 
ABCA4 encodes the adenosine triphosphate-binding cassette, subfamily A, member 
4 transporter protein, which actively removes all-trans-retinal with its conjugate 
N-retinylidene-phosphatidylethanolamine from the photoreceptor outer segment 
disks.7 Impaired removal results in condensation reactions, which lead to toxic levels of 
bisretinoids in the outer segment disks. Through phagocytosis of these outer segments, 
bisretinoids accumulate as lipofuscin deposits in the retinal pigment epithelium (RPE). 
These lipofuscin deposits are observed as yellowish-white flecks in the posterior pole.8 
The accumulation of toxic lipofuscin eventually leads to atrophy of the retinal pigment 
epithelium (RPE) and photoreceptors with subsequent loss of the neurosensory retina 
and choriocapillaris.9
Over time, RPE atrophy progresses, as uni- or multifocal areas enlarge and coalesce. 
However, there is considerable variability in these patterns of atrophy; they range from 
large central atrophic areas in early-onset STGD1 patients that can be seen at ado-
lescence2 to relatively small atrophic lesions encircling the fovea in older patients with 
late-onset STGD1.3 The difference in atrophic lesion not only varies between patients,10 
but also the patterns of RPE loss may differ significantly between eyes of one patient. 
Even though the extent of abnormalities is often similar between left and right eyes,11, 12 
some cases with remarkable differences have been described.13
Profound inter-eye differences in disease progression have impact on the statistical 
power in clinical trials; treated and untreated eyes must demonstrate a larger differ-
ence than do the inter-eye differences by their natural course. Otherwise, the required 
sample size will be unreasonably large. However, in early-phase clinical trials for novel 
treatments of STGD114-16 and other retinal dystrophies, small therapeutic effects have to 
be evaluated generally within two years with no more than a few dozen patients. Thus, 
better knowledge of inter-eye correlations is needed for fellow-eye paired controlled 
trials in which the untreated eyes of participants serve as a control.
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In view of these upcoming interventional trials, we have studied the extent of asymmetric 
inter-eye progression of RPE atrophy in patients with STGD1. Fundus autofluorescence 
(FAF) imaging is a valuable tool to evaluate progression of RPE atrophy over time.17-20 
We therefore analyzed inter-eye discordance of RPE atrophy progression using FAF 
imaging along with visual acuity. We hypothesized that a later disease onset and less 
pathogenic combinations of ABCA4 variants contribute to asymmetric inter-eye pro-
gression, and that the asymmetry will increase when asymmetry at baseline is already 
present. 
Methods
Patient selection
We selected patients from the STGD1 database, containing 454 cases, of the Depart-
ment of Ophthalmology at Radboud university medical center (Nijmegen, the Nether-
lands). We included patients in whom the clinical diagnosis of STGD1 was supported 
by the presence of ≥1 (likely) pathogenic ABCA4 variants with a follow-up data of
≥6 months on FAF imaging. Ninety-three STGD1 patients met these inclusion criteria. 
Ten cases were excluded because no RPE atrophy had developed during the entire 
follow-up time. Nine cases displayed RPE atrophy to such a degree that the lesions 
extended beyond the limits of the FAF image. One case was excluded because choroidal 
neovascularization occurred in one eye. Five cases were excluded because they partic-
ipated in an interventional trial.21 The remaining 68 cases were included in this study. 
The patient inclusion process is shown in Supplemental Figure 1. This retrospective 
cohort study was approved by the Institutional Ethics Committee and was performed in 
accordance with the Declaration of Helsinki.
Measurements
We documented sex, age at onset, age at baseline, and follow-up time. Age at onset was 
defined as either the age at which visual complaints were first noted, or, if unavailable, 
the age when the diagnosis was made. Disease onset groups were based on previ-
ously reported cut-off points: early-onset STGD1, ≤10 years2 and late-onset STGD1,
≥45 years.3 The remaining patients were grouped as intermediate-onset STGD1,
11 to 44 years. The age at baseline was the first visit with available imaging and visual 
acuity tests. 
Best-corrected visual acuity (BCVA) was measured with a Snellen or Early Treatment 
Diabetic Retinopathy Study chart, then transformed into the logarithm of the minimum 
angle of resolution (logMAR) for analysis. Fundus autofluorescence (λ = 488 nm,
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emission 500–700 nm) imaging was performed using a confocal scanning laser ophthal-
moscope (Spectralis HRA+OCT; Heidelberg Engineering, Heidelberg, Germany). The 
field of view was set at 30°×30° or 55°×55° and was centered on the macula.22 
Image quantification
The total RPE atrophy area was automatically quantified in FAF images by an observ-
er-independent image analysis algorithm. The algorithm automatically segmented 
the area starting from an arbitrarily selected seed point inside the atrophic area. This 
method was based on a combination of a region growing algorithm and a dynamic, user-
independent threshold selection procedure using Otsu thresholding. Areas were square-
root (√) transformed to correct for baseline RPE atrophy area.23  A good agreement has 
previously been observed between manual area measurements and the automatically 
quantified values (C.I. Sanchez et al. IOVS 2015;56:ARVO E-Abstract 5258), and was 
found to be consistent with the agreement within this cohort (intra-class correlation 
coefficient, 0.977; 95% confidence interval [CI], 0.951–0.987).
Genetic analysis
All reported ABCA4 variants (Supplemental Table 1) were classified as follows: 
1) pathogenic: truncating alleles, significantly enriched in ABCA4-LOVD (LOVD.
nl/ABCA4), which contains 6903 variants (861 unique variants) reported in 3987 
persons with STGD1 or autosomal recessive cone-rod dystrophy (S.S. Cornelis and 
F.P.M. Cremers, unpublished data, 2016); 2) likely pathogenic: non-truncating alleles, 
significantly enriched in ABCA4-LOVD; 3) likely benign: allele frequency (AF) ABCA4-
LOVD/AF ExAC non-Finnish Caucasian <1; 4) benign: ExAC AF >0.006; 5) unknown 
pathogenicity: AF ABCA4-LOVD/AF ExAC non-Finnish Caucasian >1, however not 
significantly enriched. Patients were then grouped by combinations of ABCA4 pathoge-
nicity: 1) pathogenic/pathogenic, 2) pathogenic/likely pathogenic, 3) likely pathogenic/
likely pathogenic, 4) pathogenic in combination with unknown pathogenicity, (likely) 
benign, or a variant that was not published until 31 December 2015, 5) likely pathogenic 
in combination with unknown pathogenicity or (likely) benign (S.S. Cornelis and F.P.M. 
Cremers, unpublished data, 2016).
Statistical analysis
We analyzed BCVA and RPE atrophy measurements using SPSS version 22 (IBM Corp., 
IBM SPSS Statistics, Chicago, IL, USA) with parametric tests. Retinal pigment atrophy 
progression rates were calculated by the difference at the baseline and last follow-up 
visit divided by the follow-up time. Differences in disease duration and follow-up time 
between disease onset groups were analyzed with the Kruskal-Wallis test.
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We used Pearson’s correlation coefficients (ρ) to assess inter-eye correlations of base-
line BCVA, baseline RPE atrophy, and RPE atrophy progression. We compared these 
correlations between disease-onset groups and ABCA4 variant combination groups by 
first performing a Fisher transformation:
Then, these z’-scores were compared for homogeneity. The test for homogeneity 
employs the χ²-distribution for two and four degrees of freedom:
where the summation is over the three disease-onset groups and five ABCA4 variant 
combination groups, respectively.24 
Baseline BCVA and RPE atrophy differences between measurements and the average 
measurements of both eyes were calculated and plotted according to the method of 
Bland and Altman to assess the intra-individual agreement graphically.25 Limits of 
agreement between eyes were plotted for each disease-onset group.
Lin’s concordance correlation coefficient ρc was calculated to evaluate the extent of 
inter-eye symmetry of baseline BCVA, baseline RPE atrophy, and RPE atrophy progres-
sion.26-28 The ρc consists of the product of a precision coefficient (Pearson’s ρ) and an 
accuracy coefficient χa.The accuracy coefficient χa indicates how far the best-fit line of all 
paired left- and right-eye measurements deviates from the 45° line on a square scatter 
plot, and is defined as 
2  +  1 /   +  2  , where scale shift  and location shift relative to 
the scale  (OD, right eye; OS, left eye).29 If all paired measurements exactly lie 
on the 45° line, a coefficient of 1 would be found, indicating perfect symmetry. Strength-
of-agreement criteria were as follows: almost perfect, >0.90; substantial, 0.80–0.90; 
moderate, 0.65–0.80; poor, <0.65.30
As standard deviations can be affected by extreme differences and rely on distribu-
tional assumptions, box-and-whisker plots were used to identify outliers by differences
>1.5 interquartile ranges (IQR) below the first (Q1) or above the third (Q3) interquartiles 
in baseline BCVA, baseline RPE atrophy, and RPE atrophy progression. Odds ratios were 
calculated to identify associations of discordant BCVA and RPE atrophy at baseline with 
RPE atrophy progression.
We performed sample size calculations and a sensitivity analysis for a theoretical 
intervention using nQuery Advisor 7.0 (Statistical Solutions, Boston, MA). We used 
’ = 12 1+1  
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a two-sided paired t-test for differences in means of RPE atrophy progression with a 
test significance level (α) of 0.05 and a power of (1 – β) of 0.80. Standard deviations 
of differences between RPE atrophy progression of treated and nontreated eyes were 
obtained from the standard deviations and correlations of left and right eyes using the 
formula: σd = √(σ1² + σ2² - 2ρσ1σ2).
Results I: Patient characteristics
A total of 68 patients (136 eyes) were included in this study (26 men, and
42 women). The median age at onset was 8.5 (range, 4–10), 20 (range, 11–42), and 
50 (range, 45–69) years for 14 early-onset STGD1, 33 intermediate-onset STGD1, 
and 21 late-onset STGD1 patients, respectively. At baseline, the median disease 
duration was 5 years (range, 0–39). The distribution did not differ between the three 
disease-onset categories. Details of patient characteristics and inter-eye correlations at 
baseline and follow-up are depicted in Table 1.
Baseline inter-eye correlations of best-corrected visual acuity
At baseline, the mean (± standard deviation) BCVA in the right and left eyes was
0.66 ± 0.51 logMAR and 0.72 ± 0.53 logMAR, respectively. Twenty-four right eyes 
and 23 left eyes were identified as the better seeing eye; 21 pairs of eyes had equal 
BCVA. The overall inter-eye correlation (ρ) in BCVA at baseline was 0.756 and did not 
differ between disease onset groups, although a trend of decreasing correlations at later 
disease onset was also observed at follow-up.
Next, we compared the average and differences of baseline BCVA between the left and 
right eyes by a Bland-Altman plot (Supplemental Figure 2A), revealing discordance up 
to 1.70 logMAR. This discordance was most pronounced in 13 patients (two early-onset 
STGD1, seven intermediate-onset STGD1, and four late-onset STGD1), as defined by 
outlying differences below Q1 – 1.5 × IQR or above Q3 + 1.5 × IQR (Supplemental Figure 
2B). Overall, this resulted in an inter-eye agreement (ρc) in baseline BCVA of 0.751
(95% confidence interval (CI), 0.626–0.838). 
Baseline inter-eye correlations of retinal pigment epithelium atrophy
At baseline, the mean √ RPE atrophy area in the right and left eyes was 1.56 ± 1.36 mm
and 1.45 ± 1.36 mm, respectively. Twenty-nine right eyes and 34 left eyes had the 
smallest RPE atrophy area; 5 pairs of eyes had no RPE atrophy. Although baseline RPE 
atrophy between the left and right eyes was highly correlated (ρ = 0.878), the correlation 
was significantly decreased in late-onset STGD1 patients.
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The Bland-Altman plot (Supplemental Figure 3A) showed inter-eye differences up to 
2.49 mm of baseline √ RPE atrophy area. An inter-eye difference below Q1 – 1.5 × IQR 
or above Q3 + 1.5 × IQR (Supplemental Figure 3B), that is, discordant RPE atrophy at 
baseline, was identified in eight patients (intermediate-onset STGD1, four patients; 
late-onset STGD1, four patients). The overall inter-eye agreement (ρc) of baseline RPE 
atrophy was 0.876 (95% CI, 0.806–0.921).
Results II: Discordance of RPE atrophy progression rates
Inter-eye correlations of retinal pigment epithelium atrophy progression
The median follow-up time was 3.9 years (range, 0.5–9.7), of which the distribution did 
not differ between all disease-onset categories. The mean √ RPE atrophy progression 
rates in the right and left eyes were 0.21 ± 0.20 mm/year and 0.20 ± 0.21 mm/year, 
respectively. Thirty-five right eyes and 31 left eyes were identified as the eye with the 
Patient characteristics Early-onset STGD1 Intermediate-onset STGD1 Late-onset STGD1 P value
Sex 7 male
7 female
9 male
24 female
10 male
11 female
Age at onset, years 
(median and range)
8.5 (4–10) 20 (11–42) 50 (45–69)
Baseline
Disease duration, years 
(median and range)
7 (0–27) 4 (0–39) 5 (0–26) 0.768*
Age, years
(median and range)
14.5 (9–31) 36 (13–56) 59 (45–81)
BCVA, logMAR
(mean and SD)
0.419†
  OD 1.08 ± 0.41 0.67 ± 0.50 0.36 ± 0.39
  OS 1.09 ± 0.28 0.77 ± 0.49 0.40 ± 0.55
  Correlation, ρ 0.830 0.723 0.619
√ RPE atrophy, mm 
(mean and SD)
5.5 × 10 -8 †
  OD 1.79 ± 1.29 1.31 ± 1.52 1.79 ± 1.10
  OS 1.76 ± 1.27 1.28 ± 1.58 1.51 ± 1.03
  Correlation, ρ 0.992 0.931 0.601
Follow-up
Follow-up time, years 
(median and range)
5.7 (1.1–9.7) 3.1 (0.9–9.5) 3.8 (0.5–7.6) 0.220*
Age, years
(median and range)
21 (11–36) 33 (15–59) 64 (47–86)
BCVA, logMAR
(mean and SD)
0.0497†
  OD 1.23 ± 0.29 0.93 ± 0.44 0.63 ± 0.60
  OS 1.23 ± 0.29 0.88 ± 0.52 0.54 ± 0.60
  Correlation, ρ 0.897 0.767 0.527
√ RPE atrophy, mm 
(mean and SD)
6.1 × 10 -4 †
  OD 2.73 ± 1.23 1.89 ± 1.69 2.29 ± 1.55
  OS 2.77 ± 1.26 1.86 ± 1.62 2.17 ± 1.49
  Correlation, ρ 0.974 0.938 0.670
Table 1. Characteristics and inter-eye correlations at baseline and at follow-up in 68 Stargardt patients. Median and 
ranges are shown for time variables. Mean and standard deviations (SD) are shown for best-corrected visual acuity 
(BCVA) and √ RPE atrophy.
* Kruskal-Wallis test for differences in disease duration and follow-up.
† χ² with two degrees of freedom for differences in inter-eye correlations.
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slowest progression rate. Two pairs of 
eyes showed no progression in 3.0 and 
3.4 years, respectively. The progression 
rates of √ RPE atrophy correlated between 
the left and right eyes with ρ = 0.766, 
and increased with earlier disease-onset 
groups (P = 9.8 × 10-7). Evaluating the 
inter-eye agreement in progression of RPE 
atrophy, the agreement between the eyes 
was ρc = 0.765 (95% CI, 0.645–0.847) 
(Figure 1). 
 
Discordant progression rates of 
RPE atrophy
Twelve out of 68 patients (early-onset 
STGD1, two patients (14%); intermediate-
onset STGD1, four patients (12%); 
late-onset STGD1, six patients (29%)) 
had discordant RPE atrophy progression 
rates between their eyes by differences below Q1 – 1.5 × IQR or above Q3 + 1.5 × IQR. In 
four of these patients, the eye with the largest RPE atrophy area progressed faster than 
the other eye, thus increasing inter-eye discordance of RPE atrophy over time (mean 
difference, 0.26 ± 0.10 mm/year; Figure 2A). In the other eight patients, the eye with 
the smallest RPE atrophy area progressed faster than the other eye, therefore reducing 
inter-eye discordance of RPE atrophy (mean difference, 0.30 ± 0.12 mm/year; Figure 
2B). The remaining 56 patients had similar progression rates between their eyes (mean 
difference, 0.05 ± 0.04 mm/year, within Q1,3 ± 1.5 × IQR; Figure 2C).
Baseline RPE atrophy and genetic associations with discordant RPE atrophy progression
Discordant RPE atrophy at baseline was associated with discordant RPE atrophy 
progression (odds ratio, 6.50; 95% CI, 1.35–31.34); this association was not found for 
discordant BCVA at baseline (odds ratio, 0.33 (95% CI, 0.04–2.85).
Furthermore, decreasing pathogenicity of ABCA4 variant combinations were signifi-
cantly associated with increasing discordant inter-eye progression (P = 0.007). Propor-
tions and correlations are depicted in Table 2.
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Figure 1. A square scatter plot of inter-eye √ RPE 
progression. Circles are patients with differences 
in baseline √ RPE atrophy between their eyes 
within Q1,3 ± 1.5 × IQR. Triangles are patients who 
fall outside the Q1,3 ± 1.5 × IQR for differences in 
baseline √ RPE atrophy. Dashed line: 45° line of 
perfect agreement. Q1, first interquartile; Q3, third 
interquartile; IQR, interquartile range.
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Results III: Power calculations of a theoretical intervention 
trial 
The power of a paired-control intervention trial will depend on the strength of correla-
tions between pairs, that is, the left and right eye of each patient, and the expected 
treatment effect. For each two-fold increase in expected treatment effect, approxi-
mately a four-fold decrease in patient numbers is needed for a study at equal power. 
Stronger inter-eye correlations will have a linear beneficial effect on the number needed 
to include. The impact on these numbers is highest when a relatively modest treatment 
effect is expected. For instance, a correlation of ρ = 0.766 would require 44 patients, 
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Figure 2.  Concordant and discordant inter-eye progression in Stargardt disease. (A) 60-year old 
female with a disease duration of 1 year and increasing inter-eye differences. ABCA4 variants: c.5461-
10T>C:p.[Thr1821Valfs*13,Thr1821Aspfs*6]/c.2757A>C:p.(Glu919Asp). (B) Eighty-one-year old female with a 
disease duration of 26 years and decreasing inter-eye differences. ABCA4 variants: c.5196+1G>T:p.(?)/+. (C) 
Twenty-six-year old female with a disease duration of 6 years and similar progression rates between eyes. 
ABCA4 variants: c.1853G>A;4297G>A:p.(Gly618Glu;Val1433Ile)/c.2588G>C:p.[Gly863Ala;Gly863del].
ABCA4 variant combination RPE Atrophy Progression
No discordance Discordant Inter-eye correlation 
(Pearson’s ρ)
1. Pathogenic/pathogenic 3 1 0.995
2. Pathogenic/likely pathogenic 21 4 0.790
3. Likely pathogenic/likely pathogenic 9 0 0.597
4. Pathogenic/* 12 3 0.079
5. Likely pathogenic/* 11 4 0.346
Table 2. Proportions of combinations of ABCA4 variants and discordant RPE atrophy progression.
* The second ABCA4 variant was likely benign, of unknown pathogenicity, or not found. 
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whereas this number is 
reduced to 20 in the case 
of a correlation of ρ = 0.9 
(Figure 3). The specific 
inclusion criteria, for exam-
ple, disease onset, ABCA4 
variant combinations, and 
baseline discordance can 
significantly affect the 
number needed to include.
 
Discussion
Based on longitudinal FAF 
data in our current study, 
the overall agreement of 
inter-eye RPE atrophy 
progression in STGD1 was 
only moderate; it was highest in early-onset STGD1 and lowest in late-onset STGD1. 
Discordant progression rates were found in 12 out of 68 (17.6%) patients—which is 
surprisingly high—given that STGD1 is assumed to be a symmetrical inherited retinal 
disease. Discordant progression rates resulted in eyes either converging or diverging 
in atrophy size. Discrepancies of RPE atrophy progression rates were associated with 
discrepancies of RPE atrophy at baseline and less pathogenic ABCA4 variant combina-
tions. 
Autosomal retinal dystrophies are expected to be symmetrical owing to the similar 
genetic and environmental background of both eyes. The majority of STGD1 patients 
exhibit bilateral symmetry in retinal features. Chen et al. illustrated this symmetry 
in left and right eyes of 24 STGD1 patients; they had highly correlated areas of RPE 
atrophy (Pearson’s ρ = 0.998).12  McBain et al. studied the atrophy progression rates in
12 STGD1 patients, reporting a strong inter-eye correlation (Spearman’s ρ = 0.846).11 In 
our cohort, these inter-eye correlations of RPE atrophy were substantially lower, but they 
can be explained by inclusion of late-onset STGD1 patients, which decreased the overall 
correlation. Inter-eye correlations of late-onset STGD1 were previously estimated to be 
moderate (ρ = 0.52).20 When late-onset STGD1 patients are excluded, our inter-eye 
correlations were similar to those reported by others.
Figure 3.  A sensitivity analysis for the power calculation of a 
theoretical intervention trial. Assuming a 30% reduction in 
disease progression (treatment effect), 44 patients are needed 
(inter-eye correlation ρ = 0.766; ρ = 0.20, ρ = 0.05, two-sided paired 
samples t-test). The sample size will decrease to 20 in the case of 
an inter-eye correlation of 0.9. In the case of a correlation in disease 
progression of 1, 0.8, 0.6, 0.4, 0.2, and 0 between left and right eyes, 
3, 38, 73, 108, 143, or 178 patients are needed, respectively.
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Previous studies were limited by standard analyses of correlations, which cannot 
address the absolute symmetry within a patient. In contrast, we used Lin’s concordance 
correlation coefficients and descriptive Bland-Altman plots, which are more appropriate 
and previously described in age-related macular degeneration.27 In addition, there is an 
inherent increase in variability of inter-eye differences when the magnitude of atrophic 
areas increases. We corrected this by expressing the inter-eye differences as the square 
root, thus the differences were proportional to the magnitude of measurements. More-
over, square-root transformation corrected baseline dependence, which was reported 
previously with an average atrophy enlargement increase of 0.016 mm2/year for each 
month of follow-up.10 
Although we found that progression rates for atrophy are more likely to be discordant 
in eyes that differ more at baseline, progression rates are rather unpredictable between 
patients and between eyes within a patient. McBain et al. suggested that electroretinog-
raphy could predict the rate of atrophy progression, but they did not account for baseline 
atrophy size. It would be interesting if discordance in electroretinography between eyes 
of a patient would also predict inter-eye differences in progression, independent of 
their baseline atrophy size.10 Burke et al. indicated that changes on optical coherence 
tomography would precede RPE atrophy and may thus predict the rates of atrophy 
progression.31 These potential predictors for disease progression need to be addressed 
in future work.
The lower inter-eye correlations in older patients could be explained by the increased 
time within which stochastic factors, for example, small initial differences leading to 
significant differences later, can influence phenotypic expression. Differences in ABCA4 
variant expression may alter disease severity between eyes with mild variants, which 
can have a slightly different pathogenicity. In contrast, differences in expression would 
not influence progression speed much in severe ABCA4 combinations as both variants 
would cause an equally severe phenotype. 
The statistical power of a randomized controlled trial increases when differences are 
measured between correlated left and right eyes. To this extent, we recommend a 
fellow-eye paired trial design for retinal dystrophies, for example, as applied in a phase 
II gene therapy trial for choroideremia with 30 patients enrolled (ClinicalTrials.gov, 
NCT02407678). To achieve 80% statistical power in this trial, an effect size of at least 
0.53 is required.32 For the same expected effect size, a patient-controlled trial would 
need 58 patients in each arm.33 Even in multicenter trials, such high sample sizes are 
difficult to obtain in rare retinal dystrophies. However, it is important to bear in mind that 
a fellow-eye paired control is impossible for pharmaceutical strategies in which both 
eyes of a patient are being treated (ClinicalTrials.gov, NCT02402660). Furthermore, it is 
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preferred that an effect on relatively slow retinal degeneration is detected to identify a 
potential long-term benefit rather than a temporary gain of visual function.34
A therapeutic trial will gain a major advantage from a fellow-eye control in early-onset 
STGD1 because of their high inter-eye correlations. However, discordance was also 
present in some of these younger patients. As the progression can be better predicted 
in similar rather than in discordant eyes, retinal asymmetry needs to be considered as 
an exclusion criterion for small early-phase trials. Such stringent criteria will increase 
the chance of detecting efficacy with fewer patients. Criteria would include early-onset 
STGD1 patients with concordant retinal abnormalities between their eyes carrying 
severe ABCA4 variants; not only do these patients have the highest inter-eye symmetry 
in disease progression, but they are also expected to have the most severe disease 
course.1, 2 In these patients, therapy will potentially provide the most benefit, and in 
these patients, its effect has the highest chance to be detected.
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BACKGROUND: Each inherited retinal disorder is rare, but together, they affect millions 
of people worldwide. No treatment is currently available for these blinding diseases, 
but promising new options—including gene therapy—are emerging. Arguably, the most 
prevalent retinal dystrophy is Stargardt disease. In each case, the specific combination 
of ABCA4 variants (>900 identified to date) and modifying factors is virtually unique. It 
accounts for the vast phenotypic heterogeneity including variable rates of functional and 
structural progression, thereby potentially limiting the ability of phase I/II clinical trials 
to assess efficacy of novel therapies with few patients. To accommodate this problem, 
we developed and validated a sensitive and reliable composite clinical trial endpoint for 
disease progression based on structural measurements of retinal degeneration.
METHODS AND FINDINGS: We used longitudinal data from early-onset Stargardt 
patients from the Netherlands (development cohort, n = 14) and the United Kingdom 
(external validation cohort, n = 18). The composite endpoint was derived from best-cor-
rected visual acuity, fundus autofluorescence, and spectral-domain optical coherence 
tomography. Weighting optimization techniques excluded visual acuity from the 
composite endpoint. After optimization, the endpoint outperformed each univariable 
outcome, and showed an average progression of 0.41° retinal eccentricity per year (95% 
confidence interval, 0.30–0.52). Comparing with actual longitudinal values, the model 
accurately predicted progression (R², 0.904). These properties were largely preserved 
in the validation cohort (0.43°/year [0.33–0.53]; prediction R², 0.872). We subsequently 
ran a two-year trial simulation with the composite endpoint, which detected a 25% 
decrease in disease progression with 80% statistical power using only 14 patients.
CONCLUSIONS: These results suggest that a multimodal endpoint, reflecting structural 
macular changes, provides a sensitive measurement of disease progression in Stargardt 
disease. It can be very useful in the evaluation of novel therapeutic modalities in rare 
disorders.
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Introduction
Inherited blindness affects millions of people worldwide—the majority suffering from 
retinal disease.1 Inherited retinal disorders now represent the primary cause of blindness 
in the working age population in the UK, and secondary in childhood.2 They are clinically 
and genetically heterogeneous, caused by sequence variants in more than 300 distinct 
genes (RetNet). Mutations in the adenosine triphosphate-binding cassette, subfamily 
A, member 4 (ABCA4) gene are linked to arguably the most common retinal dystrophy: 
autosomal recessive Stargardt disease (STGD1).3 Each case of STGD1 is, in a sense, 
unique by specific combinations of pathogenic ABCA4 variants (>900 variants identi-
fied to date) and modifying factors. Consequently, the natural course is highly variable, 
ranging from severe early-onset rapid degeneration4, 5 to relatively mild late-onset dis-
ease.6, 7 The eventual vision loss results from progressive impairment and degeneration 
of photoreceptors and their supporting retinal pigment epithelium (RPE).8 
Recently, significant advancement has been made in the development of therapies 
that aim to slow disease progression, or even to restore lost photoreceptors in STGD1. 
These include replacement of ABCA4 by gene therapy,9 cell-based therapies,10 and 
pharmacological strategies including slowing the visual cycle or inhibition of vitamin 
A dimerization.11, 12 Clinical trials are currently recruiting patients to assess safety and 
efficacy. However, successful evaluation of these therapies critically hinges on sensitive 
and reliable measures for disease progression.
To monitor efficacy of a treatment, current trials generally use functional endpoints 
(Supplemental Table S1). One of the most widely used U.S. Food and Drug Administration-
approved endpoints is best-corrected visual acuity (BCVA).13 However, the main disad-
vantage of BCVA lies in its extremely variable deterioration rate in patients with retinal 
dystrophies. Moreover, visual acuity decline can be a late phenomenon following a long 
period of pathophysiological changes.14 As a result, the endpoint has an unfavorable 
signal-to-noise ratio, which leads to a need for longer follow-up and large cohorts. This 
setup is impossible to achieve given the unacceptable long time frame and the rarity of 
these disorders. 
However, studies suggest that structural abnormalities gradually expand centrifugally,5, 
15 starting from the foveal center towards the periphery. Although loss of foveal function 
is highly important from a patient’s perspective, it is only one step in the overall pattern of 
retinal degeneration. This pattern is thought to initiate with melanization abnormalities 
in the RPE,16, 17 and is trailed by changes in lipofuscin fluorophores,18-20 degeneration of 
the RPE,21-23 and loss of the ellipsoid zone (EZ) and external limiting membrane (ELM).24-27 
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However, these transition 
zones are not present in 
every case, and do not 
always start at the center 
of the macula; many are still 
not well understood.
A composite outcome mea-
sure is likely to outperform 
single candidate outcome 
measures28 in accurately 
measuring short-term pro-
gression, and can therefore 
increase statistical power of 
pivotal clinical trials. In this 
study, we chose to measure four structural metrics of expanding transition zones and 
one psychophysical metric over time in a cohort of patients with early-onset STGD1. 
These included questionably and definitely decreased autofluorescence (QDAF and 
DDAF), and loss of the EZ, ELM and BCVA. Next, we assessed intra- and inter-grader 
differences. Having standardized all metrics, we then calculated an optimal weighted 
composite. The same measurements were made in a second patient cohort, and, using 
the composite, we predicted and compared progression with real longitudinal values. 
We subsequently ran a simulation to examine the power of the composite endpoint and 
alternatives to detect a difference in outcome given a theoretical intervention with a 
significant impact on progression rate.
Results
Characteristics of the initial patient population
A cohort of 14 patients with early-onset STGD1 ascertained at the Radboud university 
medical center in Nijmegen had a median age at disease onset of 9 years (range, 4–11). 
Seventy-four eye-visits of 28 eyes were included in this study (range, 2–4 visits per 
eye). At the time of inclusion, all eyes had abnormal fundus autofluorescence (FAF) 
imaging and evidence of loss of photoreceptors on spectral-domain optical coherence 
tomography (SD-OCT), primarily limited to the macula at their baseline visit. Due to their 
early disease onset and rapidly progressive macular changes, a significant proportion of 
patients were expected to progress to retina-wide disease over time.4, 5, 29. The follow-up 
time ranged from 1.1 to 9.7 years (median, 4.7). 
Figure 1. Visual acuity as a function of degrees of retinal eccen-
tricity.
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Visual acuity measurements indicate extra-macular dysfunction
At the first visit, the Nijmegen cohort had a median BCVA of 20/205 Snellen in both 
eyes. The highest BCVA can be obtained at the fovea and diminishes rapidly by retinal 
eccentricity (ε) as shown in Figure 1.30 According to Figure 1, 20/205 Snellen corre-
sponds to 12.76° of ε by BCVA (εBCVA), the equivalent diameter being 7.7 mm. Assuming 
a 5.5 mm diameter of the macula, the high degree of eccentricity indicated that the 
patients’ visual function corresponded to extra-macular disease at baseline.
 
Structural parameters are measured with high reproducibility
To assess the accuracy and reliability of measurements on FAF imaging and SD-OCT, 
we analyzed inter- and intra-grader agreements. These included transition zones of 
QDAF and DDAF areas, and transverse loss of the EZ and ELM. The absolute mean 
(± standard deviation) differences within one grader for εQDAF, εDDAF, εEZ and εELM were 
0.19 ± 0.18°, 0.20 ± 0.23°, 0.10 ± 0.12°, and 0.20 ± 0.22°, respectively. The intra-grader 
measurements were highly correlated with intraclass correlation coefficients (95% con-
fidence interval) of 0.995 (0.989–0.997), 0.994 (0.986–0.997), 0.998 (0.993–0.999), 
and 0.998 (0.994–0.999), respectively. The absolute mean differences between 
graders were 0.26 ± 0.23°, 0.22 ± 0.21°, 0.26 ± 0.23°, and 0.23 ± 0.18°, respectively. 
The measurements from both graders were highly correlated with intraclass correlation 
coefficients of 0.992 (0.986–0.995), 0.994 (0.990–0.996), 0.992 (0.971–0.998), and 
0.997 (0.992–0.999), respectively.
Figure 2. Schematic and representative images of measurements in fundus autofluorescence imaging 
and spectral-domain optical coherence tomography. Patient 9: area of questionably decreased auto-
fluorescence (QDAF, blue), 1.37 mm²; area of definitely decreased autofluorescence (DDAF, black), 0.33 
mm²; transverse loss of external limiting membrane (ELM loss, red), 1.75 mm, transverse loss of ellipsoid 
zone (EZ loss, blue), 2.24 mm; best-corrected visual acuity, 20/100; ABCA4 variants, c.1622T>C;3113C>T:p.
[Leu541Pro;Ala1038Val] and c.6316C>T:p.(Arg2106Cys).
(B) Spectral-domain optical coherence tomography
(A) Fundus autofluorescence
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Initial transition zones on retinal imaging
We measured the abnormalities of lipofuscin fluorophores in the RPE by determining 
both the transition zones of DDAF and QDAF on FAF imaging as shown in Figure 2A.20, 31
At the first visit, the median εDDAF and εQDAF for both eyes were 1.80° (range, 0 –5.60)
and 4.22° (range, 1.68–7.67), equivalent to an area of 0.92 mm² and 5.03 mm², 
respectively. Additionally, we measured 
the horizontal loss of the photorecep-
tor-related ELM and EZ through the foveal 
center on SD-OCT (Figure 2B). At the first 
visit, the median εELM and εEZ for both eyes 
were 5.09° (range, 2.50–10.71) and 3.54° 
(range, 2.99–7.83), equivalent to a loss of 
3.05 mm and 2.12 mm, respectively.
A structural composite measure 
of expanding transition zones 
outperforms univariable measures
We assessed the change of each individ-
ual parameter over time by linear mixed-
effects models. The models accounted 
for between-patients and between-eyes 
effects. We then calculated the sensitivity 
of each parameter by the ratio of the popu-
lation mean slope, i.e., overall disease pro-
gression, and the residual standard devi-
ation (mean-to-standard-deviation ratio, 
MSDR). εQDAF had the highest sensitivity
Slope (mean) Residual (SD) MSDR
Univariable outcomes
εBCVA 0.31°/year 3.77°/year 0.08
εQDAF 0.32°/year 0.14°/year 2.32
εDDAF 0.58°/year 0.33°/year 1.73
εELM 0.34°/year 0.17°/year 1.97
εEZ* 0.38°/year * *
Composite outcomes
Unweighted (εBCVA, εQDAF, εDDAF, εELM, εEZ) 0.35°/year 1.24°/year 0.28
Unweighted (εQDAF, εDDAF, εELM, εEZ) 0.47°/year 0.24°/year 2.00
Optimal weight (15% εQDAF,, 5% εDDAF, 15% εELM, 55% εEZ) 0.41°/year 0.13°/year 3.21
Table 1. Yearly progression rate of changes in retinal eccentricity (ε) by visual function, fundus 
autofluorescence and optical coherence tomography. *There were limited measurements available 
because it exceeded retinal scans. BCVA = best-corrected visual acuity, QDAF = questionably decreased 
autofluorescence, DDAF = definitely decreased autofluorescence, ELM = external limiting membrane, EZ 
= ellipsoid zone, MSDR = mean-to standard deviation ratio, SD = standard deviation, ε = retinal eccentricity. 
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Figure 3. Highest potential mean-to-standard 
deviation ratio (MSDR) for each single out-
come measure at different weightings with 
all possible weight combinations of the other 
metrics. MSDRs for best-corrected visual acuity 
(grey) decrease at increasing weight. MSDRs for 
transition zones of questionably decreased auto-
fluorescence (blue) increase until 25% weight, but 
gradually decrease at higher weights. MSDRs for 
transition zones of definitely decreased autoflu-
orescence (red) decrease at weights higher than 
5%. MSDRs for loss of the ellipsoid zone (green) 
are constant, but decrease substantially at weights 
higher than approximately 70%. MSDRs for loss of 
the external limiting membrane (black) decrease 
at weights higher than approximately 80%.
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(MSDR, 2.32), whereas εBCVA had the lowest (MSDR, 0.08). The MSDR for εEZ could not 
be obtained as there were not sufficient measurements available. Sensitivities of all 
individual parameters are shown in Table 1. We constructed a composite variable from 
changes in ε as measured by BCVA, QDAF, DDAF, EZ, and ELM. Results from MSDR 
calculations of every potential weighting combination indicated that the most sensitive 
composite consisted of a weighted mean of changes in εBCVA (0%), εQDAF (25%), εDDAF 
(5%), εEZ (55%), and εELM (15%). We observed an overall progression rate of 0.41°/year 
(95% confidence interval, 0.30–0.52). Potential MSDRs for all measures with different 
weighting scores are shown in Figure 3. Based on the weighted composite score we 
predicted changes in ε of six patients with a third or fourth visit. The predicted values 
correlated strongly with the measured weighted composite score (R², 0.904; slope,
0.90 [0.70–1.11]; intercept, 0.14 [-0.55 to 0.83]; Figure 4A).
Accurate prediction of disease progression is validated in a replication 
cohort
Using the identical weighted score in the mixed-effects model, we predicted the progres-
sion in a separate replication cohort of 18 Stargardt patients, ascertained at Moorfields 
Eye Hospital in London. One hundred and thirty-eight eye-visits were included (range, 
2–6 visits per patient). The London cohort was not significantly different to the Nijmegen 
cohort: with a median age at disease onset of 8 years (range, 5–11; Mann-Whitney U, 
P = 0.419), and follow-up from 1.0 to 11.0 years (median, 4.5; Mann-Whitney U, P = 0.722). 
We observed an overall progression of 0.43°/year (95% confidence interval, 0.33–0.53). 
Figure 4. Weighted composite score and predicted outcome. Matching colors represent the right 
and left eye of the same patient. (A) Results from six early-onset Stargardt patients. (B) The predicted 
outcome in the replication cohort showed comparable results. 
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Cohort characteristics compared to the Nijmegen cohort are further described in Table 2. 
Predicted values correlated with the measured weighted composite score (R², 0.872; 
slope, 1.17 [0.99–1.34]; intercept, -0.29 [-0.77–0.18]; Figure 4B).
Simulation reveals high statistical power despite small numbers of 
patients and short follow-up
Finally, to assess the value of the composite biomarker in an interventional trial, we 
simulated a randomized-controlled paired trial in 14 patients, with a two-year follow-up 
period, and different treatment effects (Figure 5). Using the optimized weighted com-
posite score as the primary endpoint, we obtained a statistical power of >80% (with a 
significance level of 0.05) in the case of a 25% treatment effect. Unweighted structural 
scores decreased the power by approximately 50%. 
Discussion
The genotypic and phenotypic heterogeneity of rare diseases are a challenge for 
designing therapeutic clinical trials using conventional parameters. This affects 
many patients; current estimates are between 6.5 and 9.9 million inhabitants of the
EU28 countries (1.3–2.0%). Jointly, these diseases represent a relevant public health 
issue,32 and to evaluate novel treatments, better strategies are needed. Current strat-
egies use biomarkers, which are often insufficient to provide appropriate sample size 
calculations, or require long-term follow-up (Supplemental Table S1). However, an 
Radboudumc MEH
Patients 7 men 11 men
7 women 7 women
Baseline characteristics
Age at onset (years) 9 (4–11) 8 (5–11)
Age at baseline (years) 13 (9–26) 14 (8–25)
εBCVA (°, Snellen equivalent) 12.76 (9.85–24.00), 20/200 12.62 (6.31–18.94), 20/200
εQDAF (°, area equivalent) 4.22 (1.68–7.67), 5.03 mm² 4.64 (1.44–9.98), 6.10 mm²
εDDAF (°, area equivalent) 1.80 (0–5.60), 0.92 mm² 2.40 (0–6.41), 1.63 mm²
εELM (°, transverse equivalent) 5.09 (2.50–10.71), 3.05 mm 4.82 (2.06–7.71), 2.89 mm
2.89 mm
εEZ (°, transverse equivalent) 3.54 (2.99–7.83), 2.12 mm 5.87 (3.86–8.58), 3.52 mm
Disease progression
Follow-up (years) 4.73 (1.13–9.71) 4.47 (1.0–10.99)
Progression (°/year) 0.41 (95% CI, 0.30–0.52) 0.43 (95% CI, 0.33–0.53)
Table 2. Characteristics of early-onset Stargardt cohorts from Radboud university medical center
(Radboudumc) and Moorfields Eye Hospital (MEH). Median and range are shown for baseline charac-
teristics and follow-up. BCVA = best-corrected visual acuity, CI = confidence interval, QDAF = questionably 
decreased autofluorescence, DDAF = definitely decreased autofluorescence, ε = retinal eccentricity, ELM = 
external limiting membrane, EZ = ellipsoid zone, SE = standard error, ε = retinal eccentricity.
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integrated approach of these individual biomarkers can result in a reliable and sensitive 
marker for disease progression. In this paper, we showed that such markers can be 
developed using composite endpoints and weighting optimization techniques.
The composite endpoint that we developed to sensitively measure disease progression 
in patients with early-onset STGD1 was based on its spatiotemporal disease course. 
Although the exact pathophysiological mechanisms of the disease pattern are still not 
completely understood, natural history studies suggest a centrifugal expansion from 
macula-only to potentially retina-wide disease.5, 15, 16, 29, 33 Visual acuity failed to detect 
this gradual expansion due to its low signal-to-noise ratio in the composite model. In the 
final model, the expansion of different transition zones is analyzed by two widely avail-
able imaging techniques. SD-OCT can visualize photoreceptor damage, represented by 
loss of the ellipsoid zone, followed by loss of the external limiting membrane,34-36 and 
FAF imaging can detect RPE atrophy associated with photoreceptor dysfunction/loss.26 
In the future, the composite 
model may be further 
optimized by incorporating 
more sophisticated retinal 
imaging techniques such 
as adaptive optics scan-
ning light ophthalmoscopy 
which affords in-vivo 
cellular imaging. Parame-
ters derived from electro-
physiological assessment 
could also potentially 
strengthen the composite 
model, although it is limited 
by significantly greater 
test-retest variability than 
aforementioned structural 
testing.37-39
We are aware that, ulti-
mately, the value of novel 
therapeutic modalities 
should be inferred from 
their impact on outcomes 
that matter to patients. In 
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Figure 5. Power calculations of a simulated therapeutic trial 
based on fourteen early-onset Stargardt patients. Dark blue line: 
a power of 80% is reached with a 25% overall treatment effect and 
a two-year follow-up period. Purple line: the power will drastically 
decrease when best-corrected visual acuity is included in the 
outcome measure. Turquoise line: worse eye treated. Green line: 
one-year follow-up. Ocher line: unweighted structural composite. 
Red line: non-paired trial design. Yellow line: best-corrected visual 
acuity as a single outcome measure.
119 • CHAPTER 4: Measuring progression in Stargardt disease
the context of eye disease, these would certainly include vision and the impact that visual 
impairments have on daily life (patient-reported outcome measures). In addition, the 
long-term safety of such novel treatments should be safeguarded. For these purposes, 
the metric that we have developed in this study is unlikely to be appropriate in isola-
tion, since its focus lies on structural abnormalities alone. We believe its value mainly 
derives from the ability to rationally select promising novel treatment modalities and 
also potentially facilitate patient selection for recruitment to clinical trials. Consequently, 
it will need to be demonstrated that the employed structural parameters correlate with 
functional outcome in the long term. 
Multimodal analysis is a powerful technique, potentially reducing costs and duration of 
clinical trials and also likely reducing beta errors in data analysis, thereby hopefully facil-
itating effective treatments being identified more readily and rapidly for patients with 
rare diseases. There is also the possibility of further improvements with the inclusion of 
other biomarkers in the future, and the potential to be extrapolated to other disorders. 
Materials and methods
Patient selection
We selected patients from the Stargardt databases of the Departments of Ophthalmol-
ogy at Radboud university medical center (Nijmegen, the Netherlands) and Moorfields 
Eye Hospital (London, United Kingdom). We used the patient data from Radboud uni-
versity medical center to develop the progression model, and the data from Moorfields 
Eye Hospital to replicate the study. We included patients with the faster progressive 
early-onset form of STGD1, harboring ≥2 likely disease-causing sequence variants in 
ABCA4 (Table 3), and with at least one year follow-up with FAF imaging and/or SD-OCT 
The early-onset phenotype typically presents with foveal atrophy that may precede 
the development of yellow-white fundus flecks. Early-onset STGD1 is associated with 
the most rapid deterioration of all patients with STGD1.5 We only included patients 
with a reported disease onset <12 years of age.4, 5 We excluded (1) patients with very 
early disease in which only thickening of the external limiting membrane was present, 
because this would preclude the OCT measurements, (2) patients with advanced dis-
ease characterized by RPE atrophy beyond the vascular arcades at first presentation, 
and (3) patients who participated in an interventional trial.40. This study was approved 
by the relevant Institutional Ethics Committees and was performed in accordance with 
the Declaration of Helsinki. All patients provided informed consent prior to receiving 
additional ophthalmologic examinations.
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Clinical examinations
We reviewed the records and imaging databases to extract information including 
BCVA, FAF imaging, and SD-OCT. Best-corrected visual acuity was measured using a 
Snellen or Early Treatment Diabetic Retinopathy Study chart. Short-wave FAF imaging 
(λ = 488 nm, emission 500–700 nm) was performed using a confocal scanning laser 
ophthalmoscope (Spectralis HRA+OCT or HRA2, Heidelberg Engineering, Heidelberg, 
Germany). The field of view was set at 30°×30° or 55°×55° and was centered at the 
Radboudumc
Patient Variant 1 Variant 2
1 c.5461-10T>C p.[Thr1821Valfs*13,
Thr1821Aspfs*6]
c.5461-10T>C p.[Thr1821Valfs*13,
Thr1821Aspfs*6]
2 c.5461-10T>C p.[Thr1821Valfs*13,
Thr1821Aspfs*6]
c.214G>A p.(Gly72Arg)
3 c.5461-10T>C p.[Thr1821Valfs*13,
Thr1821Aspfs*6]
c.5537T>C p.(Ile1846Thr)
4 c.768G>T p.(?) c.1822T>A p.(Phe608Ile)
5 c.3033-?_3364+?del p.(?) c.5714+5G>A p.(?)
6 c.5461-10T>C p.[Thr1821Valfs*13,
Thr1821Aspfs*6]
c.5337C>A p.(Tyr1779*)
7 c.286A>G p.(Asn96Asp) c.286A>G p.(Asn96Asp)
8 c.5461-10T>C p.[Thr1821Valfs*13,
Thr1821Aspfs*6]
c.4773+1G>A p.(?)
9 c.1622T>C;3113C>T p.[Leu541Pro;Ala1038Val] c.6316C>T p.(Arg2106Cys)
10 c.768G>T p.(?) c.768G>T p.(?)
11 c.3033-?_3364+?del p.(?) c.5714+5G>A p.(?)
12 c.4128+1G>A p.(?) c.3259G>A p.(Glu1087Lys)
13 c.4128+1G>A p.(?) c.3259G>A p.(Glu1087Lys)
14 c.4139C>T p.(Pro1380Leu) c.2160+1G>T p.(?)
MEH
Patient Variant 1 Variant 2
1 c.3191-1G>T p.(?) c.4139C>T p.(Pro1380Leu)
2 c.4462T>C p.(Cys1488Arg) c.4462T>C p.(Cys1488Arg)
3 c.6079C>T p.(Leu2027Phe) c.3322C>T p.(Arg1108Cys)
4 c.6479+1G>A p.(?) c.6479+1G>A p.(?)
5 c.6479+1G>A p.(?) c.6479+1G>A p.(?)
6 c.4469G>A p.(Cys1490Tyr) c.3197T>G p.(Met1066Arg)
7 c.4253+4C>T p.(?) c.4253+4C>T p.(?)
8 c.5461-10T>C p.[Thr1821Valfs*13,
Thr1821Aspfs*6]
c.3299T>A p.(Ile1100Asn)
9 c.768G>T p.(?) c.4139C>T p.(Pro1380Leu)
10 c.3081T>G p.(Tyr1027*) c.3081T>G p.(Tyr1027*)
11 c.6286G>A p.(Glu2096Lys) c.2894A>G p.(Asn965Ser)
12 c.4577C>T p.(Thr1526Met) c.3322C>T p.(Arg1108Cys)
13 c.93G>A p.(Trp31*) c.2522A>C p.(Gln841Pro)
14 c.4139C>T p.(Pro1380Leu) c.1957C>T p.(Arg653Cys)
15 c.6729+4_6729+18del p.(?) c.6729+4_6729+18del p.(?)
AGTTGGCCCTGGGGC AGTTGGCCCTGGGGC
16 c.5714+5G>A p.(?) c.1622T>C;3113C>T p.[Leu541Pro;Ala1038Val]
17 c.6729+4_6729+18del p.(?) c.6729+4_6729+18del p.(?)
AGTTGGCCCTGGGGC AGTTGGCCCTGGGGC
18 c.2912C>A p.(Thr971Asn) c.2912C>A p.(Thr971Asn)
Table 3. ABCA4 variants in early-onset Stargardt patients from Radboud university medical center 
(Radboudumc) and Moorfields Eye Hospital (MEH). 
del = deletion, fs = frameshift, ins = insertion, * = stop codon.
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macula. Cross-sectional images were obtained using SD-OCT (Spectralis HRA+OCT, 
Heidelberg Engineering, Heidelberg, Germany) centered at the macula (Supplemental 
Dataset S1). 
Functional measurements
We analyzed data with SAS Statistical Analysis Software Version 9.2 (SAS Institute, 
Cary, NC). Best-corrected visual acuity can be expressed in retinal eccentricity (ε) to 
estimate the spatial extent of retinal dysfunction spatially. It has been calculated pre-
viously that an object must grow by 0.2° in size to maintain BCVA for each degree of 
eccentricity.30. The BCVA is therefore reduced by a factor of 1/1.2 for each degree. This 
results in a transformed BCVA to the estimated equivalent of ε:
   (1) which can be written as    (2)
Quantitative measurements on imaging
Abnormalities that were expected to consistently increase over time were included 
for quantification. Two independent authors (S.L. and N.M.B.), blinded to the each 
other’s findings, manually delineated areas of abnormal autofluorescence signals 
based on darkness levels on FAF imaging, and the loss of retinal layers on SD-OCT. 
These included areas of questionably decreased autofluorescence (QDAF), definitely 
decreased autofluorescence (DDAF) , transverse loss of the external limiting membrane 
(ELM) and ellipsoid zone (EZ) on the OCT scan through the fovea. All measurements 
were standardized to retinal eccentricity. One degree of eccentricity corresponds to 
approximately 0.3 mm on the retina.41 Therefore, the eccentricity can be calculated as 
the radius of the circular equivalents of the sum of QDAF and DDAF areas using the 
previously reported conversion factor:
  (3) and    (4)
As the transverse horizontal loss of retinal layers represents the diameter of a circular 
equivalent, the eccentricities of ELM loss and EZ loss could be calculated as follows:
  (5) and    (6)
Reproducibility of measurements
If the discrepancy between graders exceeded 1°, the graders were asked to reach 
consensus on the location and extent of the transition zone. To assess the intra-grader 
reproducibility, one of the two graders (S.L.) measured each image by each method 
twice, with a two-month interval between gradings of the same image. We calculated 
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the absolute inter- and intrarater agreement of εQDAF, εDDAF (5%), εELM, and εEZ by intraclass 
correlation coefficients with 95% confidence intervals. Averaged values of the graders 
were used for final analyses.
Modelling disease progression
The composite ΔC was constructed from changes in ε as measured in all univariable 
biomarkers:
     (7)
a, b, c, d, and e are weighting scores for each biomarker.
The composite biomarker was used to detect disease progression in a linear two-level 
random effects mixed model, which can describe expansion rates of a transition zone 
quite well within a short period. It accounts for variations between patients and between 
the eyes of each patient, and can thus incorporate a potential non-linear process in the 
variance components of these random effects42:
   (8)
• ΔCij(Δt) is the change of the composite score from baseline for the ith patient in eye 
j at time since baseline Δt,
• Δtik is the kth follow-up time for patient i,
• s is the mean population slope (first level fixed effect),
• si are the deviations of the ith patient’s slope from the population value (independent 
second level random effects),
• sij are the deviations of the slope of both eyes in patient i from his mean regression 
line (independent third level random effects),
• Eijk is the residual error.
The intercept of the model was set to zero, because differences from baseline were 
used. 
Weighting scores optimization
Weighting scores were subsequently chosen by an optimization criterion,28 which 
was constructed by the ratio of the population mean slope and the residual standard 
deviation (MSDR). The criterion was empirically evaluated for different combinations of 
weighting scores of parameters: 
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MSDR= s / RMSE  (9)
• s is the mean population slope, 
• RMSE (root-mean-square error) is the residual standard deviation, a scale-
dependent measure for accuracy.
The total number of unique combinations follows a binomial coefficient , where 
n is the number of intervals, and a is the number of biomarkers. Five biomarkers with 
5% intervals (20 steps from 0 to 100%) resulted  = 10626 in combinations, which 
could be tested within reasonable computational time. A weighting of zero resulted in 
exclusion of that particular biomarker. When a certain biomarker was missing or not 
measurable, the ΔC was calculated by the changes in the other biomarkers with their 
respective weighting scores. The combination with the highest MSDR was eventually 
used in the final model (Supplemental Dataset S2 and Appendix S1).
Validation and replication of the model
In a subset of patients (six), in which three or more visits were available, we calculated 
disease progression of the last visit. These final visits were excluded in the construction 
of the weighted composite. We compared these scores with the predicted scores based 
on the mixed model. Using identical weighting scores, we replicated the study in another 
cohort.
Trial simulations
Based on these calculations, the optimal composite score difference was used to per-
form simulations of a two-year interventional trial with the change in retinal eccentricity 
as primary outcome measured by the composite biomarker. By introducing a potential 
treatment effect, we calculated the expected power of a trial with these patients. The 
treated eye was randomly assigned by a Bernoulli distribution. The progression was 
then simulated as follows:
where 
• difference of ΔCi,t(Δti,l+x) is the difference of the change of the composite score from 
baseline for the ith patient in the jth eye t at x years after the last visit l, compared to 
the last visit.
• the adjusted RMSE was calculated for residual errors of follow-up measurements 
without baseline measurements (Δti,0), where Eij is zero in all patients,
• the treatment effect δ was simulated from 0 to 1 by steps of 0.05 in treated eyes.
(10)
(11)
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As the degree of abnormalities are highly correlated between left and right eyes,21, 23 the 
power can be increased considerably when the fellow eye serves as the paired control. A 
paired-samples T-test was therefore performed to assess the differences between eyes 
in progression of changes in retinal eccentricity. Power calculations were performed by 
10000 simulations for each data point (Supplemental Appendix S2).
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4.3 Lipofuscin-associated
 photo-oxidative stress during  
 fundus autofluorescence imaging
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PURPOSE: Current standards and guidelines aimed at preventing retinal phototoxicity 
during intentional exposures do not specifically evaluate the contribution of endoge-
nous photosensitizers. However, certain retinal diseases are characterized by abnormal 
accumulations of potential photosensitizers such as lipofuscin bisretinoids in the retinal 
pigment epithelium (RPE). We sought to determine these contributions by a numerical 
assessment of in-vivo photo-oxidative stress during irradiation of RPE lipofuscin.
METHODS: Based on the literature, we calculated the retinal exposure levels, optical fil-
tering of incident radiation by the ocular lens, media, photoreceptors, and RPE melanin, 
light absorption by lipofuscin, and photochemical effects in the RPE in two situations: 
exposure to short-wavelength (λ = 488 nm) fundus autofluorescence (SW-AF) exci-
tation light and exposure to indirect (diffuse) sunlight.
RESULTS: In healthy persons at age 20, 40, and 60, respectively, the rate of oxygen 
photoconsumption by lipofuscin increases by 1.3, 1.7, and 2.4-fold during SW-AF 
imaging as compared to diffuse sunlight. In patients with STGD1 below the age of 30, 
this rate was 3.3-fold higher compared to age-matched controls during either sunlight 
or SW-AF imaging.
CONCLUSIONS: Our results suggest that the RPE of patients with STGD1 is generally 
at increased risk of photo-oxidative stress, while exposure during SW-AF imaging 
amplifies this risk. These theoretical results have not yet been verified with in-vivo data 
due to a lack of sufficiently sensitive in-vivo measurement techniques.
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Introduction
Fundus autofluorescence (AF) imaging visualizes the accumulation of fluorophores that 
constitute a substantial fraction of lipofuscin in the retinal pigment epithelium (RPE).1 
The pigments of lipofuscin are produced in the membranes of photoreceptor outer seg-
ments from non-enzymatic reactions of vitamin A aldehyde.2-5 This fluorescent material 
is transferred to RPE cells within phagocytosed outer segment disks,6, 7 and becomes 
deposited in the lysosomal compartment of the cells. As a result, RPE lipofuscin accu-
mulates with age8 and fundus AF increases linearly with age although subjects vary 
in terms of intensities.9 Short-wavelength AF (SW-AF, λexc = 488 nm, unless stated 
otherwise) is commonly regarded as a way to monitor the status of RPE cells, with areas 
of high AF indicating increased lipofuscin levels and areas of absent AF indicating loss 
of RPE cells. 
The retinal radiant exposure of the SW-AF excitation light is far below American 
National Standards Institute (ANSI) safety thresholds:10 SW-AF imaging with the widely 
used Spectralis device is safe for up to 8 hours (9 J·cm-2) whereas typical examinations 
irradiate the retina for less than 5 minutes (<0.1 J·cm-2). These thresholds were based on 
cross-sectional data of the effects of light on a cellular level, designed to protect the eye 
and skin from accidental light exposure. To reduce ocular exposures, the International 
Commission of Non-Ionizing Radiation Protection has also provided guidelines for oph-
thalmic instruments.11 Commercial or experimental ophthalmic instruments adhere to 
these standards with additional constraints for intentional exposures,12 and may thus be 
considered safe with regard to short-term effects.
However, the ANSI thresholds and Commission guidelines do not specifically evaluate 
the contribution of endogenous photosensitizers in enhancing a patient’s susceptibility 
to retinal phototoxicity. In fact, patients with certain retinal diseases may be highly 
susceptible to phototoxicity.13, 14 This has led to concerns that patients with recessive 
Stargardt disease (STGD1) may be at risk for light toxicity during SW-AF imaging.15 In 
patients with STGD1, photochemical damage may involve changes in molecules within 
the visual cycle such as all-trans-retinal.14, 16 Additionally, removal of all-trans-retinal 
from the photoreceptor outer segment disks is impaired,17 which leads to an accelerated 
accumulation of lipofuscin bisretinoids in the RPE. Some of these bisretinoids have 
been identified as potent photosensitizers in animal studies. In Abca4-/- mice, very high 
intensities (50 mW/cm2) of blue light (λ = 430 ± 20 nm) irradiation for 30 minutes caused 
severe atrophy of photoreceptors and RPE cells with elevated lipofuscin, which was 
less pronounced in age-matched wild type controls.18 Conversely, there was no photo-
receptor atrophy in Rpe65rd12 mice without RPE lipofuscin.18 Whether the mechanism 
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of photochemical damage involves changes in either lipofuscin or molecules within the 
visual cycle such as all-trans-retinal, patients with STGD1 will be highly susceptible to 
photic injury.14, 16 Consistent with this notion, even chronic exposure to normal daylight 
appears to increase the progression of RPE damage in STGD1.19
We aimed to determine the extent to which the endogenous photosensitizer lipofuscin 
makes humans more susceptible to photic injury, for which there is lack of empirical evi-
dence. Extrapolation from results from animal studies to humans is difficult because of 
their considerable differences in light susceptibility. Therefore, we numerically simulated 
in-vivo photo-oxidative stress in the human RPE subsequent to irradiation of endoge-
nous RPE lipofuscin, allowing us to estimate this extent. More precisely, we simulated 
exposure during either SW-AF imaging in common clinical practice or diffuse sunlight, 
in healthy individuals of different ages and in patients with STGD1. Daylight exposure is 
not known to cause retinal injury to healthy people except for unintentional and exces-
sive exposures,20 which thus can provide a reference frame of normally harmless effects. 
Such an approach may yield considerable insight, because it facilitates the identification 
of gaps in our knowledge of all aspects involved in retinal photo-oxidative stress. 
Methods
Retinal exposures
Exposure to daylight
We used the solar spectrum of the American Society of Testing and Materials (ASTM 
G173-03) as a reference for terrestrial solar irradiation.21 It was measured under 
atmospheric conditions considered a reasonable average over a period of one year, and 
pointing to the sun at an inclination of 37°. This inclination corresponds to the approx-
imate average latitude of the 48 contiguous states of the USA. This spectrum includes 
light scattered by the atmosphere and light reflected off the earth’s surface (Figure 
1). In such a scenario of free or Newtonian illumination,22 a distant light source—the 
sun—irradiates an area A larger than the pupil of the eye. The retinal radiant exposure 
Hr (J·cm-2) can then be expressed as a function of corneal radiant exposure Hc (J·cm-2).12 
 
 (1)
with the pupil diameter (dp), the eye’s focal length (fe), the visual angle of the source (α), 
and the ocular media transmission (τ). For free illumination, the retinal radiant exposure 
Hr can also be expressed as a function of the irradiance of the source (Ls, unit J·sr-1), 
independent of α (Eq. [1], third term).12 Using normative data of the pupil diameter at 
different ages measured under various lighting conditions,23 we calculated an average 
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pupil diameter dp at age 20, 40, and 60 of 3.8, 3.5, and 3.2 mm, respectively (Section 
A in Supplemental Text S1). We assumed that the pupil is adapted to daylight luminance 
without pharmacological dilation and we used an average focal length fe of the eye of 
17 mm.
 
Because a person will 
usually not stare directly 
into the sun, the referenced 
solar spectrum is an overes-
timation of the actual solar 
irradiation entering the eye. 
We therefore subtracted 
the ‘direct and circumsolar’ 
spectrum that measures a 
2.5° circle around the solar 
disk from the aforemen-
tioned (‘global tilt’) solar 
spectrum as an indication of 
indirect solar irradiation, i.e., 
diffuse insolation (Figure 1). 
To determine the irradiance 
Ls (W·cm-2·sr-1) of this diffuse scattered light, we used the solid angle Ω of radiation 
specified for the ASTM reference spectrum, which equals that of diffuse light scattered 
in a full hemisphere (Ω = 2π steradian).21 Consequently, . To account for 
absorption in the ocular media, we employed an algorithm that predicts the average 
media optical density at a given age and wavelength.24, 25 The algorithm of Van de Kraats 
and Van Norren is based on six optical density components with the optical density Dλ 
depending only on wavelength and age.25 We obtain: 
 
 (2)
We used Eq. (2) to predict retinal exposures to diffuse insolation at age 20, 40, and 60.
Autofluorescence imaging
In SW-AF by confocal scanning laser ophthalmoscopy, the imaging beam enters the 
eye with a known angle α through an entrance pupil smaller than the pharmacologically 
dilated pupil. In this scenario of Maxwellian illumination, the retinal radiant exposure is 
the power entering the pupil Φ, divided by the retinal exposed area12:
 
Figure 1. Solar irradiance spectra. Visible range of the American 
Society of Testing and Materials G173-03 solar irradiance spectrum, 
measured at a global tilt of 37° pointing to the sun (blue). The solar 
irradiance spectrum when not staring directly at the sun, includ-
ing light scattered by the atmosphere and light reflected off the 
earth’s surface, is also shown (red).
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  (3)
The blue autofluorescence imaging mode of the widely used Spectralis HRA+OCT 
employs an optically pumped solid-state continuous wave laser with a wavelength of 
488 ± 2 nm and a recommended maximum optical power of 260 µW to excite lipofuscin 
fluorophores in the fundus. Emitted fluorescence in the wavelength range of 500–680 nm 
is detected after passing through a barrier filter. We assumed that during AF imaging 
in a clinical setting, the retina is scanned at the high-speed mode (768×768 pixels;
8.9 frames·s-1) in square 30° fields. Imaging of 55° fields is performed frequently, although 
the resulting average retinal exposure will be lower, and it therefore should be safer. 
Although the Spectralis also offers the possibility of imaging at the ‘high-resolution’-
mode with a doubled sampling rate (i.e., each imaged area is probed twice by the imag-
ing beam), the average retinal exposure will remain the same since the beam power, 
imaging speed, and size of the imaged area remain equal. Under our assumptions, the 
average retinal radiant exposure in perfectly transparent media is 328 μW·cm-2.26 Taking 
media absorption in a healthy 20-year old person25 into account, it is 190.4 μW·cm-2.
Optical screening in the fundus
Photoreceptors
The absorption of light in the neural retina is orders of magnitude lower than that in the 
RPE.27 Since our study is focused on the paramacula (about 10° retinal eccentricity), 
we neglect the influence of macular pigments. Visual pigments in the photoreceptors, 
however, may contribute to the absorption of light. Therefore, we estimated the visual 
pigment optical density versus wavelength during daylight exposure.
A luminance of 2.9 photopic cd·m-2 is already sufficient to saturate rod electroretino-
graphic responses,28 and therefore the unbleached fraction of rod visual pigment at 
an illuminance of 4400 cd·m-2 (Section A in Supplemental Text S1) will be very low—
we consequently neglect absorption by rods during either daylight or SW-AF imag-
ing. We used data on the normalized wavelength-dependent optical density of visual 
pigments in photoreceptor outer segments, measured by microspectrophotometry on 
ex-vivo human samples.29 We fitted these data with polynomial functions to obtain 
the optical density of the entire 380-700 nm wavelength range. These normalized 
data, expressed in normalized optical density per micron outer segment length, were 
multiplied by the mean dark-adapted double-pass optical density of each of the pho-
toreceptor types, divided by two to obtain single-pass optical density. These numbers 
were multiplied by the mean length of photoreceptors at 10° retinal eccentricity.30  Next, 
we multiplied the result by the retinal area fraction occupied by cone photoreceptors at 
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9.2° retinal eccentricity, as derived from electron microscopy data obtained by Curcio et 
al.,31 and by the relative numbers of the different cone types as published by Dartnall 
et al.29 Finally, we used data on the steady-state bleach fraction of visual pigments at 
an illuminance of 4400 cd·m-2 to derive the fraction of unbleached visual pigments. We 
multiplied the wavelength-dependent optical density of cones with this fraction, which 
was determined to be 0.080374.
Melanin in the retinal pigment epithelium
The flux of photons impinging on lipofuscin is reduced due to optical screening by mela-
nin granules situated apically in RPE cells. RPE melanin consists largely of eumelanin,32  
which is able to dissipate approximately 90% of incident UV energy as heat.33 We 
performed a Monte-Carlo (MC) simulation of light scattering and absorption by melanin 
in the RPE to investigate optical screening by melanin in healthy people of different ages 
and in patients with STGD1. Monte-Carlo methods are a standard approach in numerical 
simulation and the basic methodology in simulating scattering of light in human tissues 
is, by now, strongly established. Monte-Carlo methods have been employed with great 
success in order to predict the properties of light scattering in human tissues.34-37 Our 
calculation of light scattering by melanosomes was similar to an earlier study by Cracknell 
et al., who used MC methods to investigate iris melanosomes.38 Our calculation of light 
absorption by melanin was different from the calculation by Cracknell et al.; we based it 
on empirical data of the absorption spectrum of melanin. Details of this MC simulation 
of in-vivo optical attenuation by RPE melanin in the paramacular RPE cells are depicted 
in Section B in Supplemental Text S1. We modeled the paramacular RPE as a single
9 μm thick sheet,39 and RPE melanin could occupy the apical ≤33% of the RPE cell (inward 
positive, i.e., the optical path length lmelanin ranged from 0 to +3 μm). An infinitely thin and 
non-divergent beam of light (‘pencil beam’) injected 5·105 photons into the system. We 
varied the thickness of the layer in which the scatterers (melanosomes) are present with 
age and/or the presence of STGD1, as specified in Section B in Supplemental Text S1.
Monte-Carlo simulations of optical screening by RPE melanin were performed for 
specified wavelengths (λ = 380, 405, …. , 705) for each of four different scenarios: 
healthy 20-, 40-, and 60- year old paramacular RPE, and 20-year old non-atrophic RPE 
of a patient with STGD1. MontCarl© counted the number of photons that were either 
absorbed, backscattered (upon refractive passage at the interface between two layers 
and directed towards negative depth values), or transmitted (the inverse of backscat-
tering; this could therefore include non-scattered and forward scattered photons). From 
these fractions and the total number of incident photons, we calculated attenuation 
coefficients (μa, melanin and μ’s, melanin) and the optical density (ODmelanin) as:
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   (6)
Optical absorption by lipofuscin
The high optical density of each lipofuscin granule may give rise to significant internal 
optical screening.40 Granules in the basal part of the cell may therefore receive little or no 
light; resulting in a poor correlation between the RPE lipofuscin concentration and total 
light absorbed. This may explain why—at present—we have no evidence that lipofuscin 
bisretinoid photo-oxidation varies with the lipofuscin bisretinoid concentration.
Calibrated SW-AF measurements have shown that patients with STGD1 exhibit sub-
stantially increased fluorescence from RPE lipofuscin.41-43 This may be ascribed to either 
increased fluorescence efficiency of lipofuscin bisretinoids, increased absorption of 
excitation energy, or both. The ‘dark’ or ‘silent’ choroid sign on fluorescein angiography, 
present in 37–50% of patients,44, 45 indicates a considerable reduction in light trans-
mission (λ = 488 nm) through the RPE.44, 46, 47 Increased backscatter and/or absorption 
from lipofuscin may underlie this phenomenon; however, increased backscatter is highly 
unlikely to be the sole cause. Finally, mouse studies have shown that the amount of 
the lipofuscin bisretinoid N-retinylidene-N-retinylethanolamine (A2E) decreases in 
vivo when retinal light exposure increases, due to lipofuscin oxidation and subsequent 
degradation.48
We incorporated light absorption by lipofuscin into our simulation because of these 
indications. Although an accurate approximation of the fraction of light absorbed could 
be obtained with an MC simulation, as far as we know there are no empirical data on 
certain optical parameters of lipofuscin granules. These parameters include the granule 
size distribution, wavelength-dependent absorption- and scattering cross-sections, 
and empirical data on the angular scattering function. We therefore took a different 
approach, based on the principle that light absorption tends to correlate with the granule 
concentration (ng) and the optical path length (l) through these granules. Hence, we 
considered their product (ng·l) indicative of light absorption. 
Although electron microscopy of the RPE of patients with STGD1 shows massive accu-
mulations of lipofuscin in the posterior pole,49 it is difficult to obtain an exact value of (ng·l) 
based on these images. In mice, however, the concentration of a major fluorophore of 
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lipofuscin (A2E)50 was found to correlate with the calibrated fluorescence intensity from 
RPE cells.51 Since similar data26 are available both in healthy people42 and patients with 
STGD1,43 estimations of (ng·l) in STGD1 based on fundus AF would be an alternative. We 
tested the feasibility of such estimations by determining the correlation between (ng·l) 
and SW-AF intensity (detailed in Section C [a] in Supplemental Text S1). The individual 
of whom a SW-AF image is depicted in Figure 6 has given written informed consent (as 
outlined in the PLOS consent form) to publish this image.
Oxygen photoconsumption by lipofuscin granules
The goal of our simulation was to compute oxygen uptake by lipofuscin granules in vivo 
under the considered exposure regimes, because oxygen photoconsumption by lipofus-
cin can serve as an indicator of lipofuscin oxidation.52 We considered in-vitro oxygen 
uptake measurements on isolated human RPE lipofuscin granules by Rozanowska et 
al.52 to be—at present—the most appropriate basis for this calculation. Firstly, their mea-
surement setup and results were described in sufficient detail to allow for meaningful 
and quantitative comparisons with in-vivo exposure conditions. Second, isolated—but 
intact—human RPE lipofuscin granules of different ages were used, and the pH of the 
medium is comparable to that in vivo. As such, these two factors are representative 
of physiological conditions. The results obtained in Sections 3.1 and 3.2 allow us to 
estimate the flux of photons impinging on RPE lipofuscin granules in vivo, and studies 
on photosensitizers have shown a strong relationship between total light absorbed 
and oxygen uptake.53, 54 Therefore, the results obtained in Sections 3.1 to 3.3 can be 
regarded as variables influencing oxygen uptake by lipofuscin, and are applicable to an 
in-vivo milieu. We determined the corresponding values of these variables applicable 
to the in-vitro measurements by Rozanowska et al.52 By normalizing for differences in 
these variables in vivo, we predicted the rates of oxygen uptake, were they measured in 
vivo in the RPE. Details on this normalization are described in Section D in Supplemental 
Text S1.
Results
Retinal exposures
The retinal exposure (mW·cm-2) during daylight or typical SW-AF imaging sessions was 
corrected for absorption and scattering in the lens and media (plotted in Figure 2). 
 
Optical screening in the fundus
Photoreceptors
The calculated visual pigment optical densities during daylight exposure, at a lumi-
nance of 4400 photopic cd·m-2, are shown in Figure 3. Under this condition, the optical 
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screening by photorecep-
tors in the paramacula 
ranges between 0.002 to 
0.008 optical density units
(0.46–1.83%), and is there-
fore negligible.
 
Melanin in the retinal pig-
ment epithelium
The MC results are plotted in 
Figure 4. It can be seen that 
absorption dominates over 
scattering at λ < 505 nm.
We evaluated whether this 
phenomenon is caused by 
wavelength-dependent dif-
ferences in the absorption 
and scattering properties 
of the melanosomes. By 
taking the product of each 
granule class’ concen-
tration and absorption/ 
scattering cross-section, 
and taking the arrhythmic 
sum of all granule classes 
in the medium, the theoret-
ical absorption coefficient
(μa, melanin) and scattering 
coefficient (μs, melanin) can be 
determined. The reduced 
scattering (backscattering) coefficient can be calculated by including the scattering 
anisotropy factor (g). It varies from -1 for complete backscattering, through 0 for isotro-
pic scattering, to +1 for complete forward scattering, We calculated the backscattering 
coefficient by . An estimate of light attenuation due to absorp-
tion , backscattering , and the 
total optical density (Eq. 6) can then be made. As can be seen in Figure 4A, scattering 
is expected to dominate over absorption for all wavelengths under investigation, which 
is in contrast to the MC simulation results. In addition, the MC results show several fold 
lower attenuation for both scattering and absorption. 
Fig 2. Retinal exposure from diffuse solar irradiation compared 
to excitation light of short-wavelength retinal autofluorescence.
At λ = 488 nm, the peak height is indicated by single colored 
dots. Exposures were calculated by Eqs. (2) and (3), respectively. 
Exposures in ocular media of different ages are plotted: 20 year-old 
(red), 40 year-old (green), and 60 year-old (orange).
Figure 3. Optical screening by visual pigments in the outer 
segments of paramacular photoreceptors. The wavelength-de-
pendent single-pass optical density (OD) of light passing through 
the outer segments was calculated under conditions of daylight 
illuminance, amounting to 4400 photopic cd·m-2. See text for 
details.
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Figure 4. Relative contributions of light scattering and absorption by retinall pigment epithelium 
(RPE) melanin. (A) Agreement between Monte-Carlo simulation and theory, plotted based on condi-
tions in the paramacular RPE of a healthy 20-year old person. The optical density (OD) was calculated 
based on the product of the attenuation coefficient and the melanosome layer thickness (lmelanin). 
Attenuation by absorption (striped line), scattering (dotted line), and total attenuation (straight line) are 
plotted separately. The MC results are shown in blue (left Y-axis) and the theoretical result is shown in 
red (right Y-axis). See text for details. (B) Simulations of a thin (3 μm; blue) and thick (52.5 μm; orange) 
layer of melanosomes. In case of thicker layers, there is a dominance of the absorption coefficient (μa, 
melanin, straight lines) over the backscattering coefficient (μ′s, melanin, striped lines) for all tested wavelengths.
We found that both of these phenomena can be explained by two aspects: our simu-
lation was performed for a thin layer (3 μm) in combination with a strong tendency for 
forward scattering in this layer of melanosomes. In this system, photons will deviate 
from their path by about 30° on average  at each 
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scattering event, which indicates that randomization of the direction of scattering occurs 
only after several scattering events. This would suggest that more backscattering 
occurs when the melanosome layer is thicker. We tested this suggestion by simulating 
a melanosome layer of either 3 μm or 52.5 μm with an average transmission of photons 
of 89.4% and 6.6%, respectively (Figure 4B). We found that, in the case of the thicker 
sample, absorption actually dominates over scattering for all tested wavelength and an 
overall reduction in the backscattering coefficient μ’s, melanin. This suggests that, although 
a photon may only backscatter after a given number of scattering events, it becomes 
increasingly more likely that the photon will be absorbed before it reaches that point. 
The effect of simulating a thin sample is also illustrated in Figure 5. Thus, in our MC 
Figure 5. Monte-Carlo simulation of light scattering and absorption in a thick layer of melanosomes.
In this plot generated by MontCarl, the optical paths (blue lines) of 3000 photons are ray-traced through 
a relatively thick layer of retinal pigment epithelium (RPE) melanosomes at the concentration in vivo. 
Photons are injected by an infinitely thin light beam at X/ Y = 0/ 0. The X- and Z-axes, respectively, indicate 
the lateral and vertical (depth) location in the sample. Most photons are either absorbed or scattered 
back at Z = 30 μm. At the assumed maximum in-vivo layer ‘thickness’ of RPE melanosomes (3 μm), a 
small proportion of photons are backscattered or absorbed.
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simulation (3 μm), photons have a greater tendency for absorption as compared to 
backscattering at shorter wavelengths. The MC results for the various scenarios tested 
are shown in Figure 6. We found optical screening by melanin in 20-year old patients 
with STGD1 to be less than half of that in age-matched controls, with the difference 
diminishing at longer wavelengths.
Light absorption by lipofuscin
As shown in Figure 7, we found a strong correlation between calibrated SW-AF mea-
surements (qAF8) and values we consider indicative of light absorption by lipofuscin 
(ng·l). Based on a linear regression model and our calculated average qAF8 value of 
patients with STGD1, we interpolated the value of (ng·l) in these patients. 
Oxygen photoconsumption by lipofuscin
We used the results obtained in Sections 3.1 - 3.3 together with data on the oxygen 
concentration in the RPE in vivo to normalize for differences with in-vitro studies on 
isolated lipofuscin granules (Eq. S7 in Supplemental Text S1).52 Figure 8 shows age-
related differences in the rate of oxygen uptake (pM·cm-2·s-1) during sunlight exposure. 
This is particularly evident for short-wavelength visible light. However, in patients with 
STGD1, we found an amplification of the rate of oxygen photoconsumption regardless 
of wavelength. We integrated the results along λ to better compare results for different 
Figure 6. Light attenuation by retinal pigment epithelium (RPE) melanin in vivo varies with age and 
the presence of Stargardt disease. We calculated the total optical density (OD) of paramacular RPE 
melanin versus wavelength of incident radiation with Eqs. 4–6 based on results of Monte Carlo simula-
tions. Colored lines indicate attenuation in healthy people of different ages: 20 (red), 40 (green), and 60 
(orange). The same is shown for a 20-year old patient with Stargardt disease (black).
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ages, and healthy versus 
STGD1 (Figure 9). This also 
facilitates a comparison of 
low-intensity, broadband 
radiation (diffuse sun-
light) and high-intensity 
narrowband laser light 
(SW-AF excitation light). 
Interestingly, the total rate 
of oxygen uptake during 
diffuse sunlight exposure 
in vivo varies little with age 
according to our simulation. 
During SW-AF, however, 
oxygen uptake increases 
considerably with advanc-
ing age. The results suggest 
that oxygen uptake by 
lipofuscin is increased by 
about 3.3-fold in 20-year 
old patients with STGD1 as 
compared to age-matched 
controls. To be more spe-
cific, during diffuse sunlight 
and SW-AF imaging, 
this fold-increase is 3.292 and 3.264, respectively. When comparing oxygen uptake 
during either exposure to diffuse sunlight or to the SW-AF excitation light, we found a
1.33-, 1.70-, and 2.39-fold increase for healthy individuals aged 20, 40, and 60, 
respectively. For patients with STGD1, we found a 1.32-fold increase, i.e., close to that 
in age-matched controls. 
Discussion
Herein, we performed a comprehensive simulation of photo-oxidative stress in the RPE 
in vivo, which suggests that lipofuscin granules had a 3-fold higher oxygen uptake and 
light absorption in patients with STGD1 compared to age-matched controls. To our 
knowledge, this is the first study to report STGD1 patients’ relative sensitivity to light. 
We incorporated all known factors influencing light-induced oxygen consumption by 
RPE lipofuscin, insofar sufficient empirical data was available.
Figure 7. Correlation between calibrated short-wave autofluores-
cence (SW-AF) measurements and histologic data on lipofuscin 
granules. We considered the product of optical path length (l) and 
granule concentration (ng) to be indicative of light absorption by 
lipofuscin granules. Here, we tested whether this product correlates 
with calibrated SW-AF measurements published earlier (‘qAF8’),28, 44, 
45 possibly allowing an estimation of this product (ng·l) in patients 
with Stargardt disease (STGD1) based on their qAF8 values. qAF8 
values were measured in the posterior pole of the fundus (colored 
area in the inset). Blue dots represent average values of healthy 
people of different age-ranges; the red dot represents average 
values of patients with STGD1 (age <30 years). Pearson’s correlation 
(r = 0.97) was significant (P = 0.0259); therefore, a linear regression 
analysis was performed with data from healthy people (solid line). 
With the average value of patients with STGD1, we extrapolated 
the value of (ng·l) in STGD1 prior to atrophy of the retinal pigment 
epithelium. (red dot).
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Optical screening in the fundus
We identified differences in optical attenuation (μa, melanin) by RPE melanosomes between 
our simulated in-vivo data and earlier ex-vivo studies. Weiter et al.39 found a total 
attenuation of 0.022 ± 0.008 OD·μm-1 in the apical part of RPE cells (λ = 500-600 nm). 
This agrees well with the pooled average result of our MC simulation for healthy people 
aged 20-60 (0.020 ± 0.002 OD·μm-1). The difference in μmelanin may lie in two facts. 
First, Weiter et al. could not distinguish between melanin and melanolipofuscin in their 
Figure 9. Total rates of oxygen 
uptake by lipofuscin during 
light exposure. Rates of oxygen 
uptake (Figure 8) were integrated 
along the wavelength of incident 
radiation to obtain the total rate 
of O2-uptake, as an indication of 
cellular oxidative stress in vivo 
during exposure to diffuse sun-
light (white bars) or during SW-AF 
imaging (grey bars). X-axes: age 
of healthy individuals, or patients 
with Stargardt disease (age, 20).
Figure 8. Numerical simulation of oxygen uptake by lipofuscin in paramacular retinal pigment epi-
thelium in vivo during exposure to diffuse sunlight. Oxygen uptake was calculated based on results 
from a previous investigation of oxygen uptake by isolated human lipofuscin granules,20 after correction 
for factors affecting retinal exposure levels in vivo (see text). Results were plotted for healthy people of 
different ages: 20-year old (red), 40-year old (green), and 60-year old (orange). Results for 20-year old 
patients with Stargardt disease are also shown (grey).
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measurements.39 Our MC simulation would probably have shown a higher μmelanin if we 
had included melanolipofuscin granules, since the latter granules are known to accumu-
late with advancing age concomitant with reductions in melanosomes.55 Second, our 
simulated ‘layer’ of melanosomes (1–3 micron) was thinner than the histologic sections 
used by Weiter et al. (8 micron).39 As we showed in Figure 5, there is a higher pro-
portion of backscattered photons in our simulation as compared to their study, causing 
an overall higher μmelanin. Therefore, these two facts taken together might explain the 
aforementioned slight difference with histologic data, in terms of optical attenuation by 
melanin in the RPE.
However, optical screening by melanin only marginally protects lipofuscin against irra-
diation. At an ODmelanin of 0.05, only about 11% of incident light is filtered. Assuming 
that optical parameters of melanosomes are unchanged in STGD1—as indicated by their 
normal morphological appearance49—the MC simulation showed a 50% lesser screen-
ing effect as compared to age-matched controls (Figure 6). Therefore, our data indicates 
that the apical displacement of melanin in RPE cells of patients with STGD149 is of little 
consequence with regard to intracellular optical screening.  
Light absorption by lipofuscin
Comparison of light-induced oxidative stress in patients with STGD1 versus healthy 
controls requires correction for differences in light absorption. Earlier studies used lipo-
fuscin AF as an indication of the concentration of fluorophores.8, 39 Because calibrated 
SW-AF measurements26 are the only quantitative in-vivo indication of the fluorophore 
concentration, we investigated its correlation with histologic data of the concentration 
of lipofuscin granules. The fraction of light absorbed (A) can be calculated by the for-
mula  ,56 and as shown in Figure 7, we found calibrated SW-AF and (ng·l) to 
be linearly proportional. We considered the latter directly related to the amount of light 
absorption, because of two indications of an age-invariant absorption cross-section (σa). 
First, our image analysis of previously published40 electron microscopy images shows 
no age-related difference in granule size (Section C [b] in S1 text), ruling out a change 
in the amount of light scattering. Second, the optical density of lipofuscin granules 
decreases only slightly (0 - 14%) with age.40 In the context of unchanged scattering by 
these granules, absorption will only marginally change with age. One aspect of note is 
the increased fluorescence efficiency of oxidized bisretinoids,57 with the oxidized form 
of A2E being the strongest fluorophore among them.58 Also, in lipofuscin granules, 
the ratio of oxidized A2E versus unoxidized A2E increases considerably with age.58 
These results indicate that increased qAF may not correspond with equally increased 
light absorption. Another aspect to consider is the effect of internal optical screening 
among lipofuscin granules at high concentrations, due to the high optical density of 
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each granule.40 This would also cause a lack of linear proportionality between total light 
absorbed and the granule concentration, especially at high concentrations. Since these 
two aspects would lead to an overestimation of the amount of light absorbed at high 
qAF8 or high granule concentrations, a linear relationship between qAF8 and (ng·l) may 
be expected. On the other hand, this means that light absorption in patients with STGD1 
is probably increased by less than 3-fold. 
Oxygen uptake
Our results suggest that RPE cells of patients with STGD1 are at increased risk of oxi-
dative stress. During SW-AF imaging, the potential for oxidation almost doubles from 
age 20 to age 60 (Figure 9). We found a 3.3-fold increase in the rate of oxygen uptake 
in 20-year old patients with STGD1 relative to that in age-matched controls, regardless 
of the exposure regime. However, we cannot conclude whether the oxidant/anti-oxidant 
balance is affected, and if permanent impairment will occur to the RPE or photoreceptor 
cells. RPE cells are highly resistant to oxidative stress,59 but survival of RPE cells under 
light stress is largely determined by the relative concentrations of lipofuscin and mel-
anosomes.60 This balance is clearly less favorable in patients with STGD1; the limited 
anti-oxidative capacity afforded by melanosomes may prove insufficient to cope with 
situations of increased oxidative stress when it would normally suffice. In any case, 
indirect effects of oxidative stress that likely cause damage to photoreceptors have 
been proven, in terms of a decrease of outer segment phagocytosis by RPE cells.61, 62
Impairments in this key function of RPE cells can result in retinal degenerations.63
Limitations and perspectives
This study had several limitations. First, melanosomes can reduce iron-mediated oxida-
tion in RPE in vitro by protecting against redox-active metal ion-mediated oxidation.64, 65 
However, whether the net result of this process is anti- or even pro-oxidant depends on 
many factors, such as relative concentrations of metal ions, small molecular weight ion 
chelators and melanin-binding sites, presence of oxygen, and irradiation conditions.65 
Due to lack of related in-vivo data on these parameters and their interactions, we omitted 
this part from our simulation of oxidative stress. Second, the aerobic photoreactivity of 
melanosomes and melanolipofuscin was not taken into account. These granules display 
about 6- and 3-fold less oxygen uptake upon irradiation,66 respectively. In addition, in 
comparison to lipofuscin, they have a relatively high yield of hydrogen peroxide,66 which 
has a long half-life,67 and thus is less prone to cause unwanted oxidative damage. Also, 
melanolipofuscinogenesis involves a gradual fusion of two granule types,68 and optical 
characteristics and oxygen uptake may differ with advanced progression which may be 
difficult to model accurately in an MC simulation.
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Although we calculated oxygen uptake in STGD1 under the assumption that the pho-
tophysical characteristics of RPE lipofuscin remain unchanged, this may prove incorrect 
considering the ‘abnormal form of lipofuscin’ noted in a histological study of STGD1.49 
Furthermore, we have not evaluated the consequences of the consumed oxygen; that 
requires future work that is able to culture RPE cells under replicated in-vivo conditions. 
We anticipate that this will yield insights into the tolerance of RPE cells to oxidative 
stress under physiological cell culturing—and light exposure—conditions. It is of interest 
to note that AF imaging in patients with STGD1 at λ = 532 nm, instead of 488 nm, leads 
to less oxygen uptake at equal optical power: a 0.98-fold versus a 1.32-fold increased 
uptake relative to daylight, respectively.
 
Conclusions
Our numerical simulation of susceptibility to phototoxicity in health and disease indi-
cated a substantial increase in the rate of oxygen uptake by lipofuscin in patients with 
STGD1. However, sufficient empirical data is lacking on the molecular dynamics of the 
interplay between increased oxygen uptake, synthesis of oxygen radicals, anti-oxidants, 
and mechanisms leading to permanent retinal damage. Unfortunately, current in-vivo 
measurement techniques are insufficiently sensitive to show any effect of subthreshold 
light damage in patients. Considerable insight into these dynamics can be gained by 
numerical simulation and comparisons with empirical data obtained in cells cultured in 
replicated (patho)physiological conditions. Simulations can also elucidate the relative 
vulnerability of various retinal areas with different characteristics. We anticipate that 
this can eventually lead to personalized risk assessments of patients undergoing retinal 
light exposure in various settings. In high risk patients it may be advisable to largely 
avoid chronic exposure to light with wavelengths less than 500 nm and to choose auto-
fluorescence excitation above this wavelength.
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Over 7000 rare diseases exist, and together, they represent a relevant public health 
issue. They afflict up to 10 million European Union citizens, about half of which being 
children.1 For these patients, the scientific landscape attests to the promising and 
encouraging progress in finding a cure. We would not only be intervening in behavior and 
environment, for example, avoiding excessive sun light exposure and dietary restrictions 
in Stargardt disease, but we will also have opportunities to alter disease progression and 
possibly even to restore vision. Optimists may envision therapies becoming available 
within the next five years,2 but the scientific process generally proves to be a “long and 
winding road”. Each step on this road to a cure is essential for the eventual success.
 
Eventually, a potential cure needs to be approved by the U.S. Food and Drug Admin-
istration (FDA) and/or European Medicines Agency (EMA). To be approved by these 
official agencies, a clinical trial is required to prove that a potential cure is effective. To be 
able to prove this, clinical endpoints that represent a measurable and significant effect 
are needed. In turn, the FDA/EMA must also consent with these chosen endpoints. This 
thesis directly addresses the specific challenges associated with treatment evaluation 
for rare diseases, specifically for Stargardt disease. The general aims of this thesis are 
to: [1] evaluate the effect of nature’s time by characterizing the natural history of distinct 
patient groups within the spectrum of Stargardt disease [2] identify the diagnostic chal-
lenges in distinct patient groups within Stargardt disease to be able to select the right 
patients in the right trial, and [3] choose the appropriate method for outcome evaluation 
by developing a model to measure disease progression with high accuracy. These steps 
provide a strategy for future studies which aim to identify the effect of novel treatments 
in rare and heterogeneous diseases, in which Stargardt disease serves as a model.
This discussion will outline the main findings and put the results in a broad and future 
perspective. The main findings were as follows: in Chapter 2, we described phenotypic 
and genotypic characteristics of early-onset Stargardt and late-onset Stargardt. Ear-
ly-onset Stargardt can be considered a distinct severe subtype of Stargardt disease 
that is characterized by early foveal abnormalities and the rapid loss of visual function. 
In contrast, late-onset Stargardt frequently demonstrates foveal sparing in which visual 
acuity is often preserved to a relatively advanced age. This difference in natural history 
provides the basis to create models that describe disease progression. Chapter 3 reveals 
the challenges in the clinical diagnosis of Stargardt disease. Increased awareness of the 
absence of retinal abnormalities in certain young Stargardt patients helps finding the cor-
rect diagnosis. It can prevent distress, unnecessary investigations and harmful therapies 
and may prove important in early inclusion in future trials. Inclusion in future trials is also 
challenging in older patients because of retinal abnormalities mimicked by age-related 
disease; both age-related macular degeneration and late-onset Stargardt can exhibit 
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progressive foveal sparing atrophy. However, they differ in etiology and progression 
speed. Finally, Chapter 4 creates models of disease progression in Stargardt disease. 
The inter-eye concordance decreases as the age at onset increases. This has important 
consequences for clinical trial design; potential treatment effects are best assessed in 
young patients. Moreover, there is substantial benefit of using a composite outcome 
measure to assess efficacy in clinical trials for Stargardt disease with small cohorts in 
a timely fashion. In all of these assessments, fundus autofluorescence imaging is used 
as a main tool to measure disease progression. However, we need to bear in mind that 
patients with Stargardt disease are generally at increased risk of photo-oxidative stress. 
5.1 Relevance of disease classification
Etiological and prognostic and homogeneity
To classify patients to a specific disease or disease group that is clinically relevant, both 
sufficient prognostic and etiological homogeneity between patients are required.3 Such 
a classification is necessary for appropriate patient counselling as well as treatment 
selection. Moreover, appropriate patient selection is a prerequisite to be able to evaluate 
a treatment effect in clinical trials. Patients are to be selected with sufficient prognostic 
and etiologic homogeneity when few patients are included. Otherwise, an effect may be 
observed while there is none, or it may not be observed while in fact there is. The degree 
of etiologic and prognostic homogeneity in subgroups of Stargardt disease according to 
phenotype, genotype and electrophysiology is discussed in the subsequent paragraphs.
Phenotypical similarity
Four distinct retinal features reflecting stages of Stargardt disease were previously 
described by Fishman: an atrophic-appearing macular lesion with localized perifoveal 
flecks, retinal flecks throughout the posterior pole, resorbed flecks, and extensive 
atrophic-appearing changes of the retinal pigment epithelium and choroid.4, 5 These 
phenotypes represent stages in the natural history of Stargardt disease, although not 
all patients go through these stages and some appear to halt at a certain stage. This 
classification thus only addresses phenotypical similarity at a given time point, but do 
not take etiological and prognostic similarity into account.
Patterns on electroretinography
Stargardt disease demonstrates vast prognostic heterogeneity, that is, differences in 
disease course. A classification that addresses prognostic homogeneity involves three 
patterns on electroretinography (ERG) identified by Lois: severe pattern ERG abnor-
mality with normal full-field ERG, additional loss of photopic function consistent with 
a clinical diagnosis of cone dystrophy, or loss of both photopic and scotopic function, 
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i.e., cone-rod dystrophy.6 The latter would have the worst prognosis. Although these 
patterns are suggested to have this prognostic value, a transition over time from one 
to another pattern can still occur within a patient.7 For instance, a patient can have 
a severely abnormal pattern ERG but an otherwise normal full-field ERG at his initial 
presentation. This would indicate a maculopathy consistent with Stargardt disease. 
However, additional loss of photopic and scotopic function is likely to occur over time. 
As this pattern is consistent with a cone-rod dystrophy, this patient’s prognosis changes 
as his disease progresses.
Genotype-phenotype correlations
The etiology in Stargardt disease is clearly apparent: disease-causing variants in the 
ABCA4 gene. A classification was developed by genotype: the expected residual func-
tion of the ABCA4 protein resulting in the mildest phenotype of age-related macular 
degeneration (one mild ABCA4 variant) to the most severe retinitis pigmentosa-like 
phenotype (two severe ABCA4 variants).8 This model by Van Driel may hold for the 
average of genotypic groups, but discrepancies can be observed in individual patients. 
For instance, occasionally only one variant is detected in severe retinal dystrophy,9 
whereas a combination of a severe and a mild variant can be detected in mild foveal 
sparing disease.10, 11 Comprehensive genotype-phenotype correlations may further 
help identify those patients who are expected to have prognostic homogeneity. In 
case of homozygous variants with no ABCA4 function (null variants), a rather simple 
correlation can be made with severe disease. Furthermore, specific missense variants 
are now associated with disease severity classes ranging from a mild phenotype to a 
severe null-like phenotype based on electroretinographic findings.12 Straightforward 
conclusions still cannot be made; each combination of ABCA4 variants will have a 
unique combined effect on disease severity. Moreover, the variations in phenotype can 
be caused by loss or alteration of contiguous genes, transporter proteins and activator 
proteins. Such modifiers have become increasingly recognized as an important source of 
phenotypic variation. Arrayed primer extension genotyping and Sanger sequencing are 
now standard methods of genetic analysis, but next-generation sequencing is increas-
ingly changing the diagnostic workflow of retinal specialists to identify novel variants in 
approximately 250 retinal genes.13, 14 As the entire genome sequence can now be deter-
mined, challenges lay ahead to interpret newly detected variants. Genotype-phenotype 
correlations can further unravel the heterogeneity of Stargardt disease, and let us better 
understand potential differences in the effect of new treatments.15
The age of onset
Multiple types of subgroups have now been proposed resulting in multiple possibilities of 
classifications, some of which confusingly can change over time within the same patient. 
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Each combination of genotypic, funduscopic and electrophysiologic findings could be 
considered a unique type at a specific time point. Hence, the multitude of descriptive 
classifications and stages does not identify specific diagnostic subgroups of Stargardt 
disease with sufficient clinically relevant prognostic homogeneity. Prognostic homo-
geneity can be identified by long-term follow-up that carefully evaluates the natural 
history of patients. The approach of grouping patients based on their natural history has 
led to a division of Stargardt disease into three groups based on the age at onset. Age 
dependency on the eventual visual prognosis has indeed been previously described,16 
and now translates itself into subgroups of Stargardt disease described in Chapter 2: 
[1] early-onset Stargardt (≤10 years of age) with minor initial abnormalities, early foveal 
loss, and a fast progression toward retina-wide chorioretinal atrophy with severe vision 
loss,9, 17 and [2] late-onset Stargardt (≥45 years of age) with a relatively intact fovea 
surrounded by yellow-white fundus flecks and gradually expanding, well-demarcated 
areas of atrophic retinal pigment epithelium lesions.10, 18 This age-specific incidence 
distribution allows at least a third subgroup of intermediate-onset Stargardt patients 
with an incidence between
10 and 45 of age. A com-
parable bimodal pattern 
occurs in acute lympho-
blastic leukemia, with an 
initial incidence rate peak 
among infants, a decline in 
childhood, and an exponen-
tial rise with advancing age 
beginning in young adult-
hood.19 These subgroups 
within Stargardt disease 
still contain a broad clinical 
spectrum of their natural 
courses by differences of 
electroretinographic abnor-
malities, retinal abnormalities in terms of the spatiotemporal distribution of yellow-white 
flecks, as well as combinations of ABCA4 variants. Further refinement of differential 
prognosis may therefore still lie in the severity of loss of ABCA4 function, ERG find-
ings, or other imaging modalities.6, 7, 20 Nonetheless, each of the three subgroups that 
are based on the age of onset converges to an identical single clinical and functional 
endpoint—thus demonstrating prognostic homogeneity. 
1. Evaluate the effect of time
Challenge: Rare diseases inherently have small populations. 
Moreover, they demonstrate a wide range of severity in their 
natural progression.
Case: Three subgroups of Stargardt disease that are based on 
the age of onset converges to an identical single clinical and 
functional endpoint, demonstrating prognostic homogeneity: 
early-onset Stargardt, intermediate-onset Stargardt and 
late-onset Stargardt.
Conclusion: Knowledge of the effect of time provides the 
basis to identify any intervention that aims to change the nat-
ural course of the disease. Classification of disease is therefore 
required to have patient groups with etiologic as well as prog-
nostic homogeneity. Thus, natural history studies are essential 
to be performed prior to the initiation of any clinical trial.
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5.2 Identification and selection of patients
Rare diseases are generally 
difficult to recognize and 
diagnose, because of their 
wide range of severity both 
at clinical presentation and 
natural progression. This 
also accounts for Stargardt 
disease, particularly in 
early-onset and late-onset 
Stargardt disease. 
Early diagnostics
In young patients, the retinal 
abnormalities may be very 
subtle despite major visual 
complaints (Chapter 3.1). 
In such cases, there are no 
obvious yellow-white flecks or evident atrophic macular lesion that would help direct the 
clinician to the diagnosis of Stargardt disease. The fluctuating severity of visual acuity 
loss further impedes a correct diagnosis. Color vision tests and electroretinography21 
may help in screening in the early disease stages. However, a thorough examination by 
fundus autofluorescence imaging and spectral-domain optical coherence tomography 
will enable to detect subtle abnormalities that point to the right diagnosis, which are 
otherwise left undetected. This includes parafoveal hyperautofluorescence,22 and a 
thickened external limiting membrane.23 Thickening of this hyperreflective band is more 
recently being hypothesized to represent a structural change at the level of the foveal 
cone nuclei, sparing the foveolar region.24 Early diagnostics remains challenging, but 
essential if a potential treatment requires the earliest possible intervention, i.e., in gene 
therapy.
Similar diagnostic challenges arise in late-onset Stargardt patients. Here, the challenge 
lies in distinguishing late-onset Stargardt10, 25 with atrophic age-related macular degen-
eration (Chapter 3.2).25, 26 Both include a progressive foveal sparing atrophy of the 
retinal pigment epithelium, but the underlying pathophysiologic process differs. Con-
sequently, potential treatments are different as well because of different mechanisms; 
in age-related macular degeneration, multiple factors play a role. Strategies in multi-
factorial age-related macular degeneration may better involve final common pathways 
2. Select the right patients
Challenge: Rare diseases generally have a clinical presenta-
tion that is often incompletely described and difficult to be 
recognized.
Case: In Stargardt disease, young patients initially have limited 
retinal abnormalities, while the visual acuity loss is quite severe. 
Subtle abnormalities can be detected by optical coherence 
tomography and fundus autofluorescence imaging. Patients 
with late-onset Stargardt disease can demonstrate abnormal-
ities mimicking age-related macular degeneration and need 
to be carefully distinguished.
Conclusion: Inclusion of wrong patients in clinical trials would 
blur the therapeutic effect under observation and potentially 
lead to a fail in proving efficacy. Appropriate diagnostic tools 
and information will help early and correct diagnosis to select 
the right patients for a specific trial at the right time.
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leading to cell death from choroidal perfusion enhancers over neuroprotective agents to 
complement inhibitors.27, 28 In contrast, ABCA4 will remain the main factor in late-onset 
Stargardt, and thus the primary target for interventions.29 
Timely interventions
The potential delay in diagnosis has important clinical implications; not only does it delay 
appropriate counseling and interventions, but also will it be important to have an early 
diagnosis when it comes to early disease-modifying interventions by inclusion in gene 
therapy trials. Moreover, those patients are preferably included before the disease is 
expected to rapidly progress further, increasing the chance to detect differences when 
progression is slowed down. These features have been shown to be present in early-
onset Stargardt patients (Chapter 2.1). Finally, misdiagnosis risks patients being 
selected in trials with a suboptimal therapeutic effect.
5.3 Endpoints in clinical trials
Visual function tests, such as best-corrected visual acuity or visual field may be suitable 
endpoints in clinical trials with large cohorts and long follow-up. However, when cohorts 
are small, other strategies are needed. Alternative designs in clinical trials and endpoints 
can potentially decrease the time and cost required to assess the safety and effect of 
new drugs.30 Although many of these techniques are not new, an integral approach can 
optimize clinical trials in rare diseases like Stargardt. In this thesis, such strategies are 
provided.
Surrogate endpoints
The choice of an appropriate endpoint can drastically affect the power of a study. Loss 
of visual acuity has been the primary clinical endpoint in many ocular clinical trials since 
the advent of the Early Treatment for Diabetic Retinopathy Studies. However, functional 
endpoints such as visual acuity have been shown not to be the optimal outcome mea-
sure in small clinical trials due to its high interindividual variance,16 test variability31, 32 and 
overall slow decline. This high variance can result in unrealistic large cohorts and long 
follow-up required when used in a trial.
In contrast, structural parameters on fundus autofluorescence and optical coherence 
tomography provide better characteristics in terms of detectable small short-term 
change as the disease progresses (Chapter 4.1 and 4.2). These surrogate measure-
ments can reflect changes in functional disease progression, which are otherwise 
only detectable with long follow-up.33 However, there is always an unavoidable trade-
off between clinical relevance of an outcome and the time frame in which it occurs.
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A therapeutic effect on a surrogate endpoint does not necessarily mean that the therapy 
also has an effect on the functional endpoint (Figure 1).34 The method for outcome evalu-
ation need to adhere to the requirement that the endpoint lies in the causal pathway of the 
disease process. For example, in an upcoming trial for the treatment Stargardt disease, 
Remofuscin intervenes in the removal of lipofuscin.35 Consequently, the endpoint need 
to be a measurement that rather detects a change in lipofuscin than the later stages of 
retinal pigment epithelium atrophy and loss of visual function. Because lipofuscin accu-
mulation is expected to result in the eventual retinal degeneration with associated loss in 
vision function, such a surrogate endpoint is reasonably likely to predict clinical benefit.
A valid surrogate endpoint 
is not only correlated with 
the clinically meaningful 
endpoint, but also captures 
the net effect of treatment 
on the clinical outcome 
completely.36 According to 
these criteria, no surrogate 
can possibly suffice; to show 
that a surrogate is a valid 
outcome, one would need 
an effective drug showing 
the eventual benefit on both 
the surrogate and a clini-
cally meaningful endpoint. 
However, the surrogate is 
used to prevent waiting on 
the occurrence of the clini-
cally meaningful endpoint 
in the first place—clearly 
a catch-22. Thus, Fleming 
later defined an endpoint 
validation hierarchy for 
outcome measures: level 1, 
clinical-efficacy endpoints; 
level 2, a validated surro-
gate endpoint (for a specific 
disease setting and class 
of interventions); level 3,
Adapted from Fleming et al.
Ann Intern Med. 1996 Oct 1;125(7):605-13.
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Figure 1. Reasons of possible failure of surrogate endpoints. 
[1] The surrogate is not in the causal pathway of the disease 
process, [2] of several causal pathways of disease, the intervention 
affects only the pathway mediated through the surrogate, [3] the 
surrogate is not in the pathway of the intervention’s effect or is 
insensitive to its effect, or [4] the intervention has mechanisms of 
action independent of the disease process.
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a nonvalidated surrogate endpoint, yet one established to be “reasonably likely to pre-
dict clinical benefit” (for a specific disease setting and class of interventions), and level 4,
a correlate that is a measure of biological activity, but that has not been established to 
be a higher level.37 Chapter 2.2 has shown that progression of RPE atrophy can be used 
as a “level 3” surrogate in late-onset Stargardt. Despite having a disconnect between 
visual acuity and RPE atrophy because of a frequently occurring initial foveal sparing 
pattern,11, 38-40 foveal involvement can drive the eventual vision loss, and the fovea is 
more likely to be involved as RPE atrophy progresses, both centrifugally toward the 
periphery, as well as centripetally toward the fovea. A similar structural parameter, 
geographic atrophy has been already accepted as a surrogate outcome measure by the 
FDA in age-related macular degeneration,41 and may also be valuable in other retinal 
diseases affecting the RPE. Long-term natural history studies provide further insight 
into the value of surrogate endpoints reflecting disease progression which lead to the 
eventual clinically meaningful endpoint. 
Multimodal strategy
The endpoint can be further optimized by identifying a unique combination of structural 
measurements that has the best signal-to-noise ratio, i.e., the largest change in disease 
progression with minimal variability.42 The downside of a composite outcome is that it 
increases the complexity in a trial, both for the construction as well as interpretation of 
the results.43 The concern that many published research findings are false may partic-
ularly apply to the use of these complex outcome measurements. Moreover, research 
findings are less likely to be true when the sample sizes and effect sizes are smaller. 
Therefore, in interventional trials for rare diseases including Stargardt disease, it is even 
more critical that the design is prospectively defined: being randomized and blinded 
where possible and the primary objectives clear and the complex statistical analysis (for 
example, as presented in Chapter 4.2) to address the primary objectives prespecified. 
Only then will the interpretation of the results be valid.44
Composite endpoints can be extremely valuable in highly accurate measurements of 
disease progression. The heterogeneity of Stargardt disease requires knowledge of 
which specific combination of measurements are the most important in specific patient 
groups to identify a response or non-response for a specific treatment. In Chapter 4.2, 
multimodal analysis of disease progression has been shown to be able to provide an 
appropriate composite endpoint in early-onset Stargardt disease by applying different 
weights,45 i.e., importance, to individual parameters that ultimately form the composite. 
The importance of the rate of ellipsoid zone loss, which was automatically identified 
by the model, was indeed confirmed by other studies.46, 47 Other parameters, such as 
en-face optical coherence tomography, may also prove highly valuable in measuring 
disease progression.48
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This composite endpoint outperforms any unimodal structural endpoint in terms of 
signal-to-noise ratio, further facilitating the detection of potential treatment effects. 
Statistical models can then establish the distribution of an expected range of future 
outcomes. If a treatment exceeds the predicted future ranges, the intervention can be 
considered to have an effect (Figure 2). Such potential treatment effects can be simu-
lated in varying patient populations and study designs. This approach can eventually 
optimize the trial design for the right patient group.
Other considerations in trial design
The methodology of controlled trials can be improved to facilitate patient recruitment, 
reduce the number of patients required to include, optimize trial duration and increase 
statistical power. 
The standard parallel group comparisons require large sample sizes, but a factorial 
design, based on parallel groups, can include more than two treatment arms; patients 
are randomized twice—once for treatment X or placebo and then for treatment Y or 
placebo—can be time-saving and requires fewer patients to answer two questions. 
Matched-pairs parallel groups allow patients to be matched with another patient having 
similar characteristics, taking advantage of similarities to improve power. A major advan-
tage in ocular therapies 
is the availability of the 
ideal matched-pair control. 
When a local therapy to an 
eye of a patient is applied, 
his untreated eye is the 
internal matched pair. The 
advantage will increase 
when the inter-eye, i.e., 
within-participant, correla-
tion is high. A fellow-eye 
paired trial design is there-
fore recommended in ret-
inal dystrophies: a missed 
opportunity in general. As 
presented in Chapter 4.1, 
the high inter-eye cor-
relation is an additional 
reason to prefer early-onset 
Stargardt patients to be 
3. Choose the appropriate method for outcome evaluation 
Challenge: A randomized-controlled design includes an 
appropriate sample size, statistical power, and methods to 
minimize bias. This is unfeasible with conventional methods 
in rare diseases.
Case: The heterogeneity of Stargardt disease requires knowl-
edge of which specific combination of measurements are 
the most important in specific patient groups to identify a 
response or non-response for a specific treatment. In early-on-
set Stargardt, a unique combination of structural measure-
ments has shown to have the best signal-to-noise ratio, i.e., the 
largest change in disease progression with minimal variability.
Conclusion: Clinical trials need to be adapted to small popu-
lations. A right endpoint is needed to identify any modification 
of the natural disease progression to evaluate the effective-
ness of new treatments. This endpoint depends on the patient 
selection as well as the specific treatment being evaluated. 
Herein, composite endpoints can be extremely valuable in 
highly accurate measurements of disease progression. This 
approach can eventually optimize the trial design in rare 
diseases.
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selected in clinical trials 
over intermediate-onset 
and late-onset Stargardt 
patients. However, this 
advantage does not hold for 
systemic pharmacological 
strategies, in which both 
eyes are inherently treated. 
Moreover, when the out-
come is measured at the 
patient level, the untreated eye cannot serve as a control.49 Nonetheless, inclusion of 
both eyes of a patient in a clinical trial seems to have been a missed opportunity in 
recent ocular therapies, and should be permitted unless it is not appropriate for the 
study design.50
Another improvement includes a crossover design, in which patients receive the treat-
ment and the placebo in a prespecified random sequence. Patients then serve as their 
own control. Similar to crossover includes a Latin square in which every treatment occurs 
once in each sequence and in each period, and N-of-1 trials: a within-patient randomized 
controlled multi-crossover trial design. Here, only 1 patient receives multiple cycles of 
double-blind treatment in a random sequence, which provides an estimate of individual 
effectiveness. For crossover trials, including within-patient designs, a relatively station-
ary disease is required, and a wash-out period is needed to prevent a carryover effect. 
Trial duration is therefore longer. Moreover, a crossover design cannot be used in case 
the treatment is irreversible, e.g., in case of surgical intervention with gene replacement 
therapy or cell-based therapy.51 To conclude, no single design is suited for all rare dis-
eases and interventions (Table 1).
Parallel group design Patients are assigned to treatment or control
Factorial design Multiple treatment arms
Matched-pairs Correlated pairs in treated and untreated arm
Crossover design Patients receive both treatment and placebo
Latin square Every treatment occurs once in each sequence and period
N-of-1 Within-patient multi-crossover
Table 1. Alternative designs in addition to double-blind randomization.
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Figure 2. Model of predicted future disease course. The interven-
tion is considered to have an effect if the disease course exceeds 
the expected range of predicted future measurements.
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5.4 Meaningful outcome measures
Emerging therapies
Insight into the pathogenesis of human disease is constantly increasing, as well as 
potential therapeutic opportunities. Patients have indeed been provided needed ther-
apies, but effective treatments are still unavailable for most rare diseases. The devel-
opment of gene therapy has been ongoing for over 30 years, and now, the first in-vivo 
gene replacement therapy has just been approved; treatment of RPE65-mediated 
retinal dystrophy by voretigene neparvovec-rzyl is a major milestone and has reached 
three patients up to now.52, 53 Concurrently, early-stage experiments are already going 
beyond this ‘conventional’ gene augmentation therapy, showing that a one-time, per-
manent genome editing offers new ways to reverse blindness.54 Technology is changing 
at such a fast pace, clinical implementation could eventually stay behind. Eventually, 
we risk implementing nothing into regular clinical care at all, because the treatments 
to be approved will be already outdated and outperformed by new state-of-the-art 
treatments being developed in the lab.
Regulatory reformations
The succeeding drug and device approval have been hampered by regulatory require-
ments which are rather stringent but necessary to protect patients from harm.55 
Important steps have been made in regulatory reformations to help speed up the dis-
covery and delivery of new treatments. Since the U.S. Orphan Drug Act (1983) and the 
E.U. Regulation on Orphan Medicinal Products (2000) facilitated the development of 
drugs for small populations, several treatments for rare diseases have been approved. 
Currently, over one third of indications were already approved based on a single pivotal 
trial, and about three-quarters were approved on trials with a duration of less than six 
months, supposed to be taken for a lifetime.56
The 21st Century Cures Act was introduced to speed up the pace of innovation further. 
Organizations representing patients, physicians, and researchers allied with pharma-
ceutical and medical device industries voting for this 21st Century Cures Act; others 
opposed the act because of serious concerns. The act includes funding for the National 
Institute of Health (NIH), facilitating collaborative research by encouraging data sharing 
and ensuring the reproducibility. It further reduces administrative tasks, and supports 
high-risk, high-reward research. However, a worrisome aspect of this act encourages 
the FDA to lower the standards of empirical evidence despite that the FDA already pro-
vides guidance for accelerated drug approval.57 Less strict regulations to drug approval 
may sound promising but could increase the risk of misjudging that useless treatments 
are helpful, or that helpful treatments are useless. 
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For example, the recent lampalizumab phase III trial for age-related macular degeneration 
failed to show a therapeutic effect. Natural history studies that followed the initiation of 
the lampalizumab trial showed no difference in progression speed of geographic atro-
phy in patients with different complement profiles.58 The role of complement activation 
in geographic atrophy therefore seems to be insignificant. With this knowledge, the 
trial probably needed to include different patients in an earlier disease stage before the 
development of geographic atrophy and needed to have a different primary endpoint. 
The treatment likely aimed at a different mechanism, which was not captured with the 
primary endpoint. 
Rushing to our destination may end up in taking wrong turns and can set us back to 
where we came from. If we were to reduce the standard to anecdotes of experiences 
and uncontrolled, unrandomized data, we would return to 19th-century problems we 
thought we had left behind.59, 60 Although there is an urgent need to move forward to 
find a cure for patients with rare diseases, the solution may not lie in shortcuts which 
lower the standards of robust clinical evidence. Although the freedom given will require 
greater scrutiny, such changes to accelerate the development of novel treatments for 
Stargardt disease and other rare diseases are encouraging. 
5.5 When present becomes history
Precision medicine
The societal need is high for efficient precision medicine: personalized healthcare being 
refined to have the most significant impact upon our individual needs. We want to be 
informed how to stay healthy, and how to manage and treat disease. Precision medicine 
encompasses all the information on the individual, including their environment and 
behavior. Disregarding the latter could create unrealistic expectations to both clinicians 
as well as patients, potentially changing perceptions of their risk of disease; if patients 
believe they are less at risk, they may feel excessively protected, worsening their behav-
ior, putting them at increased risk. This also holds for Stargardt disease, despite being a 
monogenetic disease; in the future, when a successful treatment has been implemented, 
patients should still protect themselves from sun light and avoid vitamin A supplements, 
as they are likely at increased risk for phototoxic injury (Chapter 4.3). 
To measure our health status, the medical armamentarium is expanding exponen-
tially.61-64 The massive amount of information should eventually guide us to diagnostic, 
therapeutic, and preventive strategies, tailored for every unique individual. However, 
this can give rise to a plethora of prognostic probabilities and ambiguity of the efficiency 
of these strategies.65 
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Pursuing perfect surrogacy
Regulatory agencies have mainly focused on single primary endpoints, but there is no 
perfect single surrogate or clinical endpoint that could encompass the complex interac-
tions in a patient. Slowly, we begin to understand the complex interactions of genomics, 
proteomics, metabolomics, behavior and environment. By thinking in these interactions 
rather than in single pathways,66 we can identify new biomarkers and new targets for 
treatment and understand their effects.67 The ground for drug approval should therefore 
arise from combined measurements within the range from biomarkers to patient-
reported outcomes. 
Universal measurement and reporting of core outcome sets could pave the way to further 
accelerate novel therapeutic strategies.68-70 An international agreement on the minimum 
sufficient set of outcomes would allow to collect and share natural history data more 
efficiently, for which The International Consortium for Health Outcomes Measurement 
(ICHOM) has already taken significant steps on this path. An international digital plat-
form is furthermore needed to rapidly facilitate collecting and sharing of standardized 
measurements. Meaningful outcome measures should comprise the complete biological 
network from the molecular level to societal interactions: from molecular biomarkers to 
patient self-reports in real-life settings. 
Chapter 4.2 integrated structural changes of the natural progression of retinal degen-
eration to provide a sensitive outcome measure within two years of follow-up. However, 
the progression detected here does not completely describe the natural progression 
of Stargardt disease. Outcomes that matter to patients are essential, and undoubtedly 
include long-term safety, vision and the impact on visual impairments in daily life. The 
value of the composite structural outcome measure mainly lies on rationally selecting 
potential novel treatments. It still needs to demonstrate how it relates to functional 
outcome in the long term. We could then gain insight into the effect of interventions, 
and how this translates to an eventual true change in disease progression. Thinking in 
interactions may eventually change medical practice with a deeper holistic view, offering 
patients the right intervention at the right time.71, 72 
Evolution of evidence synthesis
The productivity of drug development is decreasing, while the costs for drug develop-
ment can increase up to 1.2 billion US dollars.73 Evidence synthesis needs to evolve by 
“increasing value and reducing waste in biomedical research”.74 Herein, outcome mea-
sures play a crucial role; they are to be standardized and need to incorporate all aspects 
of the human biological network.71, 75, 76 Lessons can be learned from studies on rare 
diseases; dissecting common diseases into “rare” molecularly defined subtypes helps to 
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capture individual variability of these common diseases.44 As these diseases are being 
dissected more and more into rarer subtypes, clinical trials in common diseases will face 
similar challenges as studies in rare diseases: challenges such as the identification of the 
most important outcome measures and their ability to show potential treatment effects.
Stargardt disease poses the challenges of small populations and vast heterogeneity. 
This thesis outlined a strategy to provide clinical trials the right outcome measurements 
for the right patients to identify an effective drug in Stargardt disease: [1] evaluate the 
effect of time, [2] select the right patients, and [3] choose the appropriate method for 
outcome evaluation. In the next step, standardization of outcome measures can prevent 
scientists and organizations continuously reinventing the wheel. The change of our daily 
practice should ultimately focus on interweaving clinical care with scientific research 
using universal measurements and reporting of core outcome sets; the borders between 
the clinical care, patient registries, and therapeutic trials need to dissolve. It can unleash 
creativity in treatment implementation without compromising safety: toward a cure for 
Stargardt disease.
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6.1 Summary
Over 7000 rare diseases exist, and together, they afflict millions of patients worldwide. 
For these patients, there is promising and encouraging progress in finding a cure. 
However, no treatment is available for the majority of these diseases. Arguably the 
most prevalent inherited retinal disorder is Stargardt disease. In its natural course, the 
heterogeneity in the age at onset reflects the vast heterogeneity in variable rates of 
functional and structural disease progression. Herein, not only do the challenges of 
treatment evaluation—which have been present since ancient history—apply, but its 
rare nature and heterogeneity also pose additional challenges. This thesis responds to 
those challenges in treatment evaluation for Stargardt disease, providing a strategy for 
future studies which aim to identify an effect of novel treatments for rare diseases.
Chapter 1 is an introduction from the history to the current understanding of Stargardt 
disease and the evaluation of new treatments. The evaluation of new treatments has 
evolved significantly since ancient times and is nowadays known as a clinical trial. With-
out clinical trials, we may conclude that useless treatments are helpful, or that helpful 
treatments are useless.  
The first step is to evaluate the effect of nature’s time by characterizing the natural 
history of distinct patient groups within the spectrum of Stargardt disease. To clas-
sify patients to a specific group that is relevant, both sufficient prognostic as well as 
etiological homogeneity between patients are required. Chapter 2 describes unique 
phenotypic and genotypic characteristics of subgroups within the vast heterogeneity of 
Stargardt disease, established in the context of previously emerged classifications and 
staging. The natural course of early-onset Stargardt disease initially features variable 
full-field electroretinographic abnormalities and early foveal changes. As this retinal 
degeneration progresses, the spectrum of phenotypes eventually converges, causing 
profound chorioretinal atrophy and severe vision loss. In contrast, the natural course of 
late-onset Stargardt describes expanding areas of retinal pigment epithelium atrophy 
that can spare the fovea associated with prolonged preservation of visual acuity to a 
relatively advanced age.
The second step consists of selecting the right patients by identifying the diagnostic 
challenges in specific patient groups. Rare diseases generally have a clinical presenta-
tion that is difficult to be recognized and diagnosed. Chapter 3 reveals the challenges in 
the clinical diagnosis of Stargardt disease. The awareness of possible absence of retinal 
abnormalities in young patients allows early diagnosis. It can prevent distress, unneces-
sary investigations and harmful therapies and may prove important in early inclusion in 
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future trials. Inclusion in future trials is also challenged in older patients because of retinal 
abnormalities mimicked by age-related disease. Both age-related macular degeneration 
and late-onset Stargardt can exhibit progressive foveal sparing atrophy, but they differ 
in etiology and progression speed. 
The third step comprises the choice of the appropriate method for outcome evaluation 
by developing a technique to measure disease progression with high accuracy. Chapter 4 
creates models of disease progression in Stargardt disease. The inter-eye concordance 
decreases as the age at onset increases, which has important consequences in clinical 
trial design. Potential treatment effects are best assessed in young patients. Moreover, 
a composite outcome measure can be powerful in the evaluation of treatment efficacy 
in clinical trials for Stargardt disease with small cohorts in a timely fashion. In this eval-
uation, optical coherence tomography and fundus autofluorescence imaging are used as 
measurements reflecting structural macular changes. However, we need to bear in mind 
that patients with Stargardt disease are generally at increased risk of photo-oxidative 
stress. Nonetheless, these structural macular changes provide a sensitive measurement 
of disease progression in Stargardt disease. It can be very useful in the evaluation 
of novel therapeutic modalities in rare disorders. Potentially, it can reduce costs and 
duration of pivotal clinical trials, thereby hopefully facilitating effective treatments being 
identified more readily and rapidly for patients with rare diseases.
Finally, Chapter 5 puts the aforementioned results in a broad and future perspective. 
The productivity of drug development is decreasing, while the costs for drug develop-
ment is ever increasing. Evidence synthesis needs to evolve, in which outcome measures 
play a crucial role. There is no perfect single surrogate or clinical endpoint, so the ground 
for drug approval should therefore arise from combined measurements within the range 
from biomarkers to patient-reported outcomes. Universal measurement and reporting 
of core outcome sets can further accelerate drug development and approval. The change 
of our daily practice should ultimately focus on interweaving clinical care with scientific 
research; the borders between the clinical care, patient registries, and therapeutic trials 
need to dissolve. 
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6.2 Samenvatting
Meer dan 7000 zeldzame aandoeningen treffen samen wereldwijd miljoenen patiënten. 
Voor hen is er de afgelopen jaren veel vooruitgang geboekt in de zoektocht naar een 
geneesmiddel.  Een dergelijk geneesmiddel is echter nog lang niet beschikbaar voor de 
meeste zeldzame ziekten. De meest voorkomende erfelijke retinale aandoening is de 
ziekte van Stargardt. Deze ziekte kan zowel op zeer jonge leeftijd beginnen als ook op 
laatvolwassen leeftijd. Tussen deze patiënten kan de ziekteprogressie enorm verschil-
len. Dit uit zich als een enorme heterogeniteit in afwijkingen op zowel functioneel als 
op structureel niveau. De zeldzame aard en heterogeniteit van de ziekte van Stargardt 
geven nieuwe uitdagingen om het effect van een nieuwe behandeling te kunnen testen. 
Dit proefschrift speelt in op de uitdagingen in de evaluatie van een behandeling voor de 
ziekte van Stargardt. Het presenteert hiermee een strategie voor toekomstige studies 
die gericht zijn op het identificeren van effectieve nieuwe behandelingen voor zeldzame 
ziekten.
Hoofdstuk 1 is een inleiding van de geschiedenis tot aan de huidige stand van zaken 
over de ziekte Stargardt en het testen van nieuwe behandelingen. De evaluatie van 
nieuwe behandelingen is aanzienlijk veranderd sinds de oudheid en wordt nu gedaan 
aan de hand van een klinische trial. Deze klinische trials zijn nodig om aan te kunnen 
tonen of een behandeling effectief is. 
De eerste stap bestaat uit het onderzoeken van het natuurlijk beloop binnen het spec-
trum van de ziekte van Stargardt tussen verschillende patiëntengroepen. Om patiënten 
te kunnen classificeren in een bepaalde groep, moet een dergelijke groep klinische rele-
vant zijn: dat wil zeggen, een groep dat zowel voldoende prognostische als etiologische 
homogeniteit bevat. Hoofdstuk 2 geeft unieke fenotypische en genotypische kenmer-
ken van subgroepen weer binnen de enorme heterogeniteit van de ziekte van Stargardt. 
Dit wordt beschreven in de context van eerder ontstane classificaties en stadiëring. 
Het natuurlijke beloop van early-onset Stargardt vertoont in het begin subtiele foveale 
veranderingen met variabele afwijkingen op full-field elektroretinografie. Naarmate de 
degeneratie voortschrijdt, convergeert het spectrum van fenotypen en leidt dit uitein-
delijk tot forse chorioretinale atrofie en ernstig gezichtsverlies. Dit in tegenstelling tot 
late-onset Stargardt, wat zich kenmerkt zich door uitbreiding van atrofische gebieden 
van het retinaal pigmentepitheel. Van deze gebieden blijft de fovea doorgaans gespaard 
en zorgt dat de visus tot een relatief hoge leeftijd intact blijft.
De tweede stap bestaat uit het selecteren van de juiste patiënten welke wordt onder-
steund door de diagnostische uitdagingen in specifieke patiëntengroepen te kunnen 
identificeren.  Zeldzame ziekten hebben namelijk over het algemeen een klinische 
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presentatie die moeilijk te herkennen en te diagnosticeren is. Hoofdstuk 3 toont de 
uitdagingen in de klinische diagnose van de ziekte van Stargardt. De afwezigheid van 
retinale afwijkingen bij jonge patiënten maakt vroege diagnose lastig, maar wel mogelijk 
zodra we ons hiervan bewust zijn. Dit kan onnodige vertraging, onnodig diagnostisch 
onderzoek en zelfs schadelijke therapieën voorkómen. Vroege diagnose is bovendien 
belangrijk voor een tijdige en juiste inclusie in toekomstige klinische trials. Bij oudere 
patiënten is dit eveneens van belang, omdat bij deze patiënten de diagnose verward 
kan worden met leeftijdsgebonden maculadegeneratie. Zowel late-onset Stargardt als 
leeftijdsgebonden maculadegeneratie kan foveasparende atrofie van het retinaal pig-
mentepitheel vertonen, maar zij verschillen in etiologie en progressiesnelheid.
De derde stap omvat het kiezen van een geschikte uitkomstmaat voor een klinische 
trial door het ontwikkelen van een techniek om ziekteprogressie met hoge nauwkeurig-
heid te meten. Hoofdstuk 4 maakt progressiemodellen bij de ziekte van Stargardt. De 
concordantie tussen het linker- en het rechteroog neemt af naarmate de beginleeftijd 
toeneemt, wat belangrijke consequenties heeft in het ontwerp van een klinische trial. 
Een effect wordt namelijk het makkelijkst gedetecteerd bij jonge patiënten, omdat bij 
hen de concordantie het hoogst ligt. Verder kan een samengestelde uitkomstmaat de 
power van een trial met kleine cohorten aanzienlijk verhogen. Bij de samengestelde 
uitkomstmaat zijn optische coherentietomografie en fundusautofluorescentie gebruikt 
als metingen die structurele maculaire veranderingen weerspiegelen. We moeten echter 
in gedachten houden dat patiënten met de ziekte van Stargardt over het algemeen een 
verhoogd risico op foto-oxidatieve stress hebben. Niettemin geven deze structurele 
veranderingen een gevoelige meting van ziekteprogressie. Het kan zeer nuttig zijn bij 
de evaluatie van nieuwe therapeutische behandelingen bij zeldzame aandoeningen. 
Uiteindelijk kan het in potentie de kosten en de duur van cruciale klinische trials ver-
minderen, waardoor het gemakkelijker wordt om effectieve behandelingen sneller en 
gemakkelijker te identificeren.
Ten slotte zet Hoofdstuk 5 de bovengenoemde resultaten in een breed toekomstper-
spectief. De productiviteit van de ontwikkeling van geneesmiddelen neemt af, terwijl de 
kosten ervoor steeds groter worden. De synthese van bewijsvoering moet evolueren, 
waarbij uitkomstmaten een cruciale rol spelen. Er is geen enkel perfect eindpunt; de 
basis voor goedkeuring van een geneesmiddel moet daarom uitgaan van gecombi-
neerde metingen van biomarkers tot aan patiënt-gerapporteerde resultaten. Universele 
meetmethoden en rapportage van de belangrijkste uitkomstmaten kunnen de ontwik-
keling en goedkeuring van geneesmiddelen verder versnellen. De verandering in onze 
dagelijkse praktijk moet uiteindelijk gericht zijn op het verweven van klinische zorg met 
wetenschappelijk onderzoek. De grenzen tussen de klinische zorg, patiëntenregisters 
en klinische trials moeten verdwijnen. 
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6.3 Ringkasan
Ada lebih dari 7000 penyakit langka, dan bersama-sama, penyakit-penyakit itu menimpa 
jutaan pasien di seluruh dunia. Untuk pasien-pasien ini, terdapat perkembangan 
yang menjanjikan dan memberi harapan dalam penemuan obat. Namun, tidak ada 
pengobatan yang tersedia untuk sebagian besar penyakit ini. Dapat dikatakan bahwa 
gangguan retina turunan yang paling umum adalah penyakit Stargardt. Dalam perjalanan 
alaminya, heterogenitas pada usia permulaan menggambarkan heterogenitas yang luas 
dalam tingkat variabel perkembangan penyakit fungsional dan struktural. Di sini, tidak 
hanya tantangan evaluasi pengobatan—yang telah ada sejak sejarah kuno—saja yang 
terjadi, tetapi sifat dan heterogenitasnya yang langka juga menimbulkan tantangan 
lainnya. Tesis ini menanggapi tantangan-tantangan dalam evaluasi pengobatan untuk 
penyakit Stargardt, memberikan strategi untuk studi berikutnya yang bertujuan untuk 
mengidentifikasi efek pengobatan baru untuk penyakit langka.
Bab 1 adalah pendahuluan mulai dari sejarah hingga pemahaman terkini tentang 
penyakit Stargardt dan evaluasi pengobatan baru. Evaluasi pengobatan baru telah 
berkembang secara signifikan sejak zaman kuno dan saat ini dikenal dengan uji klinis. 
Tanpa uji klinis, kita dapat menyimpulkan bahwa pengobatan yang tidak berguna justru 
sangat membantu, atau bahwa pengobatan yang membantu justru tidak berguna.  
Langkah pertama yang diperlukan adalah mengevaluasi pengaruh waktu alam dengan 
mencirikan riwayat alami berbagai kelompok pasien dalam spektrum penyakit Stargardt. 
Untuk mengklasifikasikan pasien ke kelompok tertentu yang relevan, diperlukan 
prognostik yang cukup dan juga homogenitas etiologi antar pasien. Bab 2 menjelaskan 
karakteristik fenotipik dan genotipik unik dari subkelompok dalam heterogenitas 
penyakit Stargardt, yang ditetapkan dalam konteks klasifikasi dan penahapan yang 
muncul sebelumnya. Perjalanan alami penyakit Stargardt tahap awal pada mulanya 
memiliki kelainan elektroretinografi bidang penuh dan perubahan foveal awal. Ketika 
degenerasi retina berlangsung, spektrum fenotipe akhirnya menyatu, menyebabkan 
atrofi korioretinal dan kehilangan penglihatan yang parah. Sebaliknya, perjalanan alami 
Stargardt tahap lanjut menggambarkan perluasan area atrofi epitelium pigmen retina 
yang dapat menyelamatkan fovea yang terkait dengan pemeliharaan ketajaman visual 
yang berkepanjangan hingga usia yang relatif lanjut.
Langkah kedua adalah memilih pasien yang tepat dengan mengidentifikasi tantangan 
diagnostik pada kelompok pasien tertentu. Penyakit langka umumnya memiliki presentasi 
klinis yang sulit dikenali dan didiagnosis. Bab 3 mengungkap tantangan dalam diagnosis 
klinis penyakit Stargardt. Kesadaran akan kemungkinan tidak adanya kelainan retina pada 
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pasien muda memungkinkan diagnosis dini. Diagnosis ini dapat mencegah penderitaan, 
investigasi yang tidak perlu, dan terapi berbahaya serta mungkin terbukti penting pada 
inklusi awal dalam uji di masa mendatang. Inklusi dalam uji di masa mendatang juga 
memiliki tantangan pada pasien dewasa karena kelainan retina yang ditiru oleh penyakit 
yang berkaitan dengan usia. Degenerasi makula terkait usia dan Stargardt tahap lanjut 
dapat menunjukkan atrofi penyeimbang fovea yang profresif, tetapi keduanya berbeda 
dalam etiologi dan kecepatan perkembangan. 
Langkah ketiga terdiri dari pilihan metode yang tepat untuk evaluasi hasil dengan 
mengembangkan teknik untuk mengukur perkembangan penyakit dengan akurasi tinggi. 
Bab 4 menciptakan model perkembangan penyakit pada penyakit Stargardt. Konkordansi 
antar mata menurun seiring bertambahnya usia, yang memiliki konsekuensi penting 
dalam desain uji klinis. Efek pengobatan potensial paling tepat dinilai pada pasien muda. 
Selain itu, ukuran hasil gabungan dapat berpengaruh dalam evaluasi efikasi pengobatan 
dalam uji klinis untuk penyakit Stargardt dengan kohor kecil secara tepat waktu. 
Dalam evaluasi ini, tomografi koherensi optik dan pencitraan autofluoresensi fundus 
digunakan sebagai pengukuran yang menggambarkan perubahan makula struktural. 
Namun, kita harus ingat bahwa pasien dengan penyakit Stargardt umumnya berisiko 
tinggi mengalami stres foto-oksidatif. Namun demikian, perubahan makula struktural ini 
memberikan pengukuran yang sensitif terhadap perkembangan penyakit pada penyakit 
Stargardt . Pengukuran ini sangat berguna untuk evaluasi modalitas terapi baru dalam 
gangguan langka. Secara potensial, pengukuran ini dapat mengurangi biaya dan durasi 
uji klinis penting, sehingga diharapkan dapat mempermudah pengobatan yang efektif 
yang diidentifikasi semakin cepat bagi pasien dengan penyakit langka.
Terakhir, Bab 5 menyajikan hasil yang disebutkan di atas dalam perspektif yang luas dan 
berorientasi ke depan. Produktivitas pengembangan obat menurun, sementara biaya 
untuk pengembangan obat semakin meningkat. Sintesis bukti harus berkembang, di 
mana ukuran hasil berperan penting. Tidak ada satu pun pengganti atau titik akhir klinis 
yang sempurna, karenanya dasar untuk persetujuan obat harus muncul dari pengukuran 
gabungan dalam rentang dari biomarker hingga hasil yang dilaporkan pasien. Pengukuran 
dan pelaporan universal serangkaian hasil inti dapat lebih mempercepat pengembangan 
dan persetujuan obat. Perubahan praktik sehari-hari kita pada akhirnya harus fokus 
untuk menjalin perawatan klinis dengan penelitian ilmiah; batas antara perawatan klinis, 
pendaftaran pasien, dan uji terapi harus dihilangkan. 
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Dankwoord
Een terugblik op een bijzondere reis van de afgelopen jaren; tijdens een promotietraject 
leer je je grenzen ontdekken, zowel op wetenschappelijk als op persoonlijk vlak. Het 
doet een beroep op je creativiteit om die grenzen te verleggen. Het vergt veel geduld en 
doorzettingsvermogen, maar gelukkig deel je dat met een groot en hardwerkend team. 
En samen onderzoek doen geeft je ook weer energie en voldoening. In drie jaar tijd heb 
ik veel mensen leren kennen en veel samengewerkt. Het is onmogelijk om iedereen te 
bedanken, maar een aantal mensen zou ik graag bij deze in het bijzonder willen bedan-
ken.
Allereerst gaat mijn dank uit naar alle patiënten die aan het onderzoek hebben deelge-
nomen. Zonder hun medewerking was het onmogelijk om tot dit resultaat te zijn geko-
men; en het zijn ook jullie voor wie dit resultaat uiteindelijk van belang zal zijn.
Prof. dr. Hoyng, beste Carel, jij stelt altijd dat belang van de patiënt voorop door de 
essentie van het onderzoek scherp op je netvlies te hebben. De praktische uitwerking 
bleef zo nu en dan nog in het midden, maar dat gaf mij wel de vrijheid om het uit te zoe-
ken op een manier die bij mij paste. Bedankt voor het vertrouwen in mij om het onder-
zoek te kunnen volbrengen. En bedankt voor je humor en je laagdrempeligheid (en sorry 
dat ik die hoge drempel in de bocht over het hoofd had gezien).
Prof. dr. G.J. van der Wilt, beste Gert-Jan, de beste vragen waar wij als clinici niet direct 
aan denken, komen van jou! Ik heb veel geleerd door jou brede blik op zaken vanuit een 
unieke invalshoek.
Prof. dr. Klevering, beste Jeroen, bij jou kreeg ik alle zaken weer op een rij, zodat ik niet 
teveel af zou dwalen. Door jou kregen de projecten hun uiteindelijke vorm. Jij weet ten-
slotte altijd dondersgoed hoe je een boodschap moet overbrengen. Bedankt voor jouw 
kritische blik.
Lieve Nathalie, mijn Stargardtmaatje! Wat fijn om met jou te hebben samengewerkt. De 
manier waarop jij tegen dingen aankijkt in combinatie met een snufje chaos opent ideeën 
waar ik geen seconde aan zou hebben gedacht. Zo pakt het altijd weer goed uit en heb-
ben we samen toch wat fraais neergezet. En ook de tripjes naar de Keys, Yellowstone, 
Londen, de bever en de eekhoorn…dat waren mooie avonturen! Waar gaat de volgende 
reis heen? Bedankt voor je openhartigheid en eerlijkheid. En altijd vrolijk, als je tenmin-
ste hebt gegeten… (zou dat een specifiek Indo-gen zijn?) Een kop chocolademelk of een 
saucijzenbroodje doet veel goed. Heel veel succes met de laatste loodjes!
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Mijn lieve paranimfen, wat ben ik blij dat ik jullie naast mij heb staan. Lieve Mai, jij bent 
voor mij een luisterend oor: altijd oprecht geïnteresseerd hoe het gaat en waar ik in mijn 
hoofd allemaal mee bezig ben. En een steuntje in de rug op de momenten dat ik die wel 
kon gebruiken. Bedankt voor alle spelletjesavonden en je heerlijke sushi! Het is toch ook 
altijd gezellig met jou! En Sidney, was het eerst dat we zo enthousiast werden van de 
nieuwste hightech gadgets, een mooie gitaar of de laatste computerapparatuur, hebben 
we het nu over kinderwagens en babyboxen… Wat is er in al die tijd toch veel veranderd. 
Maar de eindeloze jam- en oefensessies herinner ik me als de dag van gisteren. Ik ben blij 
dat we na 15 jaar nog steeds regelmatig afspreken, ook al zal een game- of filmavond tot 
in de late uurtjes er waarschijnlijk niet meer in zitten.
Prof. dr. Keunen, beste Jan, het eerste jaar van mijn opleiding was niet makkelijk; eigen-
lijk waren er te veel ballen in de lucht te houden; promotie, opleiding, verhuizing, een 
kleine dondersteen erbij…ergens ook nog tijd voor sport en sociale contacten? Bedankt 
voor je begeleiding, zorgzaamheid en begrip hiervoor. High five!
Dr. Theelen, beste Thomas, bedankt voor alle laagdrempelige overleggen en brain-
stormmomenten om je uitgebreide kennis van imaging te kunnen benutten. Het heeft 
het onderzoek zeker tot een hoger niveau getild!
Beste Clarisa, Mark, Freerk en Bart, ook jullie bedankt voor de hulp en het delen van jullie 
kennis over alle imagingtechnieken.
Prof. dr. Cremers, beste Frans, al die genen vind ik nog steeds maar ingewikkeld. Bedankt 
voor je hulp over de essentiële genetische zaken in het onderzoek waar ik allemaal niet 
aan heb gedacht.
Drs. Groenewoud, beste Hans, wat een bron van statistische kennis en creativiteit ben jij! 
Je bent altijd enthousiast over van alles, en zelfs samen aan vele regels lange SAS-syn-
tax is dan gewoon gezellig met jou. Foutmelding? Dat kan altijd opgelost worden!
Beste Clasien, het lijkt alweer zo lang geleden, maar bedankt voor de samenwerking in 
het RD5000-project en voor al het lekkers dat uit je tuin kwam!
Dear prof. dr. Holz, prof. dr. Fleckenstein, prof. dr. Schmitz-Valckenberg, Moritz, Mat-
thias, and Matthias from the Universitäts-Augenklinik Bonn, thank you for the fruitful 
collaboration on foveal sparing. I am also glad we can agree that we should not always 
listen to Carel. Otherwise, we would have been the Foveal sparing Atrophy Research 
Team instead of the Study Team.
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Also many thanks to our collaborators at Moorfields Eye Hospital; prof. dr. Webster, prof. 
dr. Moore, prof. dr. Michaelides, and Ana for our nice collaboration. 
Beste Yara, Nicole, Freekje, Constantin, Myrte, Michel, Nathalie, Laura, Maartje, Roos, 
Eveline,  Sanne, Vivian en Dyon, in de promovendikamer zaten we allemaal in hetzelfde 
schuitje; het is er hard werken tijdens een hele lange duurloop…en het is er vooral ook 
erg gezellig! Maar poeh he...wat vliegt er toch soms een hoop onzin door zo’n kamer. 
Gelukkig kan ik me daar goed van afsluiten, maar ja....dan krijg je ook niet altijd alles 
mee. Naast al dat onderzoek hebben we zeker ook heel wat afgereisd, spelletjesavon-
den gehad, gepubquized, film(marathon)s gekeken, taart gegeten, sushi gegeten, pizza 
gegeten, en nog meer gegeten. En het opnemen en inzingen van al die promotiefilmpjes 
leverden ook altijd hilarische momenten op. Bedankt voor al die mooie momenten! Niet 
bedankt trouwens voor alle schrikmomenten die jullie mij hebben bezorgd… 
De etentjes en spellenavonden hebben we ‘beneden’ met een aantal van jullie mooi 
voortgezet in het ‘AIOS-tijdperk’ samen met Artin, Martijn, Mustapha, Elise, Linde en 
Robert. John, Dženita, Stefan, Jelina, Anita, Ramon en Ellen, jullie zijn inmiddels een 
tijdje AIOS af, maar ik wil jullie nog bedanken dat ik voor alle vragen als kersverse AIOS 
bij jullie terecht kon. En Nicole, ook jij bedankt dat je als mentormama mij wegwijs hebt 
gemaakt op de poli (ik weet alleen nog steeds niet alle lampschakelaars te vinden). 
Ramon, jou wil ik in het bijzonder bedanken voor je hulp en begeleiding tijdens mijn 
onderzoeksstage. Die archieven in de kelders (krochten?) van de afdeling waren wel saai 
hoor…en soms ook een beetje creepy. Jij zag echter een kansrijk eindresultaat voor ogen. 
Jouw enthousiasme heeft ook mij enthousiast gemaakt en misschien was ik anders wel 
nooit aan mijn promotietraject begonnen. 
Maartje, Lisanne en Ronald, dat DOPS-congres van een paar jaar terug...daar mogen we 
best trots op zijn! Wat een soepel en geslaagd congres was dat. Een geweldig, geolied 
team waren we! 
Collega’s van de verpleegpost, optometristen, administratie en het stafsecretariaat, 
bedankt voor gezelligheid en ondersteuning! Jack en Liesbeth in het bijzonder dat ik het 
maken van de ERG’s en imaging van jullie heb mogen leren!
Lieve vrienden en vriendinnen, Sidney, Robin, Mai, Jimmy, Nynke, Aart, Sherien, Aletta, 
Renée, Samantha, Koen, Roy, Thijs, Nick, Melek, Fia…lekker badmintonnen, weekendjes 
weg, BBQ’s, motorrijden, de spellenavonden, sushi maken, sushi eten (hoe vaak staat er 
nou al sushi in mijn dankwoord?!). Tja, het leven bestaat inderdaad uit meer dan alleen 
maar promoveren (en sushi). Bedankt dat jullie me daaraan hebben blijven herinneren. 
Nu ik dit kan afsluiten, wordt het hoog tijd om uit dat sociaal isolement te stappen.
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Lieve Jonathan en Dosdny, ook jullie staan klaar als ik hulp kan gebruiken. Bedankt daar-
voor!
Ook wil ik mijn schoonfamilie bedanken, lieve Marianne, René, Leanne, Robin, Imre en 
opa Wim, bedankt voor al jullie betrokkenheid, gezelligheid, leuke uitjes en skivakan-
ties. Ondanks dat ik inmiddels door jullie ook een beetje kan skiën, blijf ik het toch maar 
vreemd vinden dat jullie die ijskoude sneeuw maar al te graag verkiezen boven een 
vakantie met een warm zonnetje en een palmboom.
Kanggo kulawarga, matur suwun kanggo dukungan sampeyan kabeh. Wektu sediluk 
kanggo kumpul bebarengan iku wektu sing apik nemen lan bakal terus tak iling-iling. 
Sakjane aku kepingin njenengan ora adoh-adoh. Kanggo Mbah Kakung, matur suwun 
kanggo dungone sing kenceng. Njenengan mesti ono terus ing atiku. Kanggo Mbah Ibuk, 
rasane seneng banget kaya mulih nang omah nalika ndeleng kabungahan lan kebecikan 
ing mripat njenengan. Matur suwun wis bungah karo aku. Aku tresno njenengan.
Lieve mama, jij hebt altijd gezegd dat we zelf onze toekomst moeten opbouwen en daar-
voor hard voor zullen moeten werken. Je krijgt het niet voor niets. Dankzij jou heb ik me 
kunnen ontwikkelen tot wie ik ben. Je staat altijd klaar voor mij, en altijd is er een warm 
welkom thuis (met lekker eten)! Hoe drukker het werd, des te minder dat ik je eigenlijk 
zag en vergeet ik weleens te zeggen hoe blij en dankbaar ik ben dat ik de allerliefste 
mama van de wereld heb!
Lieve Anouk, jij kan me zo goed weghalen van alle drukte om samen te ontspannen en 
te genieten van alle mooie kleine dingen. Lekker uitwaaien op de motor, op het strand, 
of simpelweg hier om de hoek. Die momenten samen waarbij we de rest van de wereld 
eventjes kunnen vergeten, zijn misschien wel de belangrijkste in het leven. Bedankt voor 
al je steun en liefde! De laatste maandjes, en ik denk wel het hele afgelopen jaar, waren 
erg zwaar: verhuizen, promoveren, de opleiding, tussendoor competitie spelen…en we 
hadden ook nog eens bedacht dat we een gezinnetje zouden willen stichten. Samen zijn 
we erdoorheen geslagen. Zonder jou was dit nooit gelukt, ik hou van je!
Lieve Yenthe, elke ochtend opstaan met een grote glimlach op je gezicht: hoe kan een 
dag voor een trotse vader nou beter beginnen? Je bent het beste wat mij is overkomen. 
We kunnen altijd rekenen op elkaar, wij met z’n drietjes!
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Papers in international journals
Development of refractive errors —what can we learn from inherited retinal dystrophies?
Michelle Hendriks, Virginie J.M. Verhoeven, Gabriëlle H.S. Buitendijk, Jan Roelof Polling, Magda A. Meester-
Smoor, Albert Hofman, RD5000 Consortium, Maarten Kamermans, L. Ingeborgh van den Born, Caroline C.W. 
Klaver
Am J Ophthalmol. 2017 Oct;182:81-89.
Highly sensitive measurements of disease progression in rare disorders: developing and 
validating a multimodal model of retinal degeneration in Stargardt disease
Stanley Lambertus, Nathalie M. Bax, Ana Fakin, Joannes M.M. Groenewoud, B. Jeroen Klevering, Anthony T. 
Moore, Michel Michaelides, Andrew R. Webster, Gert Jan van der Wilt, and Carel B. Hoyng
PLoS One. 2017 Mar 29;12(3):e0174020.
Photo-oxidative stress during fundus autofluorescence imaging
Michel M. Teussink, Stanley Lambertus, Frits de Mul, Carel B. Hoyng, B. Jeroen Klevering, and Thomas Theelen
PLoS One. 2017 Feb 24;12(2):e0172635.
Curriculum vitae
Stanley Lambertus was born on Novem-
ber 18th, 1987 in Gendringen, the Neth-
erlands. He completed secondary school 
(VWO-certificate, Natuur, Techniek en 
Gezondheid) at the Almende College, 
Isala in Silvolde. He started his medical 
study in 2006 at the Radboud University 
in Nijmegen, and successfully completed 
this in 2012. His interest in research and 
ophthalmology developed in his final year, 
in which he took part in clinical ophthal-
mologic research on Stargardt disease at 
the Radboud university medical center. 
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